



सत्यमेव जयते

GOVERNMENT OF MEGHALAYA  
DEPARTMENT OF HEALTH AND  
FAMILY WELFARE

# THE MEGHALAYA ESSENTIAL DRUG LIST 2023



Meghalayan Medical Drugs & Services Limited  
Health & Family Welfare Department  
Government of Meghalaya

**Address:**

Meghalayan Medical Drugs and Services Limited  
Department of Health & Family Welfare,  
Health Complex, New Colony, Laitumkhrach,  
Shillong - 793003,  
East Khasi Hills,  
Meghalaya

**Email:**

contactdesk@mmdsl.in (Office)  
&  
grievance@mmdsl.in (For Grievances & Feedback)

**Contact Numbers:**

+91 9863033404 (Office)  
&  
14410 Option 4 (Toll Free Number for Grievances & Feedback)

**Grievance Form:**

<https://forms.gle/3ycrKDiTv9rzBcur7>

# FORWARD

---

I extend my heartfelt congratulations to the entire Health Department for the remarkable achievement and dedication demonstrated in improving our healthcare system. Your tireless efforts have yielded significant results, and I am immensely proud of the milestones we have reached together.

With the successful creation of the Essential Drug List (EDL) for the year 2023, we have taken a giant leap forward in ensuring the accessibility and availability of essential medicines and diagnostics for all our citizens. This carefully curated list, a testament to your expertise and commitment, will undoubtedly have a profound impact on the lives of countless people across our beloved state.

The establishment of the Meghalayan Medical Drugs and Services Limited (MMDSL) is a true testament to the department's vision and determination to streamline drug procurement and distribution. The efficient logistics, modern technology, and standardized nomenclature will undoubtedly optimize healthcare services and enhance the overall well-being of our citizens.

I want to express my deepest gratitude to the dedicated team involved in shaping this vital initiative. Your hard work and dedication have been invaluable in ensuring quality healthcare for all.

Together, we are moving forward towards a healthier and prosperous Meghalaya.



A handwritten signature in black ink, appearing to read 'Conrad K. Sangma'. The signature is stylized and fluid, with a long, sweeping underline that extends to the right.

Conrad K. Sangma

Chief Minister of Meghalaya



## MESSAGE

### HEALTH MINISTER

---

I would like to congratulate the Meghalayan Medical Drugs and Services Limited for curating the Essential Drug List-2023 to ensure the prescription of medicines using generic names, ensuring standardized nomenclature and cost-effective prescriptions.

I extend my heartfelt appreciation to the committee comprising of doctors and experts, who have been working tirelessly in preparing this comprehensive drug list, which classifies medicines for different levels of healthcare facilities, ranging from Sub-

Centres to Primary Health Centres, Community Health Centres, and District Hospitals. Their commitment to improving healthcare in Meghalaya is commendable.

I urge all healthcare providers, administrators, and stakeholders to embrace and effectively implement the Meghalaya Essential Drug List 2023 in all healthcare facilities across the state. By doing so, we will address the challenges of medicine availability, affordability, and quality, and move closer to our vision of ensuring that every individual has access to safe and effective medicines without undue financial burden.

**Dr. Ampareen Lyngdoh**

Health Minister, Meghalaya



## MESSAGE

PRINCIPAL SECRETARY, HEALTH & FW  
GOVT. OF MEGHALAYA  
CUM CHAIRMAN, MMDSL

---

I am pleased to share with you the commendable strides we are taking towards improving overall healthcare in Meghalaya, where drugs and diagnostics play indispensable roles. The establishment of the Meghalayan Medical Drugs and Services Limited (MMDSL) marks a crucial step towards streamlining our healthcare system and ensuring timely availability of essential drugs and medical supplies at all health facilities.

At the core of our efforts lies the development of the Essential Drug List (EDL), which comprises vital medicines essential for primary, secondary, and tertiary healthcare settings. The EDL has been meticulously curated to ensure these medicines are readily accessible to the public, free of cost, and of assured quality.

I extend my heartfelt appreciation to the committee of doctors and experts whose invaluable insights have contributed to the formulation of the Meghalaya Essential Drug List 2023. Your dedicated efforts have been instrumental in shaping this essential tool for our healthcare system.

A robust Essential Drug List plays a pivotal role in ensuring that recommended medicines are available at the right health facility enabling efficient purchasing and distribution of medicines. This, in turn, reduces wastage of medicines at health facilities and optimizes resource utilization, leading to improved health outcomes and increased patient satisfaction.

A handwritten signature in black ink, appearing to read 'Sampath Kumar', with a long, sweeping underline that extends to the right.

**SHRI. SAMPATH KUMAR, IAS,**  
Principal Secretary Health & FW  
Government of Meghalaya  
Cum Chairman, MMDSL



## MESSAGE

COMMISSIONER & SECRETARY HEALTH & FW  
GOVT. OF MEGHALAYA  
CUM DIRECTOR, MMDSL

---

I extend my heartfelt congratulations to the health department and Meghalayan Medical Drug and Services Limited for the curation of the Essential Drug List 2023, which is a significant milestone in our collective effort to enhance healthcare services.

The development of the EDL-2023 was guided by two important factors. Firstly, we referred to the National List of Essential Medicines (NLEM), 2022, which serves as a national reference document for essential medicines. This ensured that our list aligns with the national standards and recommendations. Secondly, we formed an expert committee consisting of specialists from various medical disciplines.

I want to express my deep appreciation to the committee of doctors and experts for the formulation of the comprehensive list of essential medicines categorized for various healthcare facilities. Your dedication, expertise, and commitment have been instrumental in shaping this essential tool for our healthcare system.

Let us continue to address barriers to access and implement effective strategies for the procurement, distribution, and utilization of essential medicines. Together, we can build a robust healthcare system that ensures better healthcare outcomes for all our citizens.

A handwritten signature in blue ink, appearing to read 'Joram Beda', written over a circular stamp or seal.

**Dr. Joram Beda, IAS,**

Commissioner & Secretary Health & FW  
Government of Meghalaya  
Cum Director, MMDSL



## MESSAGE

SECRETARY HEALTH & FW GOVT. OF MEGHALAYA  
CUM MANAGING DIRECTOR, MMDSL

---

I am pleased to announce that we have taken a significant step towards improving overall healthcare in our state by introducing the Essential Drug List (EDL) through the Meghalayan Medical Drugs and Services Limited (MMDSL). Drugs and diagnostics are pivotal components of our healthcare system, and streamlining their availability is crucial for enhancing the well-being of our citizens.

The MMDSL was established with the vision of ensuring timely availability of essential drugs and medical supplies at all health facilities. This independent agency will play a pivotal role in procuring, supplying, maintaining, and disposing of drugs and medicines, streamlining the entire process for better efficiency and accessibility.

The formulation of the Essential Drug List was a collaborative effort, involving a committee of doctors and experts. It gives me immense pride to announce that the implementation of the EDL will be made mandatory across all health facilities, ensuring that essential medicines are readily available to the public, free of cost, and of assured quality.

The EDL encourages the prescription of medicines using generic names, emphasizing the importance of standardized nomenclature. This approach not only promotes cost-effective prescribing practices but also empowers patients with accurate information about their medications, ultimately leading to better health outcomes.

While we have issued the essential drug list to health facilities regularly, it is imperative that we maximize its utilization. Prescribing medicines using generic names and adhering to the EDL will optimize resource allocation, enhance medical practices, and improve overall healthcare outcomes. This list serves as a guide for the procurement and supply of necessary medicines, ensuring that patients receive the appropriate treatment for their specific health conditions.



**Shri. Ramkumar S, IAS,**

Secretary Health & FW,  
Government of Meghalaya  
Cum MD, MMDSL

## MESSAGE

DIRECTOR OF HEALTH & SERVICES (MI) CUM DIRECTOR, MMDSL

---

I am delighted to introduce the Essential Drug List 2023. This significant achievement is the result of the collective efforts of a dedicated team of doctors, with the valuable support of the Principal Secretary Health & FW, Commissioner & Secretary Health & FW, Secretary Health cum Managing Director-MMDSL, and our esteemed colleagues from the health department.

The EDL serves as a crucial tool in our mission to improve overall healthcare in Meghalaya, as drugs and diagnostics are key components of our healthcare system. By encouraging the prescription of medicines using generic names and emphasizing standardized nomenclature, we aim to promote cost-effective practices while empowering patients with accurate information about their medications, ultimately leading to better health outcomes.

While we have consistently issued the essential drug list to health facilities, it is now imperative that we ensure its maximum utilization. By prescribing medicines using generic names and adhering to the EDL, we can optimize resource allocation, enhance medical practices, and achieve improved healthcare outcomes. This comprehensive list guides the procurement and supply of necessary medicines, ensuring that patients receive appropriate treatments for their specific health conditions.

I emphasize the importance of providing our healthcare workers with the necessary training and education on the rational use of medicines. By incorporating the EDL-2023 into their practices, they can make informed decisions in prescribing and dispensing essential medicines, avoiding unnecessary costs and potential harm to patients.

Once again, I extend my heartfelt appreciation to the entire team for their dedication and hard work in making the Essential Drug List a reality. Together, let us continue our efforts to strengthen our healthcare system and ensure a healthier and brighter future for the people of Meghalaya.



  
**Dr. H.C. Lyndem,**

Director Of Health Services (MI)  
Cum Director, MMDSL  
Government of Meghalaya



# Table of Contents

---

|  |           |
|--|-----------|
| <b>INTRODUCTION</b>  | <b>11</b> |
| <b>ABOUT MMDSL</b>   | <b>12</b> |
| <b>THE EDL FINALIZATION COMMITTEE</b>  | <b>13</b> |
| <b>SALIENT FEATURES OF EDL 2023</b>  | <b>14</b> |
| <b>ESSENTIAL DRUG LIST, 2023</b>   | <b>15</b> |
| <b>Section 1 Medicines used in Anaesthesia</b>   | <b>15</b> |
| <b>Section 2</b>   | <b>17</b> |
| Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders | <b>17</b> |
| <b>Section 3</b>   | <b>20</b> |
| Antiallergics and Medicines used in Anaphylaxis  | 20        |
| <b>Section 4</b>   | <b>21</b> |
| Antidotes and Other Substances used in Management of Poisonings/Envenomation   | 21        |
| <b>Section 5</b>   | <b>22</b> |
| Medicines used in Neurological Disorders   | 22        |
| <b>Section 6</b>   | <b>26</b> |
| Anti-infective Medicines   | 26        |
| <b>Section 7</b>   | <b>41</b> |
| Anti-cancer agents including Immunosuppressives and Medicines used in Palliative Care not defined.   | 41        |
| <b>Section 8 Medicines affecting Blood</b>   | <b>47</b> |
| <b>Section 9</b>   | <b>49</b> |
| <b>Blood products and Plasma substitutes</b>   | <b>49</b> |
| <b>Section 10 Cardiovascular Medicines</b>   | <b>49</b> |
| <b>Section 11 Dermatological Medicines (Topical)</b>   | <b>52</b> |
| <b>Section 12 Diagnostic agents</b>  | <b>53</b> |
| <b>Section 13</b>  | <b>54</b> |
| <b>Dialysis components (Haemodialysis and Peritoneal Dialysis)</b>   | <b>54</b> |
| <b>Section 14 Antiseptics and Disinfectants</b>  | <b>54</b> |

|   |           |
|---|-----------|
| <b>Section 15 Diuretics</b>   | <b>55</b> |
| <b>Section 16</b>   | <b>55</b> |
| <b>Ear, Nose and Throat Medicines</b>   | <b>55</b> |
| <b>Section 17 Gastrointestinal Medicines</b>  | <b>56</b> |
| <b>Section 18</b>   | <b>58</b> |
| <b>Hormones, other Endocrine Medicines and Contraceptives</b>                                   | <b>58</b> |
| <b>Section 19 Immunologicals</b>  | <b>61</b> |
| <b>Section 20 Medicines for Neonatal Care</b>   | <b>62</b> |
| <b>Section 21 Ophthalmological Medicines</b>  | <b>62</b> |
| <b>Section 22 Oxytocics and Antioxytocics</b>   | <b>64</b> |
| <b>Section 23</b>   | <b>64</b> |
| <b>Medicines used in treatment of Psychiatric Disorders</b>                                     | <b>64</b> |
| <b>Section 24</b>   | <b>67</b> |
| <b>Medicines acting on the Respiratory tract</b>  | <b>67</b> |
| <b>Section 25</b>   | <b>70</b> |
| <b>Solutions correcting Water, Electrolyte disturbances and Acid-base disturbances defined.</b> | <b>70</b> |
| <b>Section 26 Vitamins and Minerals</b>   | <b>71</b> |
| <b>Section 27</b>   | <b>72</b> |
| <b>Medicines for COVID 19 management</b>  | <b>72</b> |
| <b>Section 28</b>   | <b>73</b> |
| <b>Additional List Not Under The Above Category</b>   | <b>73</b> |
| SUPPLEMENTS FOR IUGR  | 73        |
| MEDICINES USED IN COLLESTASIS   | 73        |
| GYNAE DRUGS   | 73        |
| HAEMOSTATICS  | 73        |
| INFERTILITY DRUGS   | 73        |
| H1NI Drugs  | 74        |
| GENERAL DRUGS   | 74        |

|   |           |
|---|-----------|
| <b>Section 29</b>                           | <b>74</b> |
| <b>SUTURE</b>                               | <b>74</b> |
| <b>Vicryl (Round body)</b>                  | <b>74</b> |
| <b>Vicryl Rapide</b>                        | <b>75</b> |
| <b>Mersilk (Cutting)</b>                    | <b>75</b> |
| <b>Mersilk (Round body)</b>                 | <b>76</b> |
| <b>Ethilon (Cutting)</b>                    | <b>76</b> |
| <b>Prolene (Cutting)</b>                    | <b>76</b> |
| <b>SUTURE UNDER ENT</b>                     | <b>76</b> |
| <b>SUTURE UNDER OPHTHALMIC</b>              | <b>77</b> |
| <b>SUTURE UNDER ORTHOPEDIC &amp; OTHERS</b> | <b>77</b> |
| <b>SUTURE UNDER OBS &amp; GYNAE</b>         | <b>80</b> |

## INTRODUCTION

---

The Meghalayan Medical Drugs and Services Limited, an independent agency established by the government of Meghalaya, plays a vital role in procuring drugs and medical equipment for the state's health facilities. To enhance this process and create a seamless system for indenting, supplying, maintaining, and disposing of drugs and medicines, the agency takes its first step by curating the Essential Drug List (EDL).

The EDL-2023 comprises a total of 691 medicines (excluding repetitions) and 62 sutures, representing an extensive array of essential medical resources. Its fundamental goal is to ensure the ready availability of these essential medicines to the public, free of cost, while maintaining their assured quality. Emphasizing the use of generic names and standardized nomenclature, the EDL encourages the prescription of medicines in a cost-effective and efficient manner.

The development of the EDL-2023 involved extensive consultations with professionals from diverse disciplines, including Medical Officers from District Hospitals, Community Health Centers, and Primary Health Centers. These collaborative discussions allowed for the incorporation of diverse perspectives and expertise, resulting in a comprehensive list of essential medicines tailored to the state's healthcare needs.

Beyond the medicines covered under specific healthcare programs, the Essential Drug List encompasses medications required in various health facilities. The Government of Meghalaya, Health & Family Welfare, takes on the responsibility of establishing a robust healthcare system, ensuring the availability of safe and effective medicines for all citizens utilizing the public healthcare system.

With the introduction of the Essential Drug List, we aim to strengthen and improve healthcare services across Meghalaya, ultimately leading to better health outcomes and a healthier population.

## ABOUT MMDSL

---

Meghalayan Medical Drugs and Services Limited was incorporated on 13th November 2022 under the Companies Act, 2013 (18 of 2013). The corporation was established by the Government of Meghalaya with the aim of setting up an independent agency to streamline the procurement, supply, maintenance, and disposal of drugs and medical equipment for health facilities in the state. The primary focus of the corporation is to ensure the availability of essential drugs and medical supplies, with a strong emphasis on logistics and maintaining quality in drug supply.

The objectives of Meghalayan Medical Drugs and Services Limited revolve around improving the management of drug procurement and supply, ensuring the continuous availability of drugs and medical equipment in all government health facilities, and upgrading the skills of service providers in drug management and usage. The corporation also aims to standardize specifications, tender procedures, billing, and payment systems to ensure efficiency in drug distribution. To achieve its goals, the corporation plans to leverage Information and Communication Technology for logistics management and monitoring, as well as conduct training and sensitization programs for stakeholders.

Meghalayan Medical Drugs and Services Limited offers a range of services and activities, including procurement, testing, storage, and distribution of drugs, medicines, surgical items, and medical supplies to government and private medical facilities in the state. The corporation is responsible for the procurement and installation of medical equipment, finalizing annual rate contracts, and providing support services for maintaining medical and non-medical equipment in healthcare facilities. Additionally, Meghalayan Medical Drugs and Services Limited is involved in developing policies related to medical drugs and equipment to benefit the state's healthcare sector.

To address any grievances or concerns, the corporation has established a Grievance Redressal Mechanism. Beneficiaries can raise complaints through various channels, including a dedicated online portal, email, helpline, and WhatsApp groups. The mechanism ensures that complaints are promptly addressed, and complainants can track the status of their grievances easily through a unique Tracking ID provided to them.

Furthermore, Meghalayan Medical Drugs and Services Limited is implementing the Drug and Vaccine Distribution Management System (DVDMS), a web-based supply chain management application. The system enables online drug indenting, issuance, and receiving processes for healthcare facilities. The DVDMS aims to enhance the accessibility and availability of drugs and medicines for patients across the state of Meghalaya.



## THE EDL COMMITTEE

---

To finalize the Essential Drug List 2023, a committee was constituted with the following members, as per **order No: MMDSL/Drug Committee/2022-23/22 dated 03/02/2023**, issued by the Government of Meghalaya, Health & Family Welfare (GOM, H&FW):

1. Dr. Joram Beda, IAS, Commissioner & Secretary, Health & family Welfare Dept. Government of Meghalaya
2. Dr. (Mrs). H. Lyndem, Director of Health Services (Medical Institutions)
3. Dr. S. S. Nongbri, Director of Health Services (MCH & FW)
4. Dr. (Mrs). Y. Phira, Director of Health Services (Research)
5. (L) Dr. Andreas Dkhar, Additional DHS (SS), Civil Hospital Shillong, EKH
6. Dr. L. Myllemumlong, Jt. DHS (Aids Cell), DHS (Medical Institutions)
7. Dr. Noreen, MO & DMCHO i/c Ampati Southwest Garo Hills
8. Dr. LumlangBuhphang, Sr. Specialist (Anesthetist) Civil Hospital Shillong, EKH
9. Dr. (Mrs) Duiatra Pde, Sr. Specialist (Pediatrician) Ganesh Das Govt MCH Hospital, EKH
10. Dr. N.P.Laloo, Sr. Specialist (Orthopedic Surgeon) Civil Hospital Shillong, EKH
11. Dr. Baladalin Lyngdoh, Sr. Specialist (ENT) Civil Hospital Shillong, EKH
12. Dr. Maxilined.Marak, Sr. Specialist (Pharmacologist) Pasteur Institute, EKH
13. Dr. Isaac Syiem, Sr. Specialist (Surgeon) Civil Hospital Shillong, EKH
14. Dr. KathrinaMarbaniang, Sr. Specialist (Medicine) Civil Hospital Shillong, EKH
15. Dr. WandaplinShangpliang, Sr. Specialist (Gynecologist) Ganesh Das Govt. MCH Hospital, EKH
16. Dr. BaphershishaKharjana, Sr. Specialist (Chest Medicine) Civil Hospital Shillong, EKH
17. Dr. KalkambeA.Sangma, Specialist (Dermatologist) Civil Hospital Shillong, EKH
18. Dr. Anisha Mawlong, Specialist (Oncologist) Civil Hospital Shillong, EKH
19. Dr. Andreecia Mn. Mawiong, Specialist (Psychiatrist) MIMHANS, EKH
20. Shri. B.Kharsyntiew, Sr. Inspector of Drugs DHS (Medical Institutions)
21. Dr. D. P.Syiem, Sr. M&HO, Pomlum PHC, EKH
22. Dr. A.K.Nongbri, Sr. M&HO, Jongksha PHC, EKH
23. Dr. Habamutlang Lyngdoh, M&HO, Mawphlang CHC, EKH
24. Dr. PringprangD.Shira, MO. I/c Nengmandalgre PHC, EGH
25. Dr. Mukta Miah, MO. I/c Mahendraganj CHC, SWGH
26. Dr. L.E. Lyngdoh, State Nodal Officer, NOHP
27. Dr. (Mrs) S D Sarkar, State Nodal Officer, NPCB&VI
28. Dr. B. Marak, State Nodal Officer, NCVBDC
29. Dr. B. Wanbah, Chest Specialist, RP chest and TB hospital
30. Dr. MebanKharkongnor, Dr. H Gordon Robert Hospital
31. Dr. Vijay Nong Piur, NEIGRIHMS, Shillong

## SALIENT FEATURES OF EDL 2023

---

1. The Expert Core Committee recommended that all medicines provided in health facilities under the State initiative and National Health Programs be considered essential medicines.
2. Medicines have been categorized according to therapeutic areas, which may result in certain medicines appearing in multiple categories due to their multiple indications.
3. The strength and dose of each medicine have been specified.
4. Medicines have been categorized and indicated for specific facilities, including DH, CHC, PHC, and SC, based on their essentiality.
5. EDL 2023 consists of a total of 691 medicines (excluding repetitions) and 62 sutures.
6. Total Medicines Facility-Wise, including Sutures:

| Name of item  | Facility name | Nos. of Drugs/Suture | Additional items added in comparison to NLEM 2022 |
|---------------|---------------|----------------------|---|
| <b>DRUG</b>   | DH            | 560                  | 215   |
|               | CHC           | 438                  |   |
|               | PHC           | 344                  |   |
|               | SC            | 188                  |   |
| <b>SUTURE</b> | DH            | 54                   | 63  |
|               | CHC           | 6                    |   |
|               | PHC           | 3                    |   |

7. The list of essential medicines will guide hospital drug policies and the procurement and supply of medicines in the public sector.
8. The list serves as a document for prescribing the correct dosage form and strength, with preference given to single drug formulations. Using the EDL is expected to improve prescribing practices by promoting the use of generic names.
9. The appropriate use of medicines selected in the EDL promotes rational use of medicines.
10. The list also serves as a reference for assessing the healthcare access of the population.
11. Lastly, the EDL serves as a tool for training healthcare providers.
12. These salient features of the EDL 2023 aim to ensure the availability, appropriate use, and accessibility of essential medicines, ultimately improving healthcare outcomes and patient care.

**Note:**

- a) Regarding drugs that were not marked up to SC, might be obtained from the PHC upon endorsement and prescription from the relevant MO

## Essential Drug List, 2023

| Section 1 Medicines used in Anaesthesia   |                                  |  | Facility Wise |     |     |    |
|---|----------------------------------|--|---------------|-----|-----|----|
| 1.1- General Anaesthetics and Oxygen  |                                  |  |               |     |     |    |
| Drug Code   | Drug Name                        | Dosage form(s) and strength(s)             | DH            | CHC | PHC | SC |
| 1.1.1   | Halothane                        | Liquid for inhalation                      | ✓             | ✓   | ×   | ×  |
| 1.1.2   | Isoflurane                       | Liquid for inhalation                      | ✓             | ✓   | ×   | ×  |
| 1.1.3   | Ketamine                         | Injection 10 mg/mL                         | ✓             | ✓   | ×   | ×  |
|   |                                  | Injection 50 mg/mL                         | ✓             | ✓   | ×   | ×  |
| 1.1.4   | Nitrous oxide                    | As licensed for medical purpose            | ✓             | ✓   | ×   | ×  |
| 1.1.5   | Oxygen*                          | As licensed for medical purpose            | ✓             | ✓   | ✓   | ✓  |
| 1.1.6   | Propofol                         | Injection 10 mg/mL                         | ✓             | ✓   | ×   | ×  |
| 1.1.7   | Sevoflurane                      | Liquid for inhalation                      | ✓             | ✓   | ×   | ×  |
| 1.1.8   | Thiopentone                      | Powder for injection 0.5 g                 |               |     | ×   | ×  |
|   |                                  | Powder for injection 1 g                   | ✓             | ✓   |     |    |
| 1.1.9   | Etomidate<br>2mg/ml (10 ml vial) | Etomidate 2mg/ml (10 ml vial)              | ✓             | ✓   | ×   | ×  |
| 1.2.0   | Sodalime granules<br>5 kg/jar    | Sodalime granules 5 kg/jar                 | ✓             | ✓   | ×   | ×  |
| 1.2.1   | Desflurane(liquid inhalational)  | Desflurane(liquid inhalational)            | ✓             | ✓   | ×   | ×  |
| <i>*Oxygen is also listed in Section 27.5 - Medicines for COVID 19 management</i> |                                  |  |               |     |     |    |
| 1.2-Local Anaesthetics  |                                  |  |               |     |     |    |
| 1.2.1   | Bupivacaine                      | Injection 0.25 %                           | ✓             | ✓   | ×   | ×  |
|   |                                  | Injection 0.5 %                            | ✓             | ✓   | ×   | ×  |
|   |                                  | Injection 0.5 % with 7.5 % glucose         | ✓             | ✓   | ×   | ×  |
| 1.2.2   | Lignocaine*                      | Topical forms 2-5 %                        | ✓             | ✓   | ✓   | ✓  |
|   |                                  | Injection 1 %                              | ✓             | ✓   | ✓   | ×  |
|   |                                  | Injection 2 %                              | ✓             | ✓   | ✓   | ✓  |
|   |                                  | Injection 5 % with 7.5 % glucose           | ✓             | ✓   | ×   | ×  |
| 1.2.3   | Lignocaine (A) + Adrenaline (B)  | Injection 1% (A) + 1:200000 (5 mcg/mL) (B) | ✓             | ✓   | ✓   | ×  |
|   |                                  | Injection 2% (A) + 1:200000 (5 mcg/mL) (B) | ✓             | ✓   | ✓   | ×  |
| 1.2.4   | Levo-Bupivacaine<br>0.5% Heavy   | Levo-Bupivacaine 0.5% Heavy                | ✓             | ✓   | ×   | ×  |

| 1.3- Preoperative Medication and Sedation for Short Term Procedures |            |                     |   |   |   |   |
|---|------------|---------------------|---|---|---|---|
| 1.3.1   | Atropine** | Injection 0.6 mg/mL | ✓ | ✓ | ✓ | × |

*\*Lignocaine formulations are also listed in Section 10.2.5 cardiovascular medicines- Antiarrhythmic medicines*

*\*\*Atropine formulations are also listed in -*

*A. Section 4.2.1 - Antidotes and Other Substances used in Management of Poisonings/Envenomation - Specific*

*B. Section 21.5.1 - Ophthalmological Medicines- Mydriatics*

|       |                |                     |   |   |   |   |
|-------|----------------|---------------------|---|---|---|---|
| 1.3.2 | Glycopyrrolate | Injection 0.2 mg/mL | ✓ | ✓ | × | × |
| 1.3.3 | Midazolam*     | Tablet 7.5 mg       | ✓ | ✓ | × | × |
|       |                | Nasal Spray 0.5mg   | ✓ | ✓ | ✓ | ✓ |
|       |                | Nasal Spray 1.25 mg | ✓ | ✓ | ✓ | ✓ |
|       |                | Injection 1 mg/mL   | ✓ | ✓ | ✓ | × |
|       |                | Injection 5 mg/mL   | ✓ | ✓ | ✓ | × |
| 1.3.4 | Morphine**     | Injection 10 mg/mL  | ✓ | ✓ | ✓ | × |
|       |                | Injection 15 mg/mL  | ✓ | ✓ | ✓ | × |

#### Section 1.4 -Muscle Relaxants and Cholinesterase Inhibitors

|       |            |                    |   |   |   |   |
|-------|------------|--------------------|---|---|---|---|
| 1.4.1 | Atracurium | Injection 10 mg/mL | ✓ | ✓ | × | × |
| 1.4.2 | Baclofen   | Tablet 5 mg        | ✓ | ✓ | × | × |
|       |            | Tablet 10 mg       | ✓ | ✓ | × | × |
|       |            | Tablet 20 mg       | × | ✓ | × | × |

*\*Midazolam formulations are also listed in -*

*A. Section 5.1.7- Medicines used in Neurological Disorders Anticonvulsants/ Antiepileptics*

*B. Section 7.4.12- Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care*

*\*\*Morphine formulations are also listed in -*

*A. Section 2.2.2- Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Opioid Analgesics*

*B. Section 7.4.13 - Anti-cancer agents including immunosuppressives, and medicines used in Palliative Care*

|       |                        |                            |   |   |   |   |
|-------|------------------------|----------------------------|---|---|---|---|
| 1.4.3 | Neostigmine*           | Tablet 15 mg               | ✓ | ✓ | × | × |
|       |                        | Injection 0.5 mg/mL        | ✓ | ✓ | × | × |
| 1.4.4 | Succinylcholine        | Injection 50 mg/mL         | ✓ | ✓ | × | × |
| 1.4.5 | Vecuronium             | Powder for injection 4 mg  | ✓ | ✓ | × | × |
|       |                        | Powder for injection 10 mg | ✓ | ✓ | × | × |
| 1.4.6 | Rocuronium 100mg/ 10ml | Rocuronium 100mg/ 10ml     | ✓ | ✓ | × | × |
| 1.4.7 | Cis-Atracurium         | Cis-Atracurium 20mg/10 ml  | ✓ | ✓ | × | × |

|   |                        |   |   |   |   |   |
|---|------------------------|---|---|---|---|---|
|   | 20mg/10 ml             |   |   |   |   |   |
| 1.4.8   | Pancuronium            | Injection 10mg/10ml (1mg/ml)  | ✓ | × | × | × |
| <b>Section 2</b>  |                        |   |   |   |   |   |
| <b>Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders</b>   |                        |   |   |   |   |   |
| <b>2.1 - Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs</b>  |                        |   |   |   |   |   |
| 2.1.1   | Acetylsalicylic acid** | Tablet 75 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 75mg    | ✓ | ✓ | ✓ | × |
|   | Acetylsalicylic acid** | Tablet 150 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 150 mg | ✓ | ✓ | ✓ | × |
|   | Acetylsalicylic acid** | Tablet 300 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 300 mg | ✓ | ✓ | ✓ | × |
| <p><i>*Neostigmine formulations are also listed in <b>Section 4.2.8 - Antidotes and Other substances used in Management of poisoning/Envenomation - Specific</b></i></p> <p><i>**Acetylsalicylic acid formulations are also listed in -</i></p> <p style="margin-left: 40px;"><b>A. Section 5.2.1 - Medicines used in Neurological Disorders Antimigraine medicines</b></p> <p style="margin-left: 40px;"><b>B. Section 10.5.1 - Cardiovascular medicines -Antithrombotic Medicines (Cardiovascular/ Cerebrovascular) - Antiplatelet and Antithrombotic Medicines</b></p> |                        |   |   |   |   |   |
| 2.1.2   | Diclofenac             | Tablet 50 mg  | ✓ | ✓ | ✓ | × |
|   |                        | Injection 25 mg/mL  | ✓ | ✓ | ✓ | × |
| 2.1.3   | Ibuprofen*             | Tablet 200 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Tablet 400 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Oral liquid 100 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| 2.1.4   | Mefenamic acid         | Tablet 250 mg   | ✓ | ✓ | ✓ | × |
|   |                        | Oral liquid 100 mg/5 mL (p)   | ✓ | ✓ | ✓ | × |
| 2.1.5   | Paracetamol**          | Tablet 500 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Tablet 650 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Oral liquid 120 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Oral Liquid 125 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Oral Liquid 250 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
|   |                        | Injection 150 mg/ mL  | ✓ | ✓ | ✓ | ✓ |
|   |                        | Suppository 80 mg   | ✓ | ✓ | ✓ | ✓ |
| Suppository 170 mg  | ✓                      | ✓   | ✓ | ✓ |   |   |



|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 2.1.6   | Paracetamol infusion                                      | 1gm/100ml   | ✓ | ✓ | ✓ | x |
| <b>2.2-Opioid Analgesics</b>  |   |   |   |   |   |   |
| 2.2.1   | Fentanyl (inj. and Patch)                                 |   | ✓ | ✓ | x | x |
| <p><i>*Ibuprofen formulations are also listed in <b>Section 5.2.2 - Medicines used in Neurological Disorders-Antimigraine Medicines</b></i></p> <p><i>** Paracetamol formulations are also listed in -</i></p> <p style="padding-left: 40px;"><b>A. Section 5.2.3 - Medicines used in Neurological Disorders-Antimigraine Medicines</b></p> <p style="padding-left: 40px;"><b>B. Section 27.4 - Medicines for COVID 19 Management</b></p> |   |   |   |   |   |   |
| 2.2.2   | Morphine*   | Tablet 10 mg  | ✓ | ✓ | ✓ | x |
|   |   | Injection 10 mg/mL  | ✓ | ✓ | ✓ | x |
|   |   | Injection 15 mg/mL  | ✓ | ✓ | ✓ | x |
| 2.2.3   | Tramadol**  | Capsule 50 mg   | ✓ | ✓ | ✓ | x |
|   |   | Capsule 100 mg  | ✓ | ✓ | ✓ | x |
|   |   | Injection 50 mg/mL  | ✓ | ✓ | ✓ | x |
| 2.2.4   | Nalbuphine 10mg/ml  | Nalbuphine 10mg/ml  | ✓ | ✓ | x | x |
| 2.2.5   | Diclofenac (A) + CHLORZOXAZONE (B) + PARACETAMOL (C)      | TAB 50mg (A) +250mg (B) + 325mg (C)                             | ✓ | ✓ | ✓ | x |
| 2.2.6   | ACECLOFENAC (A) + CHLORZOXAZONE (B) + PARACETAMOL (C)     | TAB 100mg (A) +250mg (B) + 325mg (C)                            | ✓ | ✓ | ✓ | x |
| 2.2.7   | ACECLOFENAC (A) + TIZANIDINE (B)                          | Tab 100mg (A) + 2mg (B)   | ✓ | ✓ | ✓ | x |
| 2.2.8   | ACECLOFENAC (A) + PARACETAMOL (B) + SERRATIOPEPTIDASE (C) | TAB 100mg (A) + 325mg (B) + 15mG (C)                            | ✓ | ✓ | ✓ | x |
| 2.2.9   | DICLOFENAC (A) + PARACETAMOL (B) + CHYMOTRYPSIN (C)       | TAB 50mg (A) + 325mg (B) + 50000 ARMOUR UNIT OF ENZYME ACTIVITY | ✓ | ✓ | ✓ | x |

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 2.2.10  | DICLOFENAC (A) + TRYPSIN (B) + BROMELAIN (C) + RUTOSIDE (D) | TAB 50mg (A) + 48mg (B) + 90mg (C) + 100mg (D)  | ✓ | ✓ | ✓ | x |
| 2.2.11  | TRYPSIN - CHYMOTRYPSIN                                      | TAB 100000 AU   | ✓ | ✓ | ✓ | x |
| 2.2.12  | SERRATIOPEPTIDASE   | TAB 15mg, 10mg, 5mg   | ✓ | ✓ | ✓ | x |
| 2.2.13  | ACECLOFENAC   | TAB 100mg   | ✓ | ✓ | ✓ | x |
| <b>MOUThWASH &amp; TOOTHpASTE &amp; ORAL GELS</b> |   |   |   |   |   |   |
| 2.2.14  | CHLORHEXIDINE GLUCONATE MOUTHWASH 0.12%                     | Chlorhexidine Digluconate 0.2% w/v  | ✓ | ✓ | ✓ | ✓ |
| 2.2.14  | POVIDONE MOUTH GARGLE                                       | POVIDONE IODINE-2%W/V   | ✓ | ✓ | ✓ | ✓ |
| 2.2.16  | DESENSITISING TOOTHpASTE POTASSIUM NITRATE BASED            | POTASSIUM NITRATE-5%W/W + SODIUM MONOFLUORO PHOSPHATE-0.625%W/W   | ✓ | ✓ | ✓ | ✓ |
| 2.2.17  | ANALGESIC + ANTISEPTIC + ANAESTHETIC ORAL GEL               | Choline Salicylate 8% w/v (A), Tannic acid 5%w/v (B), LIGNOCAINE HYDROCHLORIDE 2% w/v (C), CETRIMIDE IP 0.01% w/v | ✓ | ✓ | ✓ | ✓ |
| 2.2.18  | GUM ASTRINGENT GELS   | CETRIMIDE-0.1%W/V + TANNIC ACID-2%W/V + ZINC CHLORIDE-1%W/V   | ✓ | ✓ | ✓ | ✓ |
| 2.2.19  | CLOTRIMAZOLE MOUTH PAINT                                    | CLOTRIMAZOLE-1%W/V  | ✓ | ✓ | ✓ | ✓ |
| 2.2.20  | CHLORHEXIDINE GLUCONATE 1.0% GEL                            | CHLORHEXIDINE GLUCONATE-1%W/W   | ✓ | ✓ | ✓ | ✓ |
| 2.2.21  | TRIAMCINOLONE DENTAL PASTE                                  | TRIAMCINOLONE-0.1%W/W   | ✓ | ✓ | ✓ | ✓ |
| <b>HAEMOSTATS</b>                                 |   |   |   |   |   |   |
| 2.2.22  | ETHAMSYLATE   | Tablet 250mg  | ✓ | ✓ | ✓ | ✓ |
| 2.2.23  | TRAXENAMIC  | Tablet 500mg  | ✓ | ✓ | ✓ | ✓ |

|   |                |               |   |   |   |   |
|---|----------------|---------------|---|---|---|---|
|   | ACID           |               |   |   |   |   |
| <b>2.3-Medicines used to treat Gout</b> |                |               |   |   |   |   |
| 2.3.1                                   | Allopurinol*** | Tablet 100 mg | ✓ | ✓ | ✓ | × |
|   |                | Tablet 300 mg | ✓ | ✓ | ✓ | × |
| 2.3.2                                   | Colchicine     | Tablet 0.5 mg | ✓ | ✓ | ✓ | × |
| 2.3.3                                   | Febuxostat     | Tablet 40 mg  | ✓ | ✓ | ✓ | × |
|   |                | Tablet 80 mg  | ✓ | ✓ | ✓ | × |

\*Morphine formulations are also listed in -

**A. Section 1.3.4 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures**

**B. Section 7.4.13 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

\*\* Tramadol formulations are also listed in

**Section 7.4.15 - Tramadol formulations are also listed in Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

\*\*\* Allopurinol formulations are also listed in

**Section 7.4.1 - Allopurinol formulations are also listed in Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

|  |                       |                           |   |   |   |   |
|--|-----------------------|---------------------------|---|---|---|---|
| <b>2.4-Disease Modifying Agents used in Rheumatoid Disorders</b> |                       |                           |   |   |   |   |
| 2.4.1  | Azathioprine*         | Tablet 25 mg (p)          | ✓ | ✓ | × | × |
|  |                       | Tablet 50 mg              | ✓ | ✓ | × | × |
| 2.4.2  | Hydroxychloroquine    | Tablet 200 mg             | ✓ | ✓ | ✓ | × |
|  |                       | Tablet 400 mg             | ✓ | ✓ | ✓ | × |
| 2.4.3  | Methotrexate**        | Tablet 2.5 mg             | ✓ | ✓ | ✓ | × |
|  |                       | Tablet 5 mg               | ✓ | ✓ | ✓ | × |
|  |                       | Tablet 10 mg              | ✓ | ✓ | × | × |
| 2.4.4  | Sulfasalazine         | Tablet 500 mg             | ✓ | ✓ | ✓ | × |
| 2.4.5  | Mycophenolate mofetil | Tablet 250mg              | ✓ | × | × | × |
|  |                       | Tablet 500 mg             | ✓ | × | × | × |
| <b>Section 3</b>   |                       |                           |   |   |   |   |
| <b>Antiallergics and Medicines used in Anaphylaxis</b>           |                       |                           |   |   |   |   |
| 3.1  | Adrenaline            | Injection 1 mg/mL         | ✓ | ✓ | ✓ | × |
| 3.2  | Cetirizine            | Tablet 10 mg              | ✓ | ✓ | ✓ | ✓ |
|  |                       | Oral liquid 5 mg/5 mL (p) | ✓ | ✓ | ✓ | ✓ |

\* Azathioprine formulations are also listed in **Section 7.3.1 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

\*\* Methotrexate formulations are also listed in **Section 7.1.30 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

|     |                  |                             |   |   |   |   |
|-----|------------------|-----------------------------|---|---|---|---|
| 3.3 | Dexamethasone*   | Tablet 0.5 mg               | ✓ | ✓ | ✓ | × |
|     |                  | Tablet 2 mg                 | ✓ | ✓ | ✓ | × |
|     |                  | Tablet 4 mg                 | ✓ | ✓ | ✓ | × |
|     |                  | Oral liquid 0.5 mg/5 mL (p) | ✓ | ✓ | ✓ | × |
|     |                  | Injection 4 mg/mL           | ✓ | ✓ | ✓ | ✓ |
| 3.4 | Hydrocortisone** | Tablet 5 mg                 | ✓ | ✓ | ✓ | × |
|     |                  | Tablet 10 mg                | ✓ | ✓ | ✓ | × |
|     |                  | Powder for Injection 100 mg | ✓ | ✓ | ✓ | × |
|     |                  | Powder for Injection 200 mg | ✓ | ✓ | ✓ | × |
| 3.5 | Pheniramine      | Injection 22.75 mg/mL       | ✓ | ✓ | ✓ | × |
| 3.6 | Prednisolone***  | Tablet 5 mg                 | ✓ | ✓ | ✓ | × |
|     |                  | Tablet 10 mg                | ✓ | ✓ | ✓ | × |
|     |                  | Tablet 20 mg                | ✓ | ✓ | ✓ | × |
|     |                  | Oral liquid 5 mg/5 mL (p)   | ✓ | ✓ | ✓ | × |
|     |                  | Oral liquid 15 mg/5 mL (p)  | ✓ | ✓ | ✓ | × |
| 3.7 | Dexamethasone    | Tablet 8mg                  | ✓ | ✓ | ✓ | × |
| 3.8 | Pheniramine      | Oral liquid 15 mg/5ml       | ✓ | ✓ | ✓ | × |
| 3.9 | Pheniramine      | Tablet 25 mg                | ✓ | ✓ | ✓ | × |

\*Dexamethasone formulations are also listed in -

**A. Section 7.4.3 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care**

**B. Section 18.1.1 - Hormones, other Endocrine Medicines and Contraceptives - Adrenal Hormones and Synthetic Substitutes**

**C. Section 27.1 - Medicines for COVID 19 Management**

\*\* Hydrocortisone formulations are also listed in **Section 18.1.3 - Hormones, other Endocrine Medicines and Contraceptives- Adrenal Hormones and Synthetic Substitutes**

\*\*\*Prednisolone formulations are also listed in -

**A. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Hormones and Anti-Hormones used in cancer therapy**

**B. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives -Adrenal Hormones and Synthetic Substitutes**

**C. Section 21.2.1 - Ophthalmological Medicines- Anti-inflammatory Medicine**

|   |                    |                      |   |   |   |   |
|---|--------------------|----------------------|---|---|---|---|
| <b>Section 4</b>  |                    |                      |   |   |   |   |
| <b>Antidotes and Other Substances used in Management of Poisonings/Envenomation</b> |                    |                      |   |   |   |   |
| <b>4.1-Nonspecific</b>  |                    |                      |   |   |   |   |
| 4.1.1   | Activated Charcoal | Powder (as licensed) | ✓ | ✓ | ✓ | × |
| <b>4.2 Specific</b>   |                    |                      | . | . |   |   |
| 4.2.1   | Atropine*          | Injection 0.6 mg/mL  | ✓ | ✓ | ✓ | × |

|       |  |                                   |   |   |   |   |
|-------|--|-----------------------------------|---|---|---|---|
| 4.2.2 | Calcium gluconate**                        | Injection 100 mg/mL               | ✓ | ✓ | ✓ | × |
| 4.2.3 | D- Penicillamine                           | Capsule 150 mg (p) Capsule 250 mg | ✓ | ✓ | × | × |
| 4.2.4 | Desferrioxamine                            | Powder for injection 500 mg       | ✓ | ✓ | × | × |
| 4.2.5 | Methylthioninium chloride (Methylene blue) | Injection 10 mg/mL                | ✓ | ✓ | × | × |

\*Atropine formulations are also listed in -

**A. Section 1.3.1 - Medicines used in Anaesthesia -Preoperative Medication and Sedation for short term procedures**

**B. Section 21.5.1 - Ophthalmological Medicines- Mydriatics**

\*\* Calcium gluconate formulations are also listed in **Section 26.3 - Vitamins and minerals**

|        |                              |  |   |   |   |   |
|--------|------------------------------|--|---|---|---|---|
| 4.2.6  | N-acetylcysteine             | Sachet 200 mg                            | ✓ | ✓ | ✓ | × |
|        |                              | Injection 200 mg/mL                      | ✓ | ✓ | ✓ | × |
| 4.2.7  | Naloxone                     | Injection 0.4 mg/mL                      | ✓ | ✓ | ✓ | × |
| 4.2.8  | Neostigmine*                 | Injection 0.5 mg/mL                      | ✓ | ✓ | × | × |
| 4.2.9  | Pralidoxime chloride (2-PAM) | Injection 25 mg/mL                       | ✓ | ✓ | ✓ | × |
| 4.2.10 | Snake venom antiserum**      | Soluble/ liquid polyvalent - As licensed | ✓ | ✓ | ✓ | × |
|        |                              | Lyophilized polyvalent - As licensed     | ✓ | ✓ | ✓ | × |
| 4.2.11 | Sodium nitrite               | Injection 30 mg/mL                       | ✓ | ✓ | × | × |
| 4.2.12 | Sodium thiosulphate          | Injection 250 mg/mL                      | ✓ | ✓ | × | × |
| 4.2.13 | Desferrioxamine              | Tablet 500mg                             | ✓ | ✓ | × | × |
| 4.2.14 | Deferasirox                  | Tablet 250mg                             | . | . | ▪ | ▪ |
|        |                              | Tablet 400mg                             | . | . | ▪ | ▪ |
|        |                              | Tablet 500mg                             | ✓ | × | × | × |
| 4.2.15 | Deferasirox                  | Inj 200mg/ vial                          | ✓ | × | × | × |
| 4.2.16 | Deferoxamine                 | Tablet 500mg                             | ✓ | × | × | × |
| 4.2.17 | Defereprone                  | Tablet 500mg                             | ✓ | × | × | × |
|        |                              | Syrup 100mg /5ml                         | ✓ | × | × | × |

\* Neostigmine formulations are also listed in **Section 1.4.3 - Medicines used in Anaesthesia - Muscle relaxants and cholinesterase inhibitors**

\*\* Snake Venom antiserum is also listed in **Section 19.2.7. - Immunologicals - Sera and immunoglobulins (Liquid/ Lyophilized)**

## Section 5

### Medicines used in Neurological Disorders

#### Section 5.1-Anticonvulsants/ Antiepileptics



|  |                    |                                |   |   |   |   |
|--|--------------------|--------------------------------|---|---|---|---|
| 5.1.1  | Carbamazepine*     | Tablet 100 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 200 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 400 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Modified Release -             | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 200 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 400 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Oral liquid 100 mg/5 mL (p)    | ✓ | ✓ | ✓ | ✗ |
| 5.1.2  | Clobazam           | Tablet 5 mg                    | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 10 mg                   | ✓ | ✓ | ✓ | ✗ |
| 5.1.3  | Diazepam**         | Oral liquid 2 mg/5 mL (p)      | ✓ | ✓ | ✓ | ✓ |
|  |                    | Injection 5 mg/mL              | ✓ | ✓ | ✓ | ✓ |
|  |                    | Suppository 5 mg               | ✓ | ✓ | ✓ | ✓ |
| 5.1.4  | Levetiracetam      | Tablet 250 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 500 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 750 mg                  | ✓ | ✓ | ✓ | ✗ |
|  |                    | Modified Release Tablet 750 mg | ✓ | ✓ | ✓ | ✗ |
|  |                    | Oral liquid 100 mg/mL (p)      | ✓ | ✓ | ✓ | ✗ |
|  |                    | Injection 100 mg/mL            | ✓ | ✓ | ✓ | ✗ |
| 5.1.5  | Lorazepam          | Tablet 1 mg                    | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 2 mg                    | ✓ | ✓ | ✓ | ✗ |
|  |                    | Injection 2 mg/mL              | ✓ | ✓ | ✓ | ✗ |
|  |                    | Injection 4 mg/mL              | ✓ | ✓ | ✓ | ✗ |
| <p><i>*Carbamazepine formulations are also listed in <b>Section 23.2.2.3 Medicines used in treatment of Psychiatric disorder - Medicines used in Bipolar disorders</b></i></p> <p><i>** Diazepam formulations are also listed in <b>Section 7.4.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care</b></i></p> |                    |                                |   |   |   |   |
| 5.1.6  | Magnesium sulphate | Injection 500 mg/mL            | ✓ | ✓ | ✓ | ✓ |
| 5.1.7  | Midazolam*         | Tablet 7.5 mg                  | ✓ | ✓ | ✗ | ✗ |
|  |                    | Tablet 15 mg                   | ✓ | ✓ | ✗ | ✗ |
|  |                    | Nasal Spray 0.5 mg/actuation   | ✓ | ✓ | ✓ | ✓ |
|  |                    | Nasal Spray 1.25 mg/actuation  | ✓ | ✓ | ✓ | ✓ |
|  |                    | Injection 1 mg/mL              | ✓ | ✓ | ✓ | ✗ |
|  |                    | Injection 5 mg/mL              | ✓ | ✓ | ✓ | ✗ |
| 5.1.8  | Phenobarbitone     | Tablet 30 mg                   | ✓ | ✓ | ✓ | ✗ |
|  |                    | Tablet 60 mg                   | ✓ | ✓ | ✓ | ✗ |

|   |                     |                                |   |   |   |   |
|---|---------------------|--------------------------------|---|---|---|---|
|   |                     | Oral liquid 20 mg/5 mL (p)     | ✓ | ✓ | ✓ | × |
|   |                     | Injection 200 mg/mL            | ✓ | ✓ | ✓ | × |
| 5.1.9   | Phenytoin           | Tablet 50 mg                   | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 100 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 300 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Modified Release Tablet 300 mg | ✓ | ✓ | ✓ | × |
|   |                     | Oral liquid 30 mg/5 mL (p)     | ✓ | ✓ | ✓ | × |
|   |                     | Oral liquid 125 mg/5 mL (p)    | ✓ | ✓ | ✓ | × |
|   |                     | Injection 25 mg/mL             | ✓ | ✓ | ✓ | × |
|   |                     | Injection 50 mg/mL             | ✓ | ✓ | ✓ | × |
| <p><i>*Midazolam formulations are also listed in -</i></p> <p><b>A. Section 1.3.3 - Medicines used in Anaesthesia - Preoperative Medication and Sedation for short term procedures</b></p> <p><b>B. Section 7.4.12 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care</b></p> |                     |                                |   |   |   |   |
| 5.1.10  | Sodium Valproate*   | Tablet 200 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 300 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 500 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Modified Release               | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 300 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 500 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Oral liquid 200 mg/5 mL (p)    | ✓ | ✓ | ✓ | × |
|   |                     | Injection 100 mg/mL            | ✓ | ✓ | ✓ | × |
| 5.1.11  | Tab Amisulpride     | Tablet 50 mg                   | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 100 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 200 mg                  | ✓ | ✓ | ✓ | × |
| 5.1.12  | Tab Aripirazole     | Tablet 10 mg                   | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 15 mg                   | ✓ | ✓ | ✓ | × |
| 5.1.13  | Tab Lurasidone      | Tablet 40 mg                   | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 80 mg                   | ✓ | ✓ | ✓ | × |
| 5.1.14  | Tab Quetiapine      | Tablet 50 mg                   | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 100 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 200 mg                  | ✓ | ✓ | ✓ | × |
| 5.1.15  | Tab Oxcarbamazepine | Tablet 150 mg                  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 300 mg                  | ✓ | ✓ | ✓ | × |
| <b>Section 5.2- Antimigraine Medicines</b>  |                     |                                |   |   |   |   |

|       |                        |   |   |   |   |   |
|-------|------------------------|---|---|---|---|---|
| 5.2.1 | Acetylsalicylic acid** | Tablet 75 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 75mg    | ✓ | ✓ | ✓ | × |
|       | Acetylsalicylic acid** | Tablet 150 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 150 mg | ✓ | ✓ | ✓ | × |
|       | Acetylsalicylic acid** | Tablet 300 mg Effervescent/<br>Dispersible/ Enteric coated<br>Tablet 300 mg | ✓ | ✓ | ✓ | × |

*\*Sodium Valproate formulations are also listed in-*

**Section 23.2.2.2 - Medicines used in treatment of Psychiatric Disorders -Medicines used in Bipolar disorders- Medicines used in mood disorders**

*\*\*Acetylsalicylic acid formulations are also listed in -*

**A. Section 2.1.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory**

*Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs*

**B. Section 10.5.1 - Cardiovascular medicines- Antiplatelet and Antithrombotic Medicines**

|  |                  |                             |   |   |   |   |
|--|------------------|-----------------------------|---|---|---|---|
| 5.2.2                                  | Ibuprofen*       | Tablet 200 mg               | ✓ | ✓ | ✓ | ✓ |
|  |                  | Tablet 400 mg               | ✓ | ✓ | ✓ | ✓ |
|  |                  | Oral liquid 100 mg/5 mL (p) | ✓ | ✓ | ✓ | ✓ |
| 5.2.3                                  | Paracetamol**    | Tablet 500 mg               | ✓ | ✓ | ✓ | ✓ |
|  |                  | Tablet 650 mg               | ✓ | ✓ | ✓ | ✓ |
|  |                  | Oral liquid 120 mg/5mL (p)  | ✓ | ✓ | ✓ | ✓ |
|  |                  | Oral Liquid 125 mg/5mL (p)  | ✓ | ✓ | ✓ | ✓ |
|  |                  | Oral Liquid 250 mg/5mL (p)  | ✓ | ✓ | ✓ | ✓ |
| 5.2.4                                  | Sumatriptan      | Tablet 25 mg                | ✓ | ✓ | × | × |
|  |                  | Tablet 50 mg                | ✓ | ✓ | × | × |
| <b>Section 5.2.1 - For Prophylaxis</b> |                  |                             |   |   |   |   |
| 5.2.1.1                                | Amitriptyline*** | Tablet 10 mg                | ✓ | ✓ | ✓ | × |
|  |                  | Tablet 25 mg                | ✓ | ✓ | ✓ | × |
|  |                  | Tablet 75 mg                | ✓ | ✓ | ✓ | × |

*\*Ibuprofen formulations are also listed in **Section 2.1.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs***

*\*\*Paracetamol formulations are also listed in -*

*A. **Section 2.1.5 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-opioid analgesics, antipyretics and nonsteroidal anti-inflammatory medicines***

*B. **Section 27.4 - Medicines for COVID 19 management***

*\*\*\* Amitriptyline formulations are also listed in -*

*A. **Section 7.4.2 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care-***

*B. **Section 23.2.1.1 - Medicines used in treatment of Psychiatric Disorders -Medicines used in mood disorders- Medicines used in depressive disorders***

|  |                                 |   |   |   |   |   |
|--|---------------------------------|---|---|---|---|---|
| 5.2.1.2  | Flunarizine                     | Tablet 5 mg                             | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 10 mg                            | ✓ | ✓ | ✓ | × |
| 5.2.1.3  | Propranolol                     | Tablet 10 mg                            | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 20 mg                            | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 40 mg                            | ✓ | ✓ | ✓ | × |
| <b>Section 5.3- Antiparkinsonism Medicines</b> |                                 |   |   |   |   |   |
| 5.3.1  | Levodopa (A) +<br>Carbidopa (B) | Tablet 100 mg (A) + 10 mg (B)           | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 100 mg (A) + 25 mg (B)           | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 250 mg (A) + 25 mg (B)           | ✓ | ✓ | ✓ | × |
|  |                                 | Modified Release -                      | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 100 mg (A) + 25 mg (B)           | ✓ | ✓ | ✓ | × |
|  |                                 | Tablet 200 mg (A) + 50 mg (B)           | ✓ | ✓ | ✓ | × |
| 5.3.2  | Trihexyphenidyl                 | Tablet 2 mg                             | ✓ | ✓ | × | × |
| <b>Section 5.4-Medicines used in Dementia</b>  |                                 |   |   |   |   |   |
| 5.4.1  | Donepezil                       | Tablet 5 mg                             | ✓ | ✓ | × | × |
|  |                                 | Tablet 10 mg                            | ✓ | ✓ | × | × |
| <b>Section 6</b>                               |                                 |   |   |   |   |   |
| <b>Anti-infective Medicines</b>                |                                 |   |   |   |   |   |
| <b>6.1-Anthelmintics</b>                       |                                 |   |   |   |   |   |
| <b>6.1.1- Intestinal Anthelmintics</b>         |                                 |   |   |   |   |   |
| 6.1.1.1  | Albendazole*                    | Tablet 400 mg Chewable Tablet<br>400 mg | ✓ | ✓ | ✓ | ✓ |
|  |                                 | Chewable Tablet 400 mg                  | ✓ | ✓ | ✓ | ✓ |

|   |                                       |   |   |   |   |   |
|---|---------------------------------------|---|---|---|---|---|
|   |                                       | Oral liquid 200 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| 6.1.1.2   | Mebendazole                           | Tablet 100 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Oral liquid 100 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| <b>6.1.2 Antifilarial</b>   |                                       |   |   |   |   |   |
| 6.1.2.1   | Albendazole*                          | Tablet 400 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Chewable Tablet 400 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Oral liquid 200 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| 6.1.2.2   | Diethylcarbamazine (DEC)              | Tablet 50 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Tablet 100 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Oral liquid 120 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| * Albendazole formulations are also listed <b>Section 6.1.1.1 - in Anti-infective Medicines- Antifilarial</b> |                                       |   |   |   |   |   |
| 6.1.2.3   | Ivermectin                            | Tablet 6 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Tablet 12 mg  | ✓ | ✓ | ✓ | ✓ |
| <b>6.1.3 - Anti-schistosomal and Anti-trematodal Medicine</b>   |                                       |   |   |   |   |   |
| 6.1.3.1   | Praziquantel                          | Tablet 600 mg   | ✓ | ✓ | ✓ | × |
| <b>6.2-Antibacterials</b>   |                                       |   |   |   |   |   |
| <b>6.2.1 Beta-lactam Medicines</b>  |                                       |   |   |   |   |   |
| 6.2.1.1   | Amoxicillin                           | Capsule 250 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Capsule 500 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Oral liquid 125 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Oral liquid 250 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Powder for Injection 250 mg   | ✓ | ✓ | ✓ | × |
|   |                                       | Powder for Injection 500 mg   | ✓ | ✓ | ✓ | × |
|   |                                       | Powder for injection 1000 mg  | ✓ | ✓ | ✓ | × |
| 6.2.1.2   | Amoxicillin (A) + Clavulanic acid (B) | Tablet 500 mg (A) + 125 mg (B)<br>Oral liquid 200 mg (A) + 28.5 mg (B)/5 mL (p) | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Dry Syrup 125 mg (A) + 31.25 (B)/ 5 mL (p)                                      | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Powder for Injection 500 mg (A) + 100 mg (B)                                    | ✓ | ✓ | ✓ | ✓ |
|   |                                       | Powder for Injection 1 g (A) + 200 mg (B)                                       | ✓ | ✓ | ✓ | ✓ |
| 6.2.1.3   | Ampicillin                            | Powder for Injection 500 mg   | ✓ | ✓ | ✓ | × |
|   |                                       | Powder for Injection 1000 mg  | ✓ | ✓ | ✓ | × |
| 6.2.1.4   | Benzathine                            | Powder for Injection 6 lac units  | ✓ | ✓ | ✓ | × |

|   |                                      |  |   |   |   |   |
|---|--------------------------------------|--|---|---|---|---|
|   | benzylpenicillin                     | Powder for Injection 12 lac units                          | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for injection 24 lac units                          | ✓ | ✓ | ✓ | × |
| 6.2.1.5   | Benzylpenicillin                     | Powder for injection 5 lac units                           | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for injection 10 lac units                          | ✓ | ✓ | ✓ | × |
| 6.2.1.6   | Cefadroxil                           | Tablet 500 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Tablet 100 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Oral liquid 125 mg/5 mL (p)                                | ✓ | ✓ | ✓ | × |
| 6.2.1.7   | Cefazolin                            | Powder for Injection 500 mg                                | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 1000 mg                               | ✓ | ✓ | ✓ | × |
| 6.2.1.8   | Cefixime                             | Tablet 200 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Tablet 400 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Oral liquid 50 mg/5 mL (p)                                 | ✓ | ✓ | ✓ | × |
|   |                                      | Oral liquid 100 mg/5 mL (p)                                | ✓ | ✓ | ✓ | × |
| 6.2.1.9   | Cefotaxime*                          | Powder for Injection 250 mg                                | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 500 mg                                | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 1000 mg                               | ✓ | ✓ | ✓ | × |
| <i>*Cefotaxime formulations are also listed in Section 6.7.5.2 - Anti-infective Medicines- Antiviral Medicines- Medicines for treating Opportunistic Infections in People living with HIV</i> |                                      |  |   |   |   |   |
| 6.2.1.10  | Ceftazidime                          | Powder for Injection 250 mg                                | ✓ | ✓ | × | × |
|   |                                      | Powder for Injection 1000 mg                               | ✓ | ✓ | × | × |
| 6.2.1.11  | Ceftriaxone                          | Powder for Injection 250 mg                                | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 500 mg                                | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 1000 mg                               | ✓ | ✓ | ✓ | × |
|   |                                      | Powder for Injection 2000 mg                               | ✓ | ✓ | ✓ | × |
| 6.2.1.12  | Cloxacillin                          | Capsule 250 mg   | ✓ | ✓ | ✓ | × |
|   |                                      | Capsule 500 mg   | ✓ | ✓ | ✓ | × |
|   |                                      | Oral Liquid 125 mg/5 mL (p)<br>Powder for Injection 250 mg | ✓ | ✓ | ✓ | × |
| 6.2.1.13  | Piperacillin (A) +<br>Tazobactam (B) | Powder for Injection 1000 mg<br>(A) + 125 mg (B)           | ✓ | ✓ | × | × |
|   |                                      | Powder for Injection 2000 mg<br>(A) + 250 mg (B)           | ✓ | ✓ | × | × |
|   |                                      | Powder for Injection 4000 mg<br>(A) + 500 mg (B)           | ✓ | ✓ | × | × |
| 6.2.1.14  | Meropenem                            | Powder for Injection 500 mg (as<br>trihydrate)             | ✓ | ✓ | × | × |

|   |  |   |   |   |   |   |
|---|--|---|---|---|---|---|
|   |  | Powder for Injection 1000 mg (as trihydrate)      | ✓ | ✓ | × | × |
| 6.2.1.15  | Ampicillin                                 | Cap 500mg   | ✓ | ✓ | ✓ | ✓ |
| 6.2.1.16  | Cefixime                                   | Tablet 100 mg                                     | ✓ | ✓ | ✓ | × |
|   |  | Tablet 200 mg                                     | ✓ | ✓ | ✓ | × |
| 6.2.1.17  | Zinc Acetate                               | Tablet 20mg Dispersible                           | ✓ | ✓ | ✓ | ✓ |
| 6.2.1.18  | Cloxacillin                                | Injection 500gm                                   | ✓ | ✓ | ✓ | × |
|   |  | Injection 1g                                      | ✓ | ✓ | ✓ | × |
| <b>6.2.2 - Other Antibacterials</b>   |  |   |   |   |   |   |
| 6.2.2.1   | Azithromycin*                              | Tablet 250 mg                                     | ✓ | ✓ | ✓ | × |
|   |  | Tablet 500 mg                                     | ✓ | ✓ | ✓ | × |
|   |  | Oral liquid 200 mg/5 mL (p)                       | ✓ | ✓ | ✓ | × |
|   |  | Powder for Injection 500 mg                       | ✓ | ✓ | ✓ | × |
| 6.2.2.2   | Cefuroxime                                 | Tablet 500 mg                                     | ✓ | ✓ | ✓ | × |
|   |  | Oral liquid 125 mg/ 5 mL (p)<br>Injection 1500 mg | ✓ | × | × | × |
| <i>*Azithromycin formulations are also listed in <b>Section 6.7.6.1</b> Anti-infective Medicines</i>                            |  |   |   |   |   |   |
| <i>Medicines used in the management of HIV- Additional Medicines for Syndromic Management of Sexually Transmitted Infection</i> |  |   |   |   |   |   |
| 6.2.2.3   | Ciprofloxacin*                             | Tablet 250 mg                                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Tablet 500 mg                                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Oral liquid 250 mg/ 5 mL (p)                      | ✓ | ✓ | ✓ | ✓ |
|   |  | Injection 200 mg/ 100 mL                          | ✓ | ✓ | ✓ | × |
| 6.2.2.4   | Clarithromycin**                           | Tablet 250 mg                                     | ✓ | ✓ | × | × |
|   |  | Tablet 500 mg                                     | ✓ | ✓ | × | × |
|   |  | Oral liquid 125 mg/5 mL (p)                       | ✓ | ✓ | × | × |
| 6.2.2.5   | Clindamycin***                             | Capsule 150 mg                                    | ✓ | ✓ | × | × |
|   |  | Capsule 300 mg                                    | ✓ | ✓ | × | × |
|   |  | Injection 150 mg /mL                              | ✓ | ✓ | × | × |
| 6.2.2.6   | Co-trimoxazole (A) + Trimethoprim (B)]**** | Tablet 400 mg (A) + 80 mg (B)                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Tablet 800 mg (A) + 160 mg (B)                    | ✓ | ✓ | ✓ | ✓ |
|   |  | Oral liquid 200 mg (A) + 40 mg (B)/5 mL (p)       | ✓ | ✓ | ✓ | ✓ |

\* Ciprofloxacin formulations are also listed in -

**A. Section 16.2 - Ear, Nose and Throat Medicines,**

**B. Section 21.1.2 - Ophthalmological Medicines- Anti-infective Medicines,**

\*\* Clarithromycin formulations are also listed in **Section 6.4.3 - Anti-infective medicines- Anti-tuberculosis Medicines**

\*\*\*Clindamycin formulations are also listed in -

**A. Section 6.7.5.3 - Anti-infective Medicines- Antiviral Medicines- Medicines for treating Opportunistic Infections in People living with HIV**

**B. Section 6.9.3.1 - Anti-infective Medicines- Drugs for amoebiasis and other parasitic infections -Antipneumocystis and antitoxoplasmosis medicines**

**C. Section 6.10.1.5 - Anti-infective Medicines- Antimalarial medicines- For curative treatment**

\*\*\*\* Co-trimoxazole formulations are also listed in **Section 6.9.3.2 - Anti-infective Medicines- Medicines for amoebiasis and other parasitic infections -Antipneumocystis and antitoxoplasmosis medicines**

|          |                                |  |   |   |   |   |
|----------|--------------------------------|--|---|---|---|---|
| 6.2.2.7  | Doxycycline*                   | Capsule 100 mg                               | ✓ | ✓ | ✓ | × |
|          |                                | Dry Syrup 50 mg/5 mL (p)                     | ✓ | ✓ | ✓ | × |
|          |                                | Power for Injection 100 mg                   | ✓ | ✓ | ✓ | × |
| 6.2.2.8  | Gentamicin                     | Injection 10 mg/mL                           | ✓ | ✓ | ✓ | ✓ |
|          |                                | Injection 40 mg/mL                           | ✓ | ✓ | ✓ | ✓ |
| 6.2.2.9  | Metronidazole**                | Tablet 200 mg                                | ✓ | ✓ | ✓ | ✓ |
|          |                                | Tablet 400 mg                                | ✓ | ✓ | ✓ | ✓ |
|          |                                | Oral liquid 200 mg/5 mL (p)                  | ✓ | ✓ | ✓ | ✓ |
|          |                                | Injection 500 mg/100 mL                      | ✓ | ✓ | ✓ | ✓ |
| 6.2.2.10 | Nitrofurantoin                 | Tablet 100 mg                                | ✓ | ✓ | ✓ | × |
|          |                                | Oral liquid 25 mg/5 mL (p)                   | ✓ | ✓ | ✓ | × |
| 6.2.2.11 | Phenoxymethyl penicillin       | Tablet 250 mg                                | ✓ | ✓ | ✓ | ✓ |
| 6.2.2.12 | Procaine Benzylpenicillin      | Powder for injection 1000 mg (=1 million IU) | ✓ | × | × | × |
| 6.2.2.13 | Vancomycin                     | Capsule 125 mg                               | ✓ | × | × | × |
|          |                                | Capsule 250 mg                               | ✓ | × | × | × |
|          |                                | Powder for Injection 250 mg                  | ✓ | × | × | × |
|          |                                | Powder for Injection 500 mg                  | ✓ | × | × | × |
|          |                                | Powder for Injection 1000 mg                 | ✓ | × | × | × |
| 6.2.2.14 | OFLOXACIN (A) + ORNIDAZOLE (B) | TAB 200MG (A) + 500MG (B)                    | ✓ | ✓ | ✓ | × |
|          |                                | Tab 100mg (A) + 250mg (B)                    | ✓ | ✓ | ✓ | × |

\*Doxycycline formulations are also listed in **Section 6.10.2.1 - Anti-infective Medicines- Antimalarial medicines- For prophylaxis**

\*\*Metronidazole formulations are also listed in **Section 6.9.1.1 - Anti-infective Medicines - Antiprotozoal Medicines - Medicines for amoebiasis and other parasitic infections**



| 6.3 - Antileprosy Medicines   |                       |                              |   |   |   |   |
|---|-----------------------|------------------------------|---|---|---|---|
| 6.3.1   | Clofazimine*          | Capsule 50 mg                | ✓ | ✓ | ✓ | × |
|   |                       | Capsule 100 mg               | ✓ | ✓ | ✓ | × |
| 6.3.2   | Dapsone               | Tablet 50 mg                 | ✓ | ✓ | ✓ | × |
|   |                       | Tablet 100 mg                | ✓ | ✓ | ✓ | × |
| 6.3.3   | Rifampicin**          | Capsule 150 mg               | ✓ | ✓ | ✓ | × |
|   |                       | Capsule 300 mg               | ✓ | ✓ | ✓ | × |
| 6.4-Antituberculosis Medicines  |                       |                              |   |   |   |   |
| 6.4.1   | Amikacin              | Injection 100 mg/mL          | ✓ | ✓ | ✓ | × |
|   |                       | Injection 250 mg/mL          | ✓ | ✓ | ✓ | × |
|   |                       | Injection 500 mg/mL          | ✓ | ✓ | ✓ | ✓ |
| 6.4.2   | Bedaquiline           | Tablet 100 mg                | ✓ | ✓ | ✓ | ✓ |
| 6.4.3   | Clarithromycin**<br>* | Tablet 250 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 500 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 750 mg                | ✓ | ✓ | ✓ | ✓ |
| <p><i>*Clofazimine formulations are also listed Section 6.4.5 - Anti-infective Medicines - Anti-tuberculosis medicines</i></p> <p><i>**Rifampicin formulations are also listed in Section 6.4.15 - Anti-infective Medicines - Anti-tubercular medicine</i></p> <p><i>***Clarithromycin formulations are also listed in Section 6.2.2.4 - Anti-infective Medicines- Antibacterials -Other Antibacterials</i></p> |                       |                              |   |   |   |   |
| 6.4.4   | Clofazimine*          | Capsule 50 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Capsule 100 mg               | ✓ | ✓ | ✓ | ✓ |
| 6.4.5   | Cycloserine           | Capsule 125 mg (Dispersible) | ✓ | ✓ | ✓ | ✓ |
|   |                       | Capsule 250 mg               | ✓ | ✓ | ✓ | ✓ |
| 6.4.6   | Delamanid             | Tablet 50 mg                 | ✓ | ✓ | ✓ | ✓ |
| 6.4.7   | Ethambutol            | Tablet 200 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 400 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 600 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 800 mg                | ✓ | ✓ | ✓ | ✓ |
| 6.4.8   | Ethionamide           | Tablet 125 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 250 mg                | ✓ | ✓ | ✓ | ✓ |
| 6.4.9   | Isoniazid             | Tablet 100 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 300 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Oral Liquid 50 mg/5 mL (p)   | ✓ | ✓ | ✓ | ✓ |
| 6.4.10  | Levofloxacin          | Tablet 250 mg                | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 500 mg                | ✓ | ✓ | ✓ | ✓ |

|  |  |  |   |   |   |   |
|--|--|--|---|---|---|---|
|  |  | Tablet 750 mg  | ✓ | ✓ | ✓ | ✓ |
| 6.4.11   | Linezolid                              | Tablet 300 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 600 mg  | ✓ | ✓ | ✓ | ✓ |
| 6.4.12   | Moxifloxacin                           | Tablet 400 mg  | ✓ | ✓ | ✓ | ✓ |
| <i>*Clofazimine formulations are also listed in Section 6.3.1 - Anti-infective Medicines - Antileprosy medicines</i> |  |  |   |   |   |   |
| 6.4.13   | Para-aminosalicylic acid               | Granules (As licensed)                                 | ✓ | ✓ | ✓ | ✓ |
| 6.4.14   | Pyrazinamide                           | Tablet 500 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 750 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 1000 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 1500 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Oral liquid 250 mg/5 mL (p)                            | ✓ | ✓ | ✓ | ✓ |
| 6.4.15   | Rifampicin*                            | Capsule 150 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Capsule 300 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Capsule 450 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Capsule 600 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Oral liquid 100 mg/ 5 mL (p)                           | ✓ | ✓ | ✓ | ✓ |
| 6.4.16   | Streptomycin                           | Powder for Injection 750 mg                            | ✓ | ✓ | ✓ | ✓ |
|  |  | Powder for Injection 1000 mg                           | ✓ | ✓ | ✓ | ✓ |
| 6.4.17   | 3FDC CP (A) (H75,R150 & E275)          | 3FDC CP (A) (H75,R150 & E275)<br>Blister of 28 Tabs    | ✓ | ✓ | ✓ | ✓ |
| 6.4.18   | 2FDC (P) (H50 & R75)                   | 2FDC (P) (H50 & R75)<br>Blister of 28 Tabs             | ✓ | ✓ | ✓ | ✓ |
| 6.4.19   | 3FDC(P) (H50, R75, Z150)               | 3FDC(P) (H50, R75, Z150)<br>Blister of 28 Tabs         | ✓ | ✓ | ✓ | ✓ |
| 6.4.20   | 4FDC(A) (H75, R150, Z400 & E275)       | 4FDC(A) (H75, R150, Z400 & E275)<br>Blister of 28 Tabs | ✓ | ✓ | ✓ | ✓ |
| 6.4.21   | Inj Kanamycin                          | 500mg Vial/Ampules                                     | ✓ | ✓ | ✓ | ✓ |
| 6.4.22   | Pyridoxine                             | 100mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.23   | Inj Kanamycin                          | 1000mg Vial/Ampules                                    | ✓ | ✓ | ✓ | ✓ |
| 6.4.24   | Ethionamide                            | 125mg (Dispersible) Tab                                | ✓ | ✓ | ✓ | ✓ |
| 6.4.25   | Pyridoxine                             | 50mg Tab   | ✓ | ✓ | ✓ | ✓ |
| 6.4.26   | Na PAS Sodium Aminosalicylate Granules | 9.2 gm Sachet  | ✓ | ✓ | ✓ | ✓ |

|   |                     |   |   |   |   |   |
|---|---------------------|---|---|---|---|---|
| 6.4.27  | Rifabutin           | 150mg Cap   | ✓ | ✓ | ✓ | ✓ |
| 6.4.28  | Inj Capreomycin     | 750mg Vial/Ampules                                      | ✓ | ✓ | ✓ | ✓ |
| 6.4.29  | Inj Capreomycin     | 1000mg Vial/Ampules                                     | ✓ | ✓ | ✓ | ✓ |
| 6.4.30  | Inj Capreomycin     | 500mg Vial/Ampules                                      | ✓ | ✓ | ✓ | ✓ |
| 6.4.31  | Amx                 | 1000mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.32  | Pyrazinamide        | 400mg Tab   | ✓ | ✓ | ✓ | ✓ |
| 6.4.33  | Ethambutol          | 100mg Tab   | ✓ | ✓ | ✓ | ✓ |
| 6.4.34  | Ethambutol          | 100 MG (Dispersible) Tab                                | ✓ | ✓ | ✓ | ✓ |
| 6.4.35  | Isoniazid           | 50mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.36  | Rifampicin          | 75mg Cap  | ✓ | ✓ | ✓ | ✓ |
| 6.4.37  | Pyrazinamide        | 150mg Tab   | ✓ | ✓ | ✓ | ✓ |
| 6.4.38  | Pyrazinamide        | 150mg (Dispersible) Tab                                 | ✓ | ✓ | ✓ | ✓ |
| 6.4.39  | Isoniazid           | 75mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.40  | Pyridoxine          | 25mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.41  | Inj Streptomycin    | 500mg Vial/Ampules                                      | ✓ | ✓ | ✓ | ✓ |
| 6.4.42  | PPD Vials           | Vial/Ampules  | ✓ | ✓ | ✓ | ✓ |
| 6.4.43  | Water for Injection | Ampules   | ✓ | ✓ | ✓ | ✓ |
| 6.4.44  | Pyridoxine          | 40mg Tab  | ✓ | ✓ | ✓ | ✓ |
| 6.4.45  | Levofloxacin        | 100mg (Dispersible) Tab                                 | ✓ | ✓ | ✓ | ✓ |
| 6.4.46  | Moxifloxacin        | 100mg (Dispersible) Tab                                 | ✓ | ✓ | ✓ | ✓ |
| 6.4.47  | Bedaquiline         | 20 MG Jar   | ✓ | ✓ | ✓ | ✓ |
| <b>6.5 - Antifungal Medicines</b>   |                     |   |   |   |   |   |
| 6.5.1   | Amphotericin B**    | a) Amphotericin B (conventional) - Injection 50 mg/vial | ✓ | ✓ | × | × |
|   |                     | b) Lipid Amphotericin B - Injection 50 mg/vial          | ✓ | ✓ | × | × |
|   |                     | c) Liposomal Amphotericin B - Injection 50 mg/vial      | ✓ | ✓ | × | × |
| <i>*Rifampicin formulations are also listed in Section 6.3.3 - Anti-infective Medicines- Antileprosy medicines</i>          |                     |   |   |   |   |   |
| <i>**Amphotericin B formulations are also listed Section 6.9.2.1 - Anti-infective Medicines Antileishmaniasis medicines</i> |                     |   |   |   |   |   |
| 6.5.2   | Clotrimazole*       | Pessary 100 mg  | ✓ | ✓ | ✓ | ✓ |
| 6.5.3   | Fluconazole         | Tablet 50 mg  | ✓ | ✓ | ✓ | × |
|   |                     | Tablet 100 mg   | ✓ | ✓ | ✓ | × |

|       |              |                             |   |   |   |   |
|-------|--------------|-----------------------------|---|---|---|---|
|       |              | Tablet 150 mg               | ✓ | ✓ | ✓ | × |
|       |              | Tablet 200 mg               | ✓ | ✓ | ✓ | × |
|       |              | Tablet 400 mg               | ✓ | ✓ | ✓ | × |
|       |              | Oral liquid 50 mg/ 5 mL (p) | ✓ | ✓ | ✓ | × |
|       |              | Injection 200 mg / 100 mL   | ✓ | ✓ | ✓ | × |
| 6.5.4 | Griseofulvin | Tablet 125 mg               | ✓ | ✓ | × | × |
|       |              | Tablet 250 mg               | ✓ | ✓ | × | × |
|       |              | Tablet 375 mg               | ✓ | ✓ | × | × |
| 6.5.5 | Itraconazole | Capsule 100 mg              | ✓ | ✓ | ✓ | × |
|       |              | Capsule 200 mg              | ✓ | ✓ | ✓ | × |
|       |              | Oral liquid 10 mg/mL        | ✓ | ✓ | ✓ | × |
| 6.5.6 | Mupirocin    | Ointment 2%                 | ✓ | ✓ | ✓ | ✓ |
| 6.5.7 | Nystatin     | Pessary 1 Lac IU            | ✓ | ✓ | ✓ | × |
|       |              | Oral Liquid 1 Lac IU/mL (p) | ✓ | ✓ | ✓ | × |
| 6.5.8 | Terbinafine  | Cream 1%                    | ✓ | ✓ | ✓ | × |
| 6.5.9 | Voriconazole | Tablet 200 mg               | ✓ | ✓ | × | × |
|       |              | injection 200 mg/ml i/v     | ✓ | ✓ | × | × |

*\*Clotrimazole formulations are also listed in -*

**A. Section 6.7.5.4 - Anti-infective Medicines Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV**

**B. Section 11.1.1 - Dermatological Medicines (Topical)- Antifungal medicines**

**C. Section 16.3 - Ear, Nose and Throat Medicines**

| <b>6.6 - Antiviral Medicines</b>    |                     |                             |   |   |   |   |
|-------------------------------------|---------------------|-----------------------------|---|---|---|---|
| <b>6.6.1 - Antiherpes Medicines</b> |                     |                             |   |   |   |   |
| 6.6.1.1                             | Acyclovir*          | Tablet 200 mg               | ✓ | ✓ | ✓ | × |
|                                     |                     | Tablet 400 mg               | ✓ | ✓ | ✓ | × |
|                                     |                     | Tablet 800 mg               | ✓ | ✓ | ✓ | × |
|                                     |                     | Powder for Injection 250 mg | ✓ | ✓ | × | × |
|                                     |                     | Powder for Injection 500 mg | ✓ | ✓ | × | × |
|                                     |                     | Oral liquid 400 mg/5 mL (p) | ✓ | ✓ | ✓ | × |
| 6.6.1.2                             | Famciclovir 500 mg  | Famciclovir 500 mg          | ✓ | ✓ | × | × |
| 6.6.1.3                             | Famciclovir 250 mg  | Famciclovir 250 mg          | ✓ | ✓ | × | × |
| 6.6.1.4                             | Valaciclovir 500 mg | Valaciclovir 500 mg         | ✓ | ✓ | × | × |
| 6.6.1.5                             | Valaciclovir 1 gm   | Valaciclovir 1 gm           | ✓ | ✓ | × | × |

| 6.6.2 - Anti-cytomegalovirus (CMV) medicines   |   |   |   |   |   |   |
|--|---|---|---|---|---|---|
| 6.6.2.1  | Valganciclovir**  | Tablet 450 mg                             | ✓ | ✓ | × | × |
|  |   | Powder for oral solution 50 mg/mL         | ✓ | ✓ | × | × |
| <b>6.7- Medicines used in the Management of HIV</b>  |   |   |   |   |   |   |
| <b>6.7.1 Nucleoside Reverse Transcriptase Inhibitors</b>   |   |   |   |   |   |   |
| 6.7.1.1  | Abacavir  | Tablet 60 mg (p)                          | ✓ | ✓ | ✓ | × |
|  |   | Tablet 300 mg                             | ✓ | ✓ | ✓ | × |
| *Acyclovir formulations are also listed in -   |   |   |   |   |   |   |
| <b>A. Section 6.7.5.1 - Anti-infective Medicines -Medicines used in the management of HIV - Medicines for treating Opportunistic Infections in People living with HIV</b>                          |   |   |   |   |   |   |
| <b>B. Section 21.1.1 - Ophthalmological Medicines- Anti-infective medicine</b>   |   |   |   |   |   |   |
| **Valganciclovir formulations are also listed in <b>Section 6.7.5.5 - Anti-infective Medicines- Antiviral medicines -Medicines for treating Opportunistic Infections in People living with HIV</b> |   |   |   |   |   |   |
| 6.7.1.2  | Abacavir (A) + Lamivudine (B)                                       | Tablet 60 mg (A) + 30 mg (B) (p)          | ✓ | ✓ | ✓ | × |
|  |   | Tablet 600 mg (A) + 300 mg (B)            | ✓ | ✓ | ✓ | × |
| 6.7.1.3  | Lamivudine  | Tablet 100 mg                             | ✓ | ✓ | ✓ | × |
|  |   | Tablet 150 mg                             | ✓ | ✓ | ✓ | × |
| 6.7.1.4  | Tenofovir Disproxil Fumarate (TDF)*                                 | Tablet 300 mg                             | ✓ | ✓ | ✓ | × |
| 6.7.1.5  | Tenofovir Disproxil Fumarate (A) + Lamivudine (B)                   | Tablet 300 mg (A) + 300 mg (B)            | ✓ | ✓ | ✓ | × |
| 6.7.1.6  | Tenofovir Disproxil Fumarate (A) + Lamivudine (B) +Dolutegravir (C) | Tablet 300 mg (A) + 300 mg (B)+ 50 mg ©   | ✓ | ✓ | ✓ | × |
| 6.7.1.7  | Tenofovir Disproxil Fumarate (A) + Lamivudine (B) + Efavirenz (C)   | Tablet 300 mg (A) + 300 mg (B) + 600 mg © | ✓ | ✓ | ✓ | × |
| 6.7.1.8  | Zidovudine  | Tablet 300 mg                             | ✓ | ✓ | ✓ | × |
|  |   | Oral liquid 50 mg/5 mL (p)                | ✓ | ✓ | ✓ | × |
| 6.7.1.9  | Zidovudine (A) + Lamivudine (B)                                     | Tablet 60 mg (A) + 30 mg (B) (p)          | ✓ | ✓ | ✓ | × |
|  |   | Tablet 300 mg (A) + 150 mg (B)            | ✓ | ✓ | ✓ | × |

\* *Tenofovir Disoproxil Fumarate formulations are also listed in Section 6.8.6 -*

*Anti-infective Medicines Medicines used in Hepatitis B and Hepatitis C*

|  |  |  |   |   |   |   |
|--|--|--|---|---|---|---|
| 6.7.1.10   | Zidovudine (A) + Lamivudine (B) + Nevirapine (C) | Tablet 60 mg (A) + 30 mg (B) + 50 mg (C) (p)                           | ✓ | ✓ | ✓ | × |
|  |  | Tablet 300 mg (A) + 150 mg (B) + 200 mg (C)                            | ✓ | ✓ | ✓ | × |
| <b>6.7.2 Non-nucleoside Reverse Transcriptase Inhibitors</b>                           |  |  |   |   |   | × |
| 6.7.2.1  | Efavirenz  | Tablet 200 mg (p)  | ✓ | ✓ | ✓ | × |
|  |  | Tablet 600 mg  | ✓ | ✓ | ✓ | × |
| 6.7.2.2  | Nevirapine                                       | Tablet 200 mg  | ✓ | ✓ | ✓ | × |
|  |  | Dispersible Tablet 50 mg (p)   | ✓ | ✓ | ✓ | × |
|  |  | Oral liquid 50 mg/ 5 mL (p)  | ✓ | ✓ | ✓ | × |
| <b>6.7.3 Integrase Inhibitors</b>  |  |  |   |   |   | × |
| 6.7.3.1  | Dolutegravir                                     | Tablet 50 mg   | ✓ | ✓ | ✓ | × |
| 6.7.3.2  | Raltegravir                                      | Tablet 400 mg  | ✓ | ✓ | ✓ | × |
| <b>6.7.4 Protease Inhibitors</b>   |  |  |   |   |   | × |
| 6.7.4.1  | Atazanavir (A) + Ritonavir (B)                   | Tablet 300 mg (A) + 100 mg (B)   | ✓ | ✓ | ✓ | × |
|  |  | Tablet 100 mg (B)  | ✓ | ✓ | ✓ | × |
| 6.7.4.2  | Darunavir  | Tablet 600 mg  | ✓ | ✓ | ✓ | × |
| 6.7.4.3  | Darunavir (A) + Ritonavir (B)                    | Tablet 600 mg (A) + 100 mg (B)   | ✓ | ✓ | ✓ | × |
|  |  | Tablet 100 mg (B)  | ✓ | ✓ | ✓ | × |
| 6.7.4.4  | Lopinavir (A) + Ritonavir (B)                    | Tablet 100 mg (A) + 25 mg (B)  | ✓ | ✓ | ✓ | × |
|  |  | Tablet 200 mg (A) + 50 mg (B)  | ✓ | ✓ | ✓ | × |
|  |  | Oral Liquid 80 mg (A) + 20 mg (B) /mL (p)                              | ✓ | ✓ | ✓ | × |
|  |  | Capsule/ Sachet (containing pellets/granules) 40 mg (A) +10 mg (B) (p) | ✓ | ✓ | ✓ | × |
| 6.7.4.5  | Ritonavir  | Tablet 100 mg  | ✓ | ✓ | ✓ | × |
| <b>6.7.5 Medicines for treating Opportunistic Infections in People living with HIV</b> |  |  |   |   |   |   |
| 6.7.5.1  | Acyclovir*                                       | Injection 250 mg   | ✓ | ✓ | × | × |
| 6.7.5.2  | Cefotaxime**                                     | Injection 1000 mg  | ✓ | ✓ | ✓ | × |
| 6.7.5.3  | Clindamycin***                                   | Tablet 300 mg  | ✓ | ✓ | ✓ | × |

\*Acyclovir formulations are also listed in -

**A. Section 6.6.1.1 - Anti-infective Medicines -Antiviral medicines -Anti-herpes medicines**

**B. Section 21.1.1 - Ophthalmological Medicines- Anti-infective Medicine**

\*\* Cefotaxime formulations are also listed in **Section 6.2.1.9 - Anti-infective Medicines - Antibacterials- Beta-Lactam medicines**

\*\*\*Clindamycin formulations are also listed in **-A. Section 6.2.2.5 - Anti-infective Medicines - Antibacterials -Other antibacterials**

**B. Section 6.9.3.1 - Anti-infective Medicines - Medicines for amoebiasis and other parasitic infections - Antipneumocystis and antitoxoplasmosis medicines**

**C. Section 6.10.1.5 - Anti-infective Medicines - Antimalarial medicines- For curative treatment**

|   |                  |                            |   |   |   |   |
|---|------------------|----------------------------|---|---|---|---|
| 6.7.5.4   | Clotrimazole*    | Ointment 1 %               | ✓ | ✓ | ✓ | ✓ |
| 6.7.5.5   | Valganciclovir** | Tablet/Capsule 450 mg      | ✓ | ✓ | ✓ | × |
| <b>6.7.6 Additional Medicines for Syndromic Management of Sexually Transmitted Infections</b> |                  |                            |   |   |   |   |
| 6.7.6.1   | Azithromycin***  | Tablet 1000 mg             | ✓ | ✓ | ✓ | ✓ |
| <b>Section 6.8 -Medicines used in Hepatitis B and Hepatitis C</b>                             |                  |                            |   |   |   |   |
| 6.8.1   | Daclatasvir      | Tablet 30 mg               | ✓ | ✓ | ✓ | × |
|   |                  | Tablet 60 mg               | ✓ | ✓ | ✓ | × |
| 6.8.2   | Entecavir        | Tablet 0.5 mg              | ✓ | ✓ | ✓ | × |
|   |                  | Tablet 1 mg                | ✓ | ✓ | ✓ | × |
|   |                  | Oral liquid 0.05 mg/mL (p) | ✓ | ✓ | ✓ | × |

\*Clotrimazole formulations are also listed in -

**A. Section 6.5.2 - Anti-infective Medicines -Antifungal medicines**

**B. Section 11.1.1 - Dermatological Medicines (Topical)- Antifungal medicines**

**C. Section 16.3 - Ear, Nose and Throat Medicines**

\*\*Valganciclovir formulations are also listed in **Section 6.6.2.1 - Anti-infective Medicines - Antiviral medicines -Anti Cytomegalovirus (CMV) medicines**

\*\*\*Azithromycin formulations are also listed in **Section 6.2.2.1 - Anti-infective Medicines - Other antibacterials**

|  |                                      |                |   |   |   |   |
|--|--------------------------------------|----------------|---|---|---|---|
| 6.8.3  | Ribavirin                            | Capsule 200 mg | ✓ | ✓ | ✓ | × |
| 6.8.4  | Sofosbuvir                           | Tablet 400 mg  | ✓ | ✓ | ✓ | × |
| 6.8.5  | Tenofovir Alafenamide Fumarate (TAF) | Tablet 25 mg   | ✓ | ✓ | ✓ | × |
| 6.8.6  | Tenofovir Disproxil Fumarate (TDF)*  | Tablet 300 mg  | ✓ | ✓ | ✓ | × |
| <b>Section 6.9 -Antiprotozoal Medicines</b>                            |                                      |                |   |   |   |   |
| <b>6.9.1 - Medicines for Amoebiasis and other Parasitic Infections</b> |                                      |                |   |   |   |   |
| 6.9.1.1  | Metronidazole**                      | Tablet 200 mg  | ✓ | ✓ | ✓ | ✓ |

|   |  |   |   |   |   |   |
|---|--|---|---|---|---|---|
|   |  | Tablet 400 mg                                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Injection 500 mg/100 mL                           | ✓ | ✓ | ✓ | ✓ |
|   |  | Oral liquid 200 mg/5 mL (p)                       | ✓ | ✓ | ✓ | ✓ |
| * <i>Tenofovir Disproxil Fumarate formulations are also listed in <b>Section 6.7.1.4</b> -</i>  |  |   |   |   |   |   |
| <i>Anti-infective Medicines Medicines used in the management of HIV- Nucleoside reverse transcriptase inhibitors</i>  |  |   |   |   |   |   |
| <i>** Metronidazole formulations are also listed in <b>Section 6.2.2.9</b> - Anti-infective Medicines - Antibacterials Beta-lactam medicines - Other antibacterials</i> |  |   |   |   |   |   |
| <b>6.9.2 - Antileishmaniasis Medicines</b>  |  |   |   |   |   |   |
| 6.9.2.1   | Amphotericin B*  | a) Amphotericin B (conventional)- Injection 50 mg | ✓ | × | × | × |
|   |  | b) Lipid Amphotericin B- Injection 50 mg          | ✓ | × | × | × |
|   |  | c) Liposomal Amphotericin B- Injection 50 mg      | ✓ | × | × | × |
| 6.9.2.2   | Miltefosine  | Capsule 50 mg                                     | ✓ | × | × | × |
| 6.9.2.3   | Paromomycin  | Injection 375 mg/mL                               | ✓ | × | × | × |
| <b>6.9.3 - Antipneumocystosis and Antitoxoplasmosis Medicines</b>   |  |   |   |   |   |   |
| 6.9.3.1   | Clindamycin**  | Capsule 150 mg                                    | ✓ | ✓ | ✓ | × |
|   |  | Capsule 300 mg                                    | ✓ | ✓ | ✓ | × |
| * <i>Amphotericin B formulations are also listed in <b>Section 6.5.1</b> - Anti-infective Medicines- Antifungal medicines</i>   |  |   |   |   |   |   |
| <i>**Clindamycin formulations are also listed in -</i>  |  |   |   |   |   |   |
| <i>A. <b>Section 6.2.2.5</b> - Anti-infective Medicines - Antibacterials -Other antibacterials</i>  |  |   |   |   |   |   |
| <i>B. <b>Section 6.7.5.3</b> - Anti-infective Medicines - Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV</i>            |  |   |   |   |   |   |
| <i>C. <b>Section 6.10.1.5</b> - Anti-infective Medicines- Antimalarial Medicines - For curative treatment</i>   |  |   |   |   |   |   |
| 6.9.3.2   | Co-trimoxazole* [Sulphamethoxazole (A) + Trimethoprim (B)] | Tablet 400 mg (A) + 80 mg (B)                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Tablet 800 mg (A) + 160 mg (B)                    | ✓ | ✓ | ✓ | ✓ |
|   |  | Oral liquid 200 mg (A) +40 mg (B)/5 mL (p)        | ✓ | ✓ | ✓ | ✓ |
| <b>6.10-Antimalarial Medicines</b>  |  |   |   |   |   |   |
| <b>6.10.1 - For curative treatment</b>  |  |   |   |   |   |   |
| 6.10.1.1  | Artemether (A) + Lumefantrine (B)                          | Tablet 20 mg (A) + 120 mg (B)                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Tablet 40 mg (A) + 240 mg (B)                     | ✓ | ✓ | ✓ | ✓ |
|   |  | Tablet 80 mg (A) + 480 mg (B)                     | ✓ | ✓ | ✓ | ✓ |



|  |  |  |   |   |   |   |
|--|--|--|---|---|---|---|
| 6.10.1.2   | Artesunate   | Powder for Injection 60 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Powder for Injection 120 mg  | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.3   | Artesunate (A) + Sulphadoxine - Pyrimethamine (B)  | Combi pack (A+B)   | ✓ | ✓ | ✓ | ✓ |
|  |  | 1 Tablet 25 mg (A) + 1 Tablet (250 mg + 12.5 mg) (B)   | ✓ | ✓ | ✓ | ✓ |
|  |  | 1 Tablet 50 mg (A) + 1 Tablet (500 mg + 25 mg) (B)   | ✓ | ✓ | ✓ | ✓ |
|  |  | 1 Tablet 100 mg (A) + 1 Tablet (750 mg + 37.5 mg) (B)  | ✓ | ✓ | ✓ | ✓ |
|  |  | 1 Tablet 150 mg (A) + 2 Tablet (500 mg + 25 mg) (B)  | x | x | ✓ | ✓ |
|  |  | 1 Tablet 200 mg (A) + 2 Tablet (750 mg + 37.5 mg) (B)  | x | x | ✓ | ✓ |
| <i>*Co-trimoxazole formulations are also listed in Section 6.2.2.6 - Anti-infective Medicines- Antibacterials - Other antibacterials</i> |  |  |   |   |   |   |
| 6.10.1.4   | Chloroquine  | Tablet 150 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Oral liquid 50 mg/5 mL   | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.5   | Clindamycin*   | Capsule 150 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Capsule 300 mg   | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.6   | Primaquine   | Tablet 2.5 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 7.5 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 15 mg   | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.7   | Quinine Sulphate   | Tablet 300 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Injection 300 mg/mL  | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.8   | Chloroquine Phosphate  | 250 mg Tablet  | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.9   | Artemisinin-based Combination Therapy- Artemether+Lumefantrine (ACT-AL) 6m-3years (Artemether 20 mg Lumefantrine 120 mg) | Artemisinin-based Combination Therapy- Artemether+Lumefantrine (ACT-AL) 6m-3years (Artemether 20 mg Lumefantrine 120 mg) kit (6 tablets in 1 strip ) | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.10  | Artemisinin-based Combination Therapy- Artemether+Lumefantrine (ACT-AL) 4-8 years (Artemether 20 mg Lumefantrine 120 mg) | Artemisinin-based Combination Therapy- Artemether+Lumefantrine (ACT-AL) 4-8 years (Artemether 20 mg Lumefantrine 120 mg) kit (12 tablets in 1 strip) | ✓ | ✓ | ✓ | ✓ |

|                                 |  |  |   |   |   |   |
|---------------------------------|--|--|---|---|---|---|
|                                 | mg Lumefantrine<br>120 mg)   |  |   |   |   |   |
| 6.10.1.11                       | Artemisinin-based<br>Combination<br>Therapy-<br>Artemether+Lum<br>efantrine (ACT-<br>AL) 9-14 years<br>(Artemether 20<br>mg Lumefantrine<br>120 mg)  | Artemisinin-based Combination<br>Therapy-<br>Artemether+Lumefantrine<br>(ACT-AL) 9-14 years<br>(Artemether 20 mg<br>Lumefantrine 120 mg)<br>kit (18 tablets in 1 strip)                | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.12                       | Artemisinin-based<br>Combination<br>Therapy-<br>Artemether+Lum<br>efantrine (ACT-<br>AL) > 15 years<br>(Artemether 20<br>mg Lumefantrine<br>120 mg)  | Artemisinin-based Combination<br>Therapy-<br>Artemether+Lumefantrine<br>(ACT-AL) > 15 years<br>(Artemether 20 mg<br>Lumefantrine 120 mg)<br>kit (24 tablets in 1 strip)                | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.13                       | Quinine<br>Dihydrochloride<br>Injection  | 300 mg/2 ml Ampoules   | ✓ | ✓ | ✓ | ✓ |
| 6.10.1.14                       | Artesunate<br>Injection IP<br>(sterile) 60 mg<br>with 1 ml<br>ampoule of<br>Sodium<br>Bicarbonate<br>injection IP 5%<br>w/v and 5 ml<br>ampoule of<br>sodium chloride<br>injection IP 0.9%<br>w/v. | Artesunate Injection IP (sterile)<br>60 mg with 1 ml ampoule of<br>Sodium Bicarbonate injection IP<br>5% w/v and 5 ml ampoule of<br>sodium chloride injection IP<br>0.9% w/v.<br>Vials | ✓ | ✓ | ✓ | ✓ |
| <b>6.10.2 - For prophylaxis</b> |  |  |   |   |   |   |
| 6.10.2.1                        | Doxycycline**#   | Capsule 100 mg   | ✓ | ✓ | ✓ | ✓ |
|                                 |  | Oral liquid 50 mg/ 5mL   | ✓ | ✓ | ✓ | ✓ |
|                                 |  | #for prophylaxis of <i>P. vivax</i>  | ✓ | ✓ | ✓ | ✓ |
| 6.10.2.2                        | Mefloquine#  | Tablet 250 mg  | × | × | ✓ | ✓ |

|   |                            |   |   |   |   |   |
|---|----------------------------|---|---|---|---|---|
|   |                            | #Only for use as chemoprophylaxis for long term travellers like military and travel troops, travelling from low endemic to high endemic area. | x | x | ✓ | ✓ |
| * Clindamycin formulations are also listed in -<br><b>A. Section 6.2.2.5 - Anti-infective Medicines - Antibacterials -Other antibacterials</b><br><b>B. Section 6.7.5.3 - Anti-infective Medicines - Antiviral medicines- Medicines for treating Opportunistic Infections in People living with HIV</b><br><b>C. Section 6.9.3.1 - Anti-infective Medicines - Antipneumocystis and antitoxoplasmosis medicines</b><br><br>** Doxycycline formulations are also listed in <b>Section 6.2.2.7 - Anti-infective Medicines- Antibacterials - Other antibacterials</b> |                            |   |   |   |   |   |
| <b>Section 7</b>  |                            |   |   |   |   |   |
| <b>Anti-cancer agents including Immunosuppressives and Medicines used in Palliative Care</b>  |                            |   |   |   |   |   |
| <b>7.1 - Antineoplastic medicines</b>   |                            |   |   |   |   |   |
| 7.1.1   | 5-Fluorouracil             | Injection 250 mg/ 5 mL  | ✓ | x | x | x |
| 7.1.2   | 6-Mercaptopurine           | Tablet 50 mg  | x | x | x | x |
| 7.1.3   | Actinomycin D              | Powder for Injection 0.5 mg   | ✓ | x | x | x |
| 7.1.4   | All-trans retinoic acid    | Capsule 10 mg   | x | x | x | x |
| 7.1.5   | Arsenic trioxide           | Injection 1mg/ mL   | x | x | x | x |
| 7.1.6   | Bendamustine hydrochloride | Injection 25 mg/ vial   | x | x | x | x |
|   |                            | Injection 100 mg/vial   | ✓ | x | x | x |
| 7.1.7   | Bleomycin                  | Powder for Injection 15 units   | ✓ | x | x | x |
| 7.1.8   | Bortezomib                 | Powder for Injection 2 mg   | ✓ | x | x | x |
| 7.1.9   | Calcium folinate           | Tablet 15 mg  | ✓ | x | x | x |
|   |                            | Injection 3 mg/mL   | ✓ | x | x | x |
| 7.1.10  | Capecitabine               | Tablet 500 mg   | ✓ | x | x | x |
| 7.1.11  | Carboplatin                | Injection 10 mg/mL  | ✓ | x | x | x |
| 7.1.12  | Chlorambucil               | Tablet 2 mg   | x | x | x | x |
|   |                            | Tablet 5 mg   | x | x | x | x |
| 7.1.13  | Cisplatin                  | Injection 1mg/mL  | ✓ | x | x | x |
| 7.1.14  | Cyclophosphamide           | Tablet 50 mg  | ✓ | x | x | x |
|   |                            | Powder for Injection 500 mg   | ✓ | x | x | x |
| 7.1.15  | Cytosine arabinoside       | Injection 100 mg/vial   | ✓ | x | x | x |
|   |                            | Injection 500 mg/vial   | ✓ | x | x | x |
|   |                            | Injection 1000 mg/vial  | ✓ | x | x | x |

|        |                           |                                  |   |   |   |   |
|--------|---------------------------|----------------------------------|---|---|---|---|
| 7.1.16 | Dacarbazine               | Powder for Injection 200 mg      | ✓ | x | x | x |
|        |                           | Powder for Injection 500 mg      | ✓ | x | x | x |
| 7.1.17 | Daunorubicin              | Injection 5 mg/mL                | x | x | x | x |
| 7.1.18 | Docetaxel                 | Powder for Injection 20 mg       | ✓ | x | x | x |
|        |                           | Powder for Injection 80 mg       | ✓ | x | x | x |
| 7.1.19 | Doxorubicin               | Injection 50 mg/mL               | ✓ | x | x | x |
| 7.1.20 | Etoposide                 | Capsule 50 mg                    | ✓ | x | x | x |
|        |                           | Injection 20 mg/mL               | ✓ | x | x | x |
| 7.1.21 | Gefitinib                 | Tablet 250 mg                    | ✓ | x | x | x |
| 7.1.22 | Gemcitabine               | Powder for Injection 200 mg      | ✓ | x | x | x |
|        |                           | Powder for Injection 1000 mg     | ✓ | x | x | x |
| 7.1.23 | Hydroxyurea*              | Capsule 500 mg                   | x | x | x | x |
| 7.1.24 | Ifosfamide                | Powder for Injection 1000 mg     | ✓ | x | x | x |
|        |                           | Powder for Injection 2000 mg     | ✓ | x | x | x |
| 7.1.25 | Imatinib                  | Tablet 100 mg                    | ✓ | x | x | x |
|        |                           | Tablet 400 mg                    | ✓ | x | x | x |
| 7.1.26 | Irinotecan HCl trihydrate | Solution for injection 20 mg/ mL | ✓ | x | x | x |
| 7.1.27 | L-Asparaginase            | Powder for Injection 5000 KU     | x | x | x | x |
|        |                           | Powder for Injection 10000 KU    | x | x | x | x |
| 7.1.28 | Lenalidomide              | Capsule 5 mg                     | ✓ | x | x | x |
|        |                           | Capsule 25 mg                    | ✓ | x | x | x |
| 7.1.29 | Melphalan                 | Tablet 2 mg                      | x | x | x | x |
|        |                           | Tablet 5 mg                      | x | x | x | x |
| 7.1.30 | Methotrexate**            | Tablet 2.5 mg                    | x | x | x | x |
|        |                           | Tablet 5 mg                      | ✓ | x | x | x |
|        |                           | Tablet 10 mg                     | ✓ | x | x | x |
|        |                           | Injection 50 mg/mL               | ✓ | x | x | x |
| 7.1.31 | Carboplatin               | Injection 150 mg/mL              | ✓ | x | x | x |
| 7.1.32 | Carboplatin               | Injection 450 mg/mL              | ✓ | x | x | x |
| 7.1.33 | Cisplatin                 | Injection 10mg/mL                | ✓ | x | x | x |
| 7.1.34 | Cisplatin                 | Injection 50mg/mL                | ✓ | x | x | x |
| 7.1.35 | Methotrexate              | Injection 10mg/ml                | ✓ | x | x | x |

*\*Hydroxyurea formulations are also listed in Section 8.1.6 - Medicines affecting Blood Antianaemia Medicines*

*\*\*Methotrexate formulations are also listed in Section 2.4.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Disease Modifying Agents used in Rheumatoid Disorders*

|   |                                   |                                   |   |   |   |   |
|---|-----------------------------------|-----------------------------------|---|---|---|---|
| 7.1.35                                    | Oxaliplatin                       | Injection 5 mg/mL in 10 mL vial   | ✓ | x | x | x |
|   |                                   | Injection 5 mg/mL in 20 mL vial   | ✓ | x | x | x |
| 7.1.36                                    | Paclitaxel                        | Injection 30 mg/5 mL              | ✓ | x | x | x |
|   |                                   | Injection 100 mg/16.7 mL          | ✓ | x | x | x |
| 7.1.37                                    | Rituximab                         | Injection 10 mg/mL                | ✓ | x | x | x |
| 7.1.38                                    | Temozolomide                      | Capsule 20 mg                     | ✓ | x | x | x |
|   |                                   | Capsule 100 mg                    | ✓ | x | x | x |
|   |                                   | Capsule 250 mg                    | ✓ | x | x | x |
| 7.1.39                                    | Thalidomide                       | Capsule 50 mg                     | ✓ | x | x | x |
|   |                                   | Capsule 100 mg                    | ✓ | x | x | x |
| 7.1.40                                    | Trastuzumab                       | Injection 440 mg/50 mL            | ✓ | x | x | x |
| 7.1.41                                    | Vinblastine                       | Injection 1 mg/mL                 | ✓ | x | x | x |
| 7.1.42                                    | Vincristine                       | Injection 1 mg/mL                 | ✓ | x | x | x |
| 7.1.43                                    | Paclitaxel                        | Injection 100 mg/5 mL             | ✓ | x | x | x |
|   |                                   | Injection 260 mg/5 mL             | ✓ | x | x | x |
|   |                                   | Injection 300 mg/16.7 mL          | ✓ | x | x | x |
| 7.1.44                                    | Benzydamine                       | Mouth wash 0.15 %                 | ✓ | x | x | x |
| 7.1.45                                    | Lignocaine viscous gargle         | Lignocaine viscous gargle         | ✓ | x | x | x |
| 7.1.46                                    | Xylocaine                         | Spray 10%                         | ✓ | x | x | x |
| 7.1.47                                    | Fentanyl patch                    | 25 ucgm                           | ✓ | x | x | x |
| 7.1.48                                    | Metronidazole ointment            | 0.75%                             | ✓ | x | x | x |
| 7.1.49                                    | Codeine cough syrup               | 15mg/5ml                          | ✓ | x | x | x |
| 7.1.50                                    | Barium Sulphate powder            | 94.8%                             | ✓ | x | x | x |
| <b>Additional Chemotherapy/Medicines:</b> |                                   |                                   |   |   |   |   |
| 7.1.51                                    | Pegfilgrastim 6 MG                | Pegfilgrastim 6 MG                | ✓ | x | x | x |
| 7.1.52                                    | Docetaxel                         | Powder for Injection 120 mg       | ✓ | x | x | x |
| 7.1.53                                    | Inj. Iron Carboxymaltose 1000 MG. | Inj. Iron Carboxymaltose 1000 MG. | ✓ | x | x | x |

|  |                                     |                                     |   |   |   |   |
|--|-------------------------------------|-------------------------------------|---|---|---|---|
| 7.1.54   | Buphenorphine Patch 10 CMG          | Buphenorphine Patch 10 CMG          | ✓ | × | × | × |
| 7.1.55   | Buphenorphine Patch 20 CMG.         | Buphenorphine Patch 20 CMG.         | ✓ | × | × | × |
| 7.1.56   | Betadine Liquid for dressing        | Betadine Liquid for dressing        | ✓ | × | × | × |
| 7.1.57   | Rectified Spirit                    | Rectified Spirit                    | ✓ | × | × | × |
| 7.1.58   | Xylocaine gargle                    | Xylocaine gargle                    | ✓ | × | × | × |
| 7.1.59   | Botroclot drops                     | Botroclot drops                     | ✓ | × | × | × |
| 7.1.60   | Metronidazole + Sucralfate ointment | Metronidazole + Sucralfate ointment | ✓ | × | × | × |
| 7.1.61   | Tab. Ciprofloxacin + Tinidazole.    | Tab. Ciprofloxacin + Tinidazole.    | ✓ | × | × | × |
| <b>7.2-Hormones and Anti-hormones used in Cancer Therapy</b> |                                     |                                     |   |   |   |   |
| 7.2.1  | Bicalutamide                        | Tablet 50 mg                        | ✓ | × | × | × |
| 7.2.2  | Letrozole                           | Tablet 2.5 mg                       | ✓ | × | × | × |
| 7.2.3  | Leuprolide acetate                  | Powder for injection 3.75 mg        | × | × | × | × |
|  |                                     | Powder for injection 11.25 mg       | ✓ | × | × | × |
|  |                                     | Powder for injection 22.5 mg        | ✓ | × | × | × |
| 7.2.4  | Prednisolone*                       | Tablet 10 mg                        | ✓ | ✓ | × | × |
|  |                                     | Tablet 20 mg                        | ✓ | ✓ | × | × |
|  |                                     | Tablet 40 mg                        | ✓ | ✓ | × | × |
|  |                                     | Oral liquid 5 mg/5 mL (p)           | ✓ | ✓ | × | × |
|  |                                     | Oral liquid 15 mg/5 mL (p)          | × | ✓ | × | × |
|  |                                     | Injection 20 mg/2 mL                | ✓ | ✓ | × | × |
| 7.2.5  | Tamoxifen                           | Tablet 10 mg                        | × | × | × | × |
|  |                                     | Tablet 20 mg                        | ✓ | × | × | × |
| <b>7.3 - Immunosuppressive Medicines</b>                     |                                     |                                     |   |   |   |   |
| 7.3.1  | Azathioprine**                      | Tablet 50 mg                        | ✓ | × | × | × |
| 7.3.2  | Cyclosporine                        | Capsule 25 mg                       | ✓ | × | × | × |
|  |                                     | Capsule 50 mg                       | ✓ | × | × | × |
|  |                                     | Capsule 100 mg                      | ✓ | × | × | × |
|  |                                     | Oral liquid 100 mg/mL (p)           | ✓ | × | × | × |
|  |                                     | Injection 50 mg/mL                  | ✓ | × | × | × |

\*Prednisolone formulations are also listed in -

**A. Section 3.6 - Antiallergics and Medicines used in Anaphylaxis**

**B. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives -Adrenal Hormones and synthetic substitutes**

**C. Section 21.2.1 - Ophthalmological Medicines - Antiinflammatory Medicine**

\*\*Azathioprine formulations are also listed in **Section 2.4.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Disease Modifying Agents used in Rheumatoid Disorders**

|  |                       |                   |   |   |   |   |
|--|-----------------------|-------------------|---|---|---|---|
| 7.3.3  | Mycophenolate mofetil | Tablet 250 mg     | ✓ | ✓ | × | × |
|  |                       | Tablet 500 mg     | ✓ | ✓ | × | × |
| 7.3.4  | Tacrolimus            | Capsule 0.5 mg    | ✓ | × | × | × |
|  |                       | Capsule 1 mg      | ✓ | × | × | × |
|  |                       | Capsule 2 mg      | ✓ | × | × | × |
| <b>7.4-Medicines used in Palliative Care</b> |                       |                   |   |   |   |   |
| 7.4.1  | Allopurinol*          | Tablet 100 mg     | ✓ | ✓ | ✓ | × |
| 7.4.2  | Amitriptyline**       | Tablet 10 mg      | ✓ | ✓ | ✓ | × |
|  |                       | Tablet 25 mg      | ✓ | ✓ | ✓ | × |
| 7.4.3  | Dexamethasone**<br>*  | Tablet 0.5 mg     | ✓ | ✓ | ✓ | × |
|  |                       | Tablet 4 mg       | ✓ | ✓ | ✓ | × |
|  |                       | Injection 4 mg/mL | ✓ | ✓ | ✓ | × |

\*Allopurinol formulations are also listed in **Section 2.3.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Medicines used to treat Gout**

\*\*Amitriptyline formulations are also listed in **A. Section 5.2.5 - Medicines used in Neurological Disorders - Anti-migraine medicines - For prophylaxis**

**B. Section 23.2.1.1 - Medicines in treatment of Psychiatric Disorders -Medicines used in mood disorders- Medicines used in depressive disorders**

\*\*\*Dexamethasone formulations are also listed in

**A. Section 3.4 - Antiallergics and medicines used in anaphylaxis**

**B. Section 18.1.1 - Hormones, other Endocrine Medicines and Contraceptives - Adrenal hormones and synthetic substitutes**

**C. Section 27.1 - Medicines for COVID 19 management**

|       |                |                   |   |   |   |   |
|-------|----------------|-------------------|---|---|---|---|
| 7.4.4 | Diazepam*      | Tablet 2 mg       | ✓ | ✓ | ✓ | × |
|       |                | Tablet 5 mg       | ✓ | ✓ | ✓ | × |
|       |                | Injection 5 mg/mL | ✓ | ✓ | ✓ | × |
| 7.4.5 | Filgrastim     | Injection 300 mcg | ✓ | × | × | × |
| 7.4.6 | Fluoxetine**   | Capsule 20 mg     | × | ✓ | × | × |
| 7.4.7 | Haloperidol*** | Tablet 1.5 mg     | × | ✓ | × | × |

|   |                 |                               |   |   |   |   |
|---|-----------------|-------------------------------|---|---|---|---|
|   |                 | Tablet 5 mg                   | x | ✓ | x | x |
|   |                 | Injection 5 mg/mL             | x | ✓ | x | x |
| 7.4.8   | Lactulose****   | Oral liquid 10 g/15 mL        | ✓ | ✓ | ✓ | ✓ |
| 7.4.9   | Loperamide      | Tablet 2 mg                   | ✓ | ✓ | ✓ | ✓ |
| <p><i>*Diazepam formulations are also listed <b>Section 5.1.3 - Medicines used in Neurological Disorders - Anticonvulsants/Antiepileptics</b></i></p> <p><i>**Fluoxetine formulations are also listed in</i></p> <p><b>A. Section 23.2.1.3 - Medicines in used in treatment of Psychiatric Disorders - Medicines used in mood disorders - Medicines used in depressive disorders</b></p> <p><b>B. Section 23.4.2 - Medicines used in treatment of Psychiatric Disorders - Medicines used in obsessive compulsive disorders and panic attacks</b></p> <p><i>***Haloperidol formulations are also listed in <b>Section 23.1.3 - Medicines used in treatment of psychiatric Disorders - Medicines used in psychotic disorders</b></i></p> <p><i>****Lactulose formulations are also listed in <b>Section 17.5.3 - Gastrointestinal Medicines - Laxatives</b></i></p> |                 |                               |   |   |   |   |
|   |                 | Tablet 10 mg                  | ✓ | ✓ | ✓ | ✓ |
| 7.4.10  | Metoclopramide* | Oral liquid 5 mg/5 mL (p)     | ✓ | ✓ | ✓ | ✓ |
|   |                 | Injection 5 mg/mL             | ✓ | ✓ | ✓ | ✓ |
| 7.4.11  | Mesna           | Injection 100 mg/mL           | ✓ | ✓ | x | x |
| 7.4.12  | Midazolam**     | Injection 1 mg/mL             | ✓ | ✓ | x | x |
|   |                 | Tablet 10 mg                  | ✓ | ✓ | ✓ | x |
| 7.4.13  | Morphine***     | Modified Release Tablet 30 mg | ✓ | ✓ | ✓ | x |
|   |                 | Tablet 4 mg                   | ✓ | ✓ | ✓ | ✓ |
| 7.4.14  | Ondansetron**** | Tablet 8 mg                   | ✓ | ✓ | ✓ | ✓ |
|   |                 | Oral liquid 2 mg/5 mL (p)     | ✓ | ✓ | ✓ | ✓ |
|   |                 | Injection 2 mg/mL             | ✓ | ✓ | ✓ | ✓ |
| <p><i>*Metoclopramide formulations are also listed in <b>Section 17.2.2 - Gastrointestinal Medicines Antiemetics</b></i></p> <p><i>**Midazolam formulations are also listed in -</i></p> <p><b>A. Section 1.3.3 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures</b></p> <p><b>B. Section 5.1.7 - Medicines used in Neurological Disorders - Anticonvulsants/Antiepileptics</b></p> <p><i>***Morphine formulations are also listed in -</i></p> <p><b>A. Section 1.3.4 - Medicines used in Anaesthesia - Preoperative medication and sedation for short term procedures</b></p> <p><b>B. Section 2.2.2 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Opioid Analgesics</b></p>             |                 |                               |   |   |   |   |



\*\*\*\*Ondansetron formulations are also listed **Section 17.2.3 - Gastrointestinal Medicines anti-ulcer medicines**

|  |  |   |   |   |   |   |
|--|--|---|---|---|---|---|
| 7.4.15   | Tramadol*  | Capsule 50 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Capsule 100 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Injection 50 mg/mL  | ✓ | ✓ | ✓ | × |
| 7.4.16   | Zoledronic acid  | Powder for Injection 4 mg                                 | ✓ | ✓ | ✓ | × |
| <b>Section 8 Medicines affecting Blood</b>   |  |   |   |   |   |   |
| <b>8.1- Antianaemia Medicines</b>  |  |   |   |   |   |   |
| 8.1.1  | Erythropoietin   | Injection 2000 IU/mL                                      | ✓ | ✓ | × | × |
|  |  | Injection 10000 IU/mL                                     | ✓ | ✓ | ✓ | ✓ |
| 8.1.2  | Ferrous salts<br>(a) Iron Dextran<br>(b) Iron sorbitol citrate complex | Tablet equivalent to 60 mg of elemental iron              | ✓ | ✓ | ✓ | ✓ |
|  |  | Injection 50 mg/mL  | ✓ | ✓ | ✓ | ✓ |
| 8.1.3  | Ferrous Salt (A)+<br>Folic acid (B)                                    | Tablet 45 mg elemental iron (A)+ 400 mcg (B)              | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 100 mg elemental iron (A) + 500 mcg (B)            | ✓ | ✓ | ✓ | ✓ |
|  |  | Oral liquid 20 mg elemental iron (A) + 100 mcg/mL (B) (p) | ✓ | ✓ | ✓ | ✓ |
| *Tramadol formulations are also listed in <b>Section 2.2.3 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and disease Modifying agents used in Rheumatoid Disorders- Opioid Analgesics</b> |  |   |   |   |   |   |
| 8.1.4  | Folic Acid   | Tablet 1 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 5 mg   | ✓ | ✓ | ✓ | ✓ |
| 8.1.5  | Hydroxocobalamin   | Injection 1 mg/mL   | ✓ | ✓ | ✓ | × |
| 8.1.6  | Hydroxyurea*   | Capsule 500 mg  | × | × | × | × |
| 8.1.7  | Iron sucrose   | Injection 100 mg/5mL                                      | ✓ | ✓ | ✓ | ✓ |
| <b>Additional List</b>   |  |   |   |   |   |   |
| 8.1.8  | Ferric Carboxymaltose 500 mg (Single dose iron therapy)                | Injection   | ✓ | ✓ | ✓ | ✓ |

|  |  |   |   |   |   |   |
|--|--|---|---|---|---|---|
| 8.1.9  | Ferrous Ascorbate equivalent to 100 mg elemental iron  | Tab 100 mg  | ✓ | ✓ | ✓ | ✓ |
| 8.1.10   | Iron Folic Acid (IFA) Syrup (with auto dispenser)  | Dried Ferrous Sulphate I.P equivalent to 20mg Elemental Iron & Folic Acid I.P 0.1mg per ml                                      | ✓ | ✓ | ✓ | ✓ |
| 8.1.11   | Iron Folic Acid (IFA) Tablets Small (Pink Colour)  | 45mg Elemental Iron & 400mcg Folic acid I.P, sugar coated   | ✓ | ✓ | ✓ | ✓ |
| 8.1.12   | Iron Folic Acid (IFA) Tablets Large (Red Colour)   | 60mg elemental Iron and 500mcg Folic Acid, sugar coated   | ✓ | ✓ | ✓ | ✓ |
| 8.1.13   | IFA Tablets (Blue colour)- AnemiaMukt Bharat contain Ferrous Sulphate and Folic Acid, Sugar Coated and Blue in Colour: | Each sugar coated tablet shall contain:<br>Dried Ferrous Sulphate IP equivalent to Ferrous Iron - 60mg<br>Folic Acid I.P -0.5mg | ✓ | ✓ | ✓ | ✓ |
| 8.1.14   | Darbepoetin  | Injection 40mcg   | ✓ | ✓ | ✓ | ✗ |
| 8.1.14   |  |   |   |   |   |   |
| 8.2.1  | Enoxaparin**   | Injection 40 mg/ 0.4 mL   | ✓ | ✓ | ✗ | ✗ |
|  |  | Injection 60 mg/ 0.6 mL   | ✓ | ✓ | ✗ | ✗ |
| 8.2.2  | Heparin***   | Injection 1000 IU/mL  | ✓ | ✓ | ✗ | ✗ |
|  |  | Injection 5000 IU/mL  | ✓ | ✓ | ✗ | ✗ |
| 8.2.3  | Phytomenadione (Vitamin K <sub>1</sub> )   | Tablet 10 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Injection 10 mg/mL  | ✓ | ✓ | ✓ | ✓ |
| 8.2.4  | Protamine Sulphate   | Injection 10 mg/mL  | ✓ | ✓ | ✗ | ✗ |
| 8.2.5  | Tranexamic acid  | Tablet 500 mg   | ✓ | ✓ | ✓ | ✓ |
|  |  | Injection 100 mg/mL   | ✓ | ✓ | ✓ | ✗ |
| <p>* Hydroxyurea formulations are also listed in <b>Section 7.1.26 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care Antineoplastic medicines</b></p> <p>** Enoxaparin formulations are also listed in<br/> <b>A. Section 10.5.4 - Cardiovascular Medicines - Antiplatelet and Antithrombotic Medicines</b><br/> <b>B. Section 27.2 - Medicines for COVID 19 management</b></p> <p>*** Heparin formulations are also listed in <b>Section 10.5.5 - Cardiovascular Medicines - Antiplatelet and Antithrombotic Medicines</b></p> |  |   |   |   |   |   |
| 8.2.6  | Warfarin   | Tablet 1 mg   | ✓ | ✓ | ✗ | ✗ |
|  |  | Tablet 2 mg   | ✓ | ✓ | ✗ | ✗ |

|   |                         |                                |   |   |   |   |
|---|-------------------------|--------------------------------|---|---|---|---|
|   |                         | Tablet 3 mg                    | ✓ | ✓ | × | × |
|   |                         | Tablet 5 mg                    | ✓ | ✓ | × | × |
| <b>Section 9</b>  |                         |                                |   |   |   |   |
| <b>Blood products and Plasma substitutes</b>  |                         |                                |   |   |   |   |
| <b>9.1 - Blood and Blood components</b>   |                         |                                |   |   |   |   |
| All forms of the following as approved by licensing authority are considered as included in NLEM. However, considering the process, technology and other relevant aspects, they should be considered differently for purposes such as procurement policy, pricing etc.  |                         |                                |   |   |   |   |
| 9.1.1   | Fresh frozen plasma     | As licensed                    | ✓ | ✓ | ✓ | × |
| 9.1.2   | Platelet rich plasma/   | As licensed                    | ✓ | ✓ | ✓ | × |
|   | Platelet concentrates   |                                | ✓ | ✓ | ✓ | × |
| 9.1.3   | Red blood cells/        | As licensed                    | ✓ | ✓ | ✓ | × |
|   | Packed RBCs             |                                | ✓ | ✓ | ✓ | × |
| 9.1.4   | Whole blood             | As licensed                    | ✓ | ✓ | ✓ | × |
| <b>9.2 - Plasma substitutes</b>   |                         |                                |   |   |   |   |
| 9.2.1   | Dextran-40              | Injection 10 %                 | ✓ | ✓ | ✓ | × |
| <b>9.3 - Plasma fractions for specific use</b>  |                         |                                |   |   |   |   |
| In case of coagulation factors and other blood products, irrespective of variation in source, all forms of these products as approved by licensing authority are considered as included in NLEM. However, considering the source, process, technology and other relevant aspects, they should be considered differently for purposes such as procurement policy, pricing etc. |                         |                                |   |   |   |   |
| 9.3.1   | Coagulation factor IX   | Powder for Injection 600 IU    | ✓ | × | × | × |
| 9.3.2   | Coagulation factor VIII | Powder for Injection 250 IU    | ✓ | × | × | × |
|   |                         | Powder for Injection 500 IU    | ✓ | × | × | × |
| 9.3.3   | Cryoprecipitate         | As licensed                    | ✓ | × | × | × |
| <b>Section 10 Cardiovascular Medicines</b>  |                         |                                |   |   |   |   |
| <b>10.1-Medicines used in Angina</b>  |                         |                                |   |   |   |   |
| 10.1.1  | Diltiazem               | Tablet 30 mg                   | ✓ | ✓ | × | × |
|   |                         | Tablet 60 mg                   | ✓ | ✓ | × | × |
|   |                         | Modified Release Tablet 180 mg | ✓ | ✓ | × | × |
|   |                         | Injection 5 mg/mL              | ✓ | × | × | × |
| 10.1.2  | Glyceryl trinitrate     | Sublingual Tablet 0.5 mg       | ✓ | ✓ | ✓ | ✓ |
|   |                         | Injection 5 mg/mL              | ✓ | ✓ | × | × |
| 10.1.3  | Isosorbide              | Tablet 5 mg                    | ✓ | ✓ | ✓ | ✓ |

|   |                      |                                |   |   |   |   |
|---|----------------------|--------------------------------|---|---|---|---|
|   | dinitrate            | Tablet 10 mg                   | ✓ | ✓ | ✓ | ✓ |
| 10.1.4  | Metoprolol           | Tablet 25 mg                   | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 50 mg                   | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 100 mg                  | ✓ | ✓ | ✓ | ✗ |
|   |                      | Modified Release Tablet 100 mg | ✓ | ✓ | ✓ | ✗ |
|   |                      | Injection 1 mg/mL              |   |   |   |   |
| <b>10.2 - Antiarrhythmic medicines</b>  |                      |                                |   |   |   |   |
| 10.2.1  | Adenosine            | Injection 3 mg/mL              | ✓ | ✓ | ✗ | ✗ |
| 10.2.2  | Amiodarone           | Tablet 100 mg                  | ✓ | ✓ | ✗ | ✗ |
|   |                      | Tablet 200 mg                  | ✓ | ✓ | ✗ | ✗ |
|   |                      | Injection 50 mg/mL             | ✓ | ✓ | ✗ | ✗ |
| 10.2.3  | Digoxin*             | Tablet 0.25 mg                 | ✓ | ✓ | ✓ | ✗ |
|   |                      | Oral liquid 0.05 mg/mL         | ✓ | ✓ | ✓ | ✗ |
|   |                      | Injection 0.25 mg/mL           | ✓ | ✓ | ✗ | ✗ |
| 10.2.4  | Esmolol              | Injection 10 mg/mL             | ✓ | ✗ | ✗ | ✗ |
| 10.2.5  | Lignocaine**         | Injection 2%                   | ✓ | ✓ | ✓ | ✗ |
| 10.2.6  | Verapamil            | Tablet 40 mg                   | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 80 mg                   | ✓ | ✓ | ✓ | ✗ |
|   |                      | Injection 2.5 mg/ mL           | ✓ | ✗ | ✗ | ✗ |
| <b>10.3 - Antihypertensive Medicines</b>  |                      |                                |   |   |   |   |
| 10.3.1  | Amlodipine           | Tablet 2.5 mg                  | ✓ | ✓ | ✓ | ✓ |
|   |                      | Tablet 5 mg                    | ✓ | ✓ | ✓ | ✓ |
|   |                      | Tablet 10 mg                   | ✓ | ✓ | ✓ | ✓ |
| *Digoxin formulations are also listed in <b>Section 10.4.1 - Cardiovascular Medicines -</b>         |                      |                                |   |   |   |   |
| <i>Medicines used in Shock and Heart Failure</i>  |                      |                                |   |   |   |   |
| **Lignocaine formulations are also listed in <b>Section 1.2.2 - Medicines used in Anaesthesia -</b> |                      |                                |   |   |   |   |
| <i>Local Anaesthetics</i>   |                      |                                |   |   |   |   |
| 10.3.2  | Enalapril            | Tablet 2.5 mg                  | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 5 mg                    | ✓ | ✓ | ✓ | ✗ |
| 10.3.3  | Hydrochlorothiazide* | Tablet 12.5 mg                 | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 25 mg                   | ✓ | ✓ | ✓ | ✗ |
| 10.3.4  | Labetalol            | Tablet 50 mg                   | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 100 mg                  | ✓ | ✓ | ✓ | ✗ |
|   |                      | Injection 5 mg/mL              | ✓ | ✓ | ✓ | ✗ |
| 10.3.5  | Ramipril             | Tablet 2.5 mg                  | ✓ | ✓ | ✓ | ✗ |
|   |                      | Tablet 5 mg                    | ✓ | ✓ | ✗ | ✗ |

|   |                                      |   |   |   |   |   |
|---|--------------------------------------|---|---|---|---|---|
| 10.3.6  | Sodium nitroprusside                 | Injection 10 mg/mL  | ✓ | ✓ | × | × |
| 10.3.7  | Telmisartan                          | Tablet 20 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                      | Tablet 40 mg  | ✓ | ✓ | ✓ | ✓ |
|   |                                      | Tablet 80 mg  | ✓ | ✓ | ✓ | ✓ |
| 10.3.8  | Nitroglycerine 25mg/5ml              | Nitroglycerine 25mg/5ml   | ✓ | ✓ | × | × |
| <b>10.4 - Medicines used in Shock and Heart failure</b>   |                                      |   |   |   |   |   |
| 10.4.1  | Digoxin**                            | Tablet 0.25 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Oral liquid 0.05 mg/mL  | ✓ | ✓ | ✓ | × |
|   |                                      | Injection 0.25 mg/mL  | ✓ | × | × | × |
| <p><i>*Hydrochlorothiazide formulations are also listed in Section 15.2 - Diuretics</i></p> <p><i>**Digoxin formulations are also listed in Section 10.2.3 - Cardiovascular Medicines - Antiarrhythmic medicines</i></p>  |                                      |   |   |   |   |   |
| 10.4.2  | Dobutamine                           | Injection 50 mg/mL  | ✓ | ✓ | ✓ | × |
| 10.4.3  | Dopamine                             | Injection 40 mg/mL  | ✓ | ✓ | ✓ | × |
| 10.4.4  | Noradrenaline                        | Injection 2 mg/mL   | ✓ | ✓ | ✓ | × |
| 10.4.5  | Spironolactone*                      | Tablet 25 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Tablet 50 mg  | ✓ | ✓ | × | × |
| 10.4.6  | Ephedrine 30mg/ml                    | Ephedrine 30mg/ml   | ✓ | ✓ | × | × |
| 10.4.7  | Inj.Mephentermine 30mg/ml(10 mlvial) | Inj.Mephentermine 30mg/ml(10 mlvial)                                  | ✓ | ✓ | × | × |
| <b>10.5- Antiplatelet and Antithrombotic Medicines</b>  |                                      |   |   |   |   |   |
| 10.5.1  | Acetylsalicylic acid**               | Conventional/Effervescent/Dispensible/ Enteric coated Tablets 150 mg  | ✓ | × | × | × |
|   |                                      | Conventional/Effervescent/ Dispersible/ Enteric coated Tablets 325 mg | ✓ | ✓ | ✓ | ✓ |
|   |                                      | Enteric coated Tablet 75 mg   | ✓ | ✓ | ✓ | ✓ |
|   |                                      | Enteric coated Tablet 100 mg  | ✓ | ✓ | ✓ | ✓ |
| <p><i>*Spironolactone formulations are also listed in Section 15.4 - Diuretics</i></p> <p><i>**Acetylsalicylic acid formulations are also listed in -</i></p> <p><b>A. Section 2.1.1 - Analgesics, Antipyretics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Medicines used to treat Gout and Disease Modifying Agents used in Rheumatoid Disorders - Non-opioid Analgesics, Antipyretics and Non-steroidal Anti-inflammatory Drugs</b></p> <p><b>B. Section 5.2.1 - Medicines used in Neurological Disorders- Antimigraine medicines</b></p> |                                      |   |   |   |   |   |
| 10.5.2  | Clopidogrel                          | Tablet 75 mg  | ✓ | ✓ | ✓ | × |
|   |                                      | Tablet 150 mg   | ✓ | ✓ | ✓ | × |

|  |                        |                         |   |   |   |   |
|--|------------------------|-------------------------|---|---|---|---|
| 10.5.3   | Dabigatran             | Tablet 110 mg           | ✓ | ✓ | × | × |
|  |                        | Tablet 150 mg           | ✓ | ✓ | × | × |
| 10.5.4   | Enoxaparin*            | Injection 40 mg/ 0.4 mL | ✓ | ✓ | × | × |
|  |                        | Injection 60 mg/ 0.6 mL | ✓ | ✓ | × | × |
| 10.5.5   | Heparin**              | Injection 1000 IU/mL    | ✓ | ✓ | × | × |
|  |                        | Injection 5000 IU/mL    | ✓ | ✓ | × | × |
| 10.5.6   | Streptokinase          | Injection 750,000 IU    | ✓ | × | × | × |
|  |                        | Injection 15,00,000 IU  | ✓ | × | × | × |
| 10.5.7   | Tenecteplase           | Injection 30 mg/vial    | ✓ | × | × | × |
|  |                        | Injection 40 mg/vial    | ✓ | × | × | × |
| <b>10.6 - Hypolipidemic Medicines</b>  |                        |                         | • | • | • | • |
| 10.6.1   | Atorvastatin           | Tablet 10 mg            | ✓ | ✓ | ✓ | × |
|  |                        | Tablet 20 mg            | ✓ | ✓ | ✓ | × |
|  |                        | Tablet 40 mg            | ✓ | ✓ | ✓ | × |
|  |                        | Tablet 80 mg            | ✓ | ✓ | × | × |
| <i>*Enoxaparin formulations are also listed in -</i>   |                        |                         |   |   |   |   |
| <i>A. Section 8.2.1 - Medicines affecting Blood - Medicines affecting coagulation</i>  |                        |                         |   |   |   |   |
| <i>B. Section 27.2 - Medicines for COVID 19 management</i>   |                        |                         |   |   |   |   |
| <i>**Heparin formulations are also listed in Section 8.2.2 - Medicines affecting Blood - Medicines affecting coagulation</i> |                        |                         |   |   |   |   |
| <b>Section 11 Dermatological Medicines (Topical)</b>   |                        |                         |   |   |   |   |
| <b>11.1 - Antifungal Medicines</b>   |                        |                         |   |   |   |   |
| 11.1.1   | Clotrimazole*          | Cream 1 %               | ✓ | ✓ | ✓ | ✓ |
|  |                        | Lotion 1 %              | ✓ | ✓ | ✓ | ✓ |
| 11.1.2   | Luliconazole cream 1%  | Luliconazole cream 1%   | ✓ | ✓ | ✓ | ✓ |
| 11.1.3   | Ketoconazole lotion 2% | Ketoconazole lotion 2%  | ✓ | ✓ | ✓ | ✓ |
| <b>11.2 - Antibacterial Medicines</b>  |                        |                         |   |   |   |   |
| 11.2.1   | Framycetin             | Cream 1 %               | ✓ | ✓ | ✓ | ✓ |
| 11.2.2   | Fusidic acid           | Cream 2 %               | ✓ | ✓ | ✓ | ✓ |
| 11.2.3   | Silver sulphadiazine   | Cream 1 %               | ✓ | ✓ | ✓ | ✓ |
| <b>11.3-Anti-inflammatory and Antipruritic Medicines</b>   |                        |                         |   |   |   |   |
| 11.3.1   | Betamethasone valerate | Cream 0.05 %            | ✓ | ✓ | ✓ | ✓ |
|  |                        | Cream 0.1 %             | ✓ | ✓ | ✓ | ✓ |
| <i>*Clotrimazole formulations are also listed in -</i>   |                        |                         |   |   |   |   |
| <i>A. Section 6.5.2 - Anti-infective Medicines -Antifungal medicines</i>   |                        |                         |   |   |   |   |

**B. Section 6.7.5.4 - Anti-infective Medicines Antiviral medicines- Medicines used in the management of HIV**

**C. Section 16.3 - Ear, Nose and Throat Medicines**

|  |  |                                   |   |   |   |   |
|--|--|-----------------------------------|---|---|---|---|
| 11.3.2                                     | Calamine                               | Lotion (As per IP)                | ✓ | ✓ | ✓ | ✗ |
| 11.3.3                                     | Fusidic + Mometasone cream             | Fusidic + Mometasone cream        | ✓ | ✓ | ✓ | ✓ |
| 11.3.4                                     | Mometasone cream                       | Mometasone cream                  | ✓ | ✓ | ✓ | ✗ |
| <b>11.4 - Keratolytic agents</b>           |  |                                   |   |   |   |   |
| 11.4.1                                     | Benzoyl peroxide                       | Gel 2.5 % - 5 %                   | ✓ | ✓ | ✓ | ✗ |
| 11.4.2                                     | Coal tar (A) + Salicylic Acid (B)      | Solution 1 % (A) + 3 % (B)        | ✓ | ✓ | ✓ | ✓ |
| 11.4.3                                     | Podophyllin resin                      | Solution 20 %                     | ✓ | ✗ | ✗ | ✗ |
| 11.4.4                                     | Salicylic acid                         | Ointment 3-6 %                    | ✓ | ✓ | ✓ | ✓ |
| <b>11.5 - Scabicides and Pediculicides</b> |  |                                   |   |   |   |   |
| 11.5.1                                     | Permethrin                             | Lotion 1 %                        | ✓ | ✓ | ✓ | ✓ |
|  |  | Cream 5 %                         | ✓ | ✓ | ✓ | ✓ |
| <b>11.6 Miscellaneous</b>                  |  |                                   |   |   |   |   |
| 11.6.1                                     | Glycerin/glycerol (as mentioned in IP) | Topical                           | ✓ | ✓ | ✓ | ✓ |
| <b>Section 12 Diagnostic agents</b>        |  |                                   |   |   |   |   |
| <b>12.1 - Ophthalmic Medicines</b>         |  |                                   |   |   |   |   |
| 12.1.1                                     | Fluorescein                            | Ophthalmic Strips                 | ✓ | ✗ | ✗ | ✗ |
| 12.1.2                                     | Proparacaine*                          | Eye Drops 0.5%                    | ✓ | ✗ | ✗ | ✗ |
| 12.1.3                                     | Tropicamide**                          | Eye drop 1 %                      | ✓ | ✗ | ✗ | ✗ |
| 12.1.4                                     | Ciprofloxacin                          | Eye Drop 0.3%                     | ✓ | ✓ | ✓ | ✓ |
| 12.1.5                                     | Chloramphenicol                        | Eye Ointment 1%                   | ✓ | ✓ | ✓ | ✓ |
| 12.1.6                                     | Nepafenac                              | Eye drop 0.1 %                    | ✓ | ✓ | ✓ | ✓ |
| 12.1.7                                     | Olopatadine                            | Eye drop 0.1 %                    | ✓ | ✓ | ✓ | ✓ |
| 12.1.8                                     | Tobramycin                             | Eye Drop 0.3%                     | ✓ | ✓ | ✓ | ✓ |
| 12.1.9                                     | Carboxymethylcellulose                 | sodium 1%                         | ✓ | ✓ | ✓ | ✓ |
| <b>12.2 - Radiocontrast Media</b>          |  |                                   |   |   |   |   |
| 12.2.1                                     | Barium sulphate                        | Oral Liquid 95% w/v               | ✓ | ✓ | ✗ | ✗ |
| 12.2.2                                     | Gadobenedimeglumine                    | Injection 529 mg/mL               | ✓ | ✓ | ✗ | ✗ |
| 12.2.3                                     | Iohexol                                | Injection 140 to 350 mg iodine/mL | ✓ | ✓ | ✗ | ✗ |
| 12.2.4                                     | Meglumine                              | Injection 60 % w/v                | ✓ | ✓ | ✗ | ✗ |

|   |   |                                       |   |   |   |   |
|---|---|---------------------------------------|---|---|---|---|
|   | diatrizoate                                   | Injection 76 % w/v                    | ✓ | ✓ | × | × |
| * Proparacaine formulations are also listed in <b>Section 21.3.1 - Ophthalmological Medicines- Local Anaesthetics</b>         |   |                                       |   |   |   |   |
| ** Tropicamide formulations are also listed in <b>Section 21.5.4 - Ophthalmological Medicines Mydriatics</b>                  |   |                                       |   |   |   |   |
| <b>Section 13</b>   |   |                                       |   |   |   |   |
| <b>Dialysis components (Haemodialysis and Peritoneal Dialysis)</b>  |   |                                       |   |   |   |   |
| 13.1  | Haemodialysis fluid                           | As licensed                           | ✓ | × | × | × |
| 13.2  | Peritoneal dialysis solution                  | As licensed                           | ✓ | × | × | × |
| 13.3  | PD Fluid 1.5% Dextrose Concentration          | PD Fluid 1.5% Dextrose Concentration  | ✓ | × | × | × |
| 13.4  | PD Fluid 2.5 % Dextrose Concentration         | PD Fluid 2.5 % Dextrose Concentration | ✓ | × | × | × |
| 13.5  | PD Fluid 4.25% Dextrose Concentration         | PD Fluid 4.25% Dextrose Concentration | ✓ | × | × | × |
| <b>Section 14 Antiseptics and Disinfectants</b>   |   |                                       |   |   |   |   |
| <b>14.1 Antiseptics</b>   |   |                                       |   |   |   |   |
| 14.1.1  | Chlorhexidine                                 | Solution 5% (Concentrate)             | ✓ | ✓ | ✓ | ✓ |
| 14.1.2  | Ethyl alcohol (Denatured)                     | Solution 70%                          | ✓ | ✓ | ✓ | ✓ |
| 14.1.3  | Hydrogen peroxide                             | Solution 6 %                          | ✓ | ✓ | ✓ | ✓ |
| 14.1.4  | Methylrosaniliniu m chloride (Gentian Violet) | Topical preparation 0.25% to 2%       | ✓ | ✓ | ✓ | ✓ |
| 14.1.5  | Povidone iodine*                              | Solution 4 % to 10 %                  | ✓ | ✓ | ✓ | ✓ |
| 14.1.6  | Bleaching powder                              | Bleaching powder                      | ✓ | ✓ | ✓ | ✓ |
| 14.1.7  | Absolute Alcohol 95% w/v                      | Absolute Alcohol 95% w/v              | ✓ | ✓ | ✓ | ✓ |
| 14.1.8  | Liquid Glycerine                              | Liquid Glycerine                      | ✓ | ✓ | ✓ | ✓ |
| 14.1.9  | Liquid Phenyl (Scented)                       | Liquid Phenyl (Scented)               | ✓ | ✓ | ✓ | ✓ |
| 14.1.10   | Liquid Phenyl(Black)                          | Liquid Phenyl(Black)                  | ✓ | ✓ | ✓ | ✓ |
| 14.1.11   | Sol Rectified Spirit                          | Sol Rectified Spirit                  | ✓ | ✓ | ✓ | ✓ |
| 14.1.12   | Povidone Iodine Ointment 15gm                 | Povidone Iodine Ointment              | ✓ | ✓ | ✓ | ✓ |
| *Povidone Iodine formulations are also listed in <b>Section 21.1.5 - Ophthalmological Medicines - Anti-infective medicine</b> |   |                                       |   |   |   |   |
| <b>14.2 Disinfectants</b>   |   |                                       |   |   |   |   |



|  |   |   |   |   |   |   |
|--|---|---|---|---|---|---|
| 14.2.1   | Glutaraldehyde  | As Licensed   | ✓ | ✓ | ✓ | ✓ |
| 14.2.2   | Potassium permanganate                                  | Crystals for topical solution                           | ✓ | ✓ | ✓ | ✓ |
| <b>Section 15 Diuretics</b>  |   |   |   |   |   |   |
| 15.1   | Furosemide  | Tablet 40 mg  | ✓ | ✓ | ✓ | × |
|  |   | Oral liquid 10 mg/mL                                    | ✓ | ✓ | ✓ | × |
|  |   | Injection 10 mg/ mL                                     | ✓ | ✓ | ✓ | × |
| 15.2   | Hydrochlorothiazide*                                    | Tablet 25 mg  | ✓ | ✓ | ✓ | × |
|  |   | Tablet 50 mg  | ✓ | ✓ | ✓ | × |
| 15.3   | Mannitol  | Injection 10 %  | ✓ | ✓ | ✓ | × |
|  |   | Injection 20 %  | ✓ | ✓ | ✓ | × |
| 15.4   | Spironolactone**  | Tablet 25 mg  | ✓ | ✓ | ✓ | × |
|  |   | Tablet 50 mg  | ✓ | ✓ | ✓ | × |
| 15.5   | Furosemide Drop   | Furosemide Drop   | ✓ | ✓ | ✓ | × |
| <p>* Hydrochlorothiazide formulations are also listed in <b>Section 10.3.3 - Antihypertensive Medicines</b></p> <p>**Spironolactone formulations are also listed in <b>Section 10.4.5 - Cardiovascular Medicines - Medicines used in shock and heart failure</b></p> |   |   |   |   |   |   |
| <b>Section 16</b>  |   |   |   |   |   |   |
| <b>Ear, Nose and Throat Medicines</b>  |   |   |   |   |   |   |
| 16.1   | Budesonide*   | Nasal Spray 50 mcg/dose                                 | × | × | × | × |
|  |   | Nasal Spray 100 mcg/dose                                | × | × | × | × |
| 16.2   | Ciprofloxacin**   | Drops 0.3 %   | ✓ | ✓ | ✓ | ✓ |
| 16.3   | Clotrimazole***   | Drops 1 %   | ✓ | ✓ | ✓ | ✓ |
| 16.4   | Xylometazoline  | Nasal drops 0.05 %                                      | ✓ | ✓ | ✓ | ✓ |
|  |   | Nasal drops 0.1 %                                       | ✓ | ✓ | ✓ | ✓ |
| 16.5   | Fluticasone Furoate Nasal spray 10.0gm/120 metered dose | Fluticasone Furoate Nasal spray 10.0gm/120 metered dose | ✓ | × | × | × |
| 16.6   | Fluticasone propionate 50mcg/120 metered dose           | Fluticasone propionate 50mcg/120 metered dose           | ✓ | × | × | × |
| 16.7   | Mometasone 0.05% nasal spray                            | Mometasone 0.05% nasal spray                            | ✓ | × | × | × |
| 16.8   | Saline Nasal Drop                                       | Saline Nasal Drop                                       | ✓ | ✓ | ✓ | ✓ |
| 16.9   | Ear drop (Neomycin / Polymixin B /                      | Ear drop (Neomycin / Polymixin B / Bacitracin)          | ✓ | × | × | × |

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
|   | Bacitracin)   |   |   |   |   |   |
| 16.10   | Clotrimazole + Lignocaine eardrop   | Clotrimazole + Lignocaine eardrop   | ✓ | ✓ | ✓ | ✓ |
| 16.11   | Wax softener (Benzocaine, Chlorbutol, Paradichlorobenzene & Turpentine oil) | Wax softener (Benzocaine, Chlorbutol, Paradichlorobenzene & Turpentine oil) | ✓ | ✓ | ✓ | ✓ |
| 16.12   | Tab Levocetirizine + Montelukast 5mg & 10 mg; 2.5mg & 4mg                   | Tab Levocetirizine + Montelukast 5mg & 10 mg; 2.5mg & 4mg                   | ✓ | ✓ | ✓ | x |
| 16.13   | Tab Levocetirizine + Montelukast + Ambroxol                                 | Tab Levocetirizine + Montelukast + Ambroxol                                 | ✓ | x | x | x |
| 16.14   | Gargle (Chlorhexidine gluconate solution 0.2%)                              | Gargle (Chlorhexidine gluconate solution 0.2%)                              | ✓ | ✓ | ✓ | ✓ |
| 16.15   | Betadine 2% w/v gargle  | Betadine 2% w/v gargle  | ✓ | ✓ | ✓ | ✓ |
| 16.16   | Haemocoagulase Topical solution 0.2 CU (Botroclot drop)                     | Haemocoagulase Topical solution 0.2 CU (Botroclot drop)                     | ✓ | ✓ | ✓ | ✓ |
| 16.17   | Lidocaine spray 10%   | Lidocaine spray 10%   | ✓ | x | x | x |
| 16.18   | Sodium chloride 0.9% nasal spray  | Sodium chloride 0.9% nasal spray  | ✓ | ✓ | ✓ | ✓ |
| 16.19   | Isotonic spray  | Isotonic spray  | ✓ | x | x | x |
| <p><i>*Budesonide formulations are also listed in <b>Section 24.1 - Medicines acting on the respiratory tract - Antiasthmatic Medicines</b></i></p> <p><i>**Ciprofloxacin formulations are also listed in</i></p> <p><i><b>A. Section 6.2.2.3 - Anti-infective Medicines- Antibacterials -Other Antibacterials</b></i></p> <p><i><b>B. Section 21.1.2 - Ophthalmological Medicines- Anti-infective Medicines</b></i></p> <p><i>***Clotrimazole formulations are also listed in -</i></p> <p><i><b>A. Section 6.5.2 - Anti-infective Medicines -Antifungal medicines</b></i></p> <p><i><b>B. Section 6.7.5.4 - Anti-infective Medicines Antiviral medicines- Medicines used in the management of HIV</b></i></p> <p><i><b>C. Section 11.1.1 - Dermatological Medicines (Topical) -Antifungal medicines</b></i></p> |   |   |   |   |   |   |
| <b>Section 17 Gastrointestinal Medicines</b>  |   |   |   |   |   |   |
| <b>17.1 - Antiulcer Medicines</b>   |   |   |   |   |   |   |
| 17.1.1  | Omeprazole  | Capsule 10 mg   | ✓ | ✓ | ✓ | ✓ |
|   |   | Capsule 20 mg   | ✓ | ✓ | ✓ | ✓ |

|  |   |                              |   |   |   |   |
|--|---|------------------------------|---|---|---|---|
|  |   | Capsule 40 mg                | ✓ | ✓ | ✓ | ✓ |
|  |   | Powder for oral liquid 20 mg | ✓ | ✓ | ✓ | ✓ |
| 17.1.2   | Pantoprazole                                  | Injection 40 mg              | ✓ | ✓ | ✓ | ✓ |
| <b>17.2 Antiemetics</b>  |   |                              |   |   |   |   |
| 17.2.1   | Domperidone                                   | Tablet 10 mg                 | ✓ | ✓ | ✓ | ✓ |
|  |   | Oral Liquid 1 mg/mL          | ✓ | ✓ | ✓ | ✓ |
| 17.2.2   | Metoclopramide*                               | Tablet 10 mg                 | ✓ | ✓ | ✓ | ✓ |
|  |   | Injection 5 mg/mL            | ✓ | ✓ | ✓ | ✗ |
| 17.2.3   | Ondansetron*                                  | Tablet 4 mg                  | ✓ | ✓ | ✓ | ✓ |
|  |   | Oral Liquid 2 mg/5 mL (p)    | ✓ | ✓ | ✓ | ✓ |
|  |   | Injection 2 mg/ mL           | ✓ | ✓ | ✓ | ✗ |
| <p><i>*Metoclopramide formulations are also listed in <b>Section 7.4.10 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care Medicines used in Palliative Care</b></i></p> <p><i>*Ondansetron formulations are also listed in <b>Section 7.4.14 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care Medicines used in Palliative Care</b></i></p> |   |                              |   |   |   |   |
| <b>17.3 Anti-inflammatory medicines</b>  |   |                              |   |   |   |   |
| 17.3.1   | 5-aminosalicylic acid (Mesalazine/ Mesalaine) | Tablet 400 mg                | ✓ | ✓ | ✗ | ✗ |
|  |   | Suppository 500 mg           | ✓ | ✓ | ✗ | ✗ |
|  |   | Retention Enema              | ✓ | ✓ | ✓ | ✗ |
| <b>17.4 Antispasmodic medicines</b>  |   |                              |   |   |   |   |
| 17.4.1   | Dicyclomine                                   | Tablet 10 mg                 | ✓ | ✓ | ✓ | ✓ |
|  |   | Oral Solution 10 mg/5mL      | ✓ | ✓ | ✓ | ✓ |
|  |   | Injection 10 mg/ mL          | ✓ | ✓ | ✓ | ✓ |
| 17.4.2   | Hyoscine butyl bromide                        | Tablet 100 mg                | ✓ | ✓ | ✓ | ✓ |
|  |   | Injection 20 mg/ mL          | ✓ | ✓ | ✓ | ✓ |
| <b>17.5 Laxatives</b>  |   |                              |   |   |   |   |
| 17.5.1   | Bisacodyl                                     | Tablet 5 mg                  | ✓ | ✓ | ✓ | ✓ |
|  |   | Suppository 5 mg             | ✓ | ✓ | ✓ | ✓ |
| 17.5.2   | Ispaghula                                     | Granules/ Husk/ Powder       | ✓ | ✓ | ✓ | ✓ |
| 17.5.3   | Lactulose*                                    | Oral Liquid 10 g/15 mL       | ✓ | ✓ | ✓ | ✓ |
| <b>17.6 Medicines used in diarrhea</b>   |   |                              |   |   |   |   |
| 17.6.1   | Oral rehydration salts**                      | As licensed                  | ✓ | ✓ | ✓ | ✓ |
| 17.6.2   | Zinc Sulphate                                 | Dispersible Tablet 20 mg     | ✓ | ✓ | ✓ | ✓ |
| <b>17.7 Other medicines</b>  |   |                              |   |   |   |   |
| 17.7.1   | Somatostatin                                  | Powder for Injection 3 mg    | ✓ | ✓ | ✗ | ✗ |

|        |             |   |   |   |   |   |
|--------|-------------|---|---|---|---|---|
| 17.7.2 | Antacid Gel | Dried Aluminium Hydroxide 250mg + Magnesium Hydroxide 250mg + Simethicon 50mg | ✓ | ✓ | ✓ | × |
|        |             | Megaldrate 540mg + Simethicon 50mg + Oxetacaine 10mg                          | ✓ | ✓ | ✓ | × |

*\*Lactulose formulations are also listed in **Section 7.4.8** - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care*

*\*\*Oral rehydration salts formulations are also listed in **Section 25.3** - Solutions correcting water, electrolyte disturbances and acid-base disturbances*

|   |  |  |  |  |  |  |
|---|--|--|--|--|--|--|
| <b>Section 18</b>   |  |  |  |  |  |  |
| <b>Hormones, other Endocrine Medicines and Contraceptives</b> |  |  |  |  |  |  |

|  |  |  |  |  |  |  |
|--|--|--|--|--|--|--|
| <b>18.1-Adrenal Hormones and Synthetic substitutes</b> |  |  |  |  |  |  |
|--|--|--|--|--|--|--|

|        |                       |                             |   |   |   |   |
|--------|-----------------------|-----------------------------|---|---|---|---|
| 18.1.1 | Dexamethasone*        | Tablet 0.5 mg               | ✓ | ✓ | ✓ | × |
|        |                       | Injection 4 mg/mL           | ✓ | ✓ | ✓ | × |
| 18.1.2 | Fludrocortisone       | Tablet 0.1 mg               | ✓ | ✓ | ✓ | × |
| 18.1.3 | Hydrocortisone**      | Tablet 5 mg                 | ✓ | ✓ | ✓ | × |
|        |                       | Tablet 10 mg                | ✓ | ✓ | ✓ | × |
|        |                       | Tablet 20 mg                | ✓ | ✓ | ✓ | × |
|        |                       | Powder for Injection 100 mg | ✓ | ✓ | ✓ | × |
| 18.1.4 | Methylprednisolone*** | Injection 40mg/mL           | ✓ | ✓ | ✓ | × |

*\*Dexamethasone formulations are also listed in -*

***A. Section 3.4** - Antiallergics and Medicines used in Anaphylaxis*

***B. Section 7.4.3** - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care - Medicines used in Palliative Care*

***C. Section 27.1** - Medicines for COVID 19 Management*

*\*\* Hydrocortisone formulations are also listed in **Section 3.5** - Antiallergics and Medicines used in Anaphylaxis*

*\*\*\* Methylprednisolone formulations are also listed in **section 27.3**- Medicines for COVID - 19 management*

|        |               |                            |   |   |   |   |
|--------|---------------|----------------------------|---|---|---|---|
| 18.1.5 | Prednisolone* | Tablet 5 mg                | ✓ | ✓ | ✓ | × |
|        |               | Tablet 10 mg               | ✓ | ✓ | ✓ | × |
|        |               | Tablet 20 mg               | ✓ | ✓ | ✓ | × |
|        |               | Oral liquid 5 mg/5 mL (p)  | ✓ | ✓ | ✓ | × |
|        |               | Oral liquid 15 mg/5 mL (p) | ✓ | ✓ | ✓ | × |

|                            |  |  |  |  |  |  |
|----------------------------|--|--|--|--|--|--|
| <b>18.2 Contraceptives</b> |  |  |  |  |  |  |
|----------------------------|--|--|--|--|--|--|

|   |  |  |  |  |  |  |
|---|--|--|--|--|--|--|
| <b>18.2.1 - Hormonal Contraceptives</b> |  |  |  |  |  |  |
|---|--|--|--|--|--|--|

|          |                  |                      |   |   |   |   |
|----------|------------------|----------------------|---|---|---|---|
| 18.2.1.1 | Ethinylestradiol | Tablet 0.03 mg (A) + | ✓ | ✓ | ✓ | ✓ |
|----------|------------------|----------------------|---|---|---|---|

|  |  |   |   |   |   |   |
|--|--|---|---|---|---|---|
|  | (A)+<br>Levonorgestrel<br>(B)                  | Tablet 0.15 mg (B)                                    | ✓ | ✓ | ✓ | ✓ |
| 18.2.1.2   | Levonorgestrel                                 | Tablet 0.75 mg  | ✓ | ✓ | ✓ | ✓ |
|  |  | Tablet 1.5 mg   | ✓ | ✓ | × | × |
| 18.2.1.3   | Ormeloxifene<br>(Centchroman)                  | Tablet 30 mg  | ✓ | ✓ | ✓ | ✓ |
| *Prednisolone formulations are also listed in -  |  |   |   |   |   |   |
| <i>A. Section 3.7 - Antiallergics and Medicines used in Anaphylaxis</i>  |  |   |   |   |   |   |
| <i>B. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care</i> |  |   |   |   |   |   |
| <i>Hormones and anti- hormones used in cancer therapy</i>  |  |   |   |   |   |   |
| <i>C. Section 21.2.1 - Ophthalmological Medicines - Antiinflammatory medicine</i>                                |  |   |   |   |   |   |
| <b>18.2.2 - Intrauterine Devices</b>   |  |   |   |   |   |   |
| 18.2.2.1   | Hormone releasing IUD                          | Contains 52 mg of Levonorgestrel                      | ✓ | ✓ | × | × |
| 18.2.2.2   | IUD containing Copper                          | As licensed   | ✓ | ✓ | ✓ | ✓ |
| <b>18.2.3 - Barrier methods</b>  |  |   |   |   |   |   |
| 18.2.3.1   | Condom   | As Licensed as per the standards of Drugs Rules, 1945 | ✓ | ✓ | ✓ | ✓ |
| <b>18.3 - Medicines used in Diabetes Mellitus</b>  |  |   |   |   |   |   |
| <b>18.3.1 - Insulins and other Antidiabetic agents</b>   |  |   |   |   |   |   |
| 18.3.1.1   | Glimepiride                                    | Tablet 1 mg   | ✓ | ✓ | × | × |
|  |  | Tablet 2 mg   | ✓ | ✓ | ✓ | × |
| 18.3.1.2   | Insulin (Soluble)                              | Injection 40 IU/mL                                    | ✓ | ✓ | ✓ | × |
| 18.3.1.3   | Insulin Intermediate Acting (NPH)              | Injection 40 IU/mL                                    | ✓ | ✓ | ✓ | × |
| 18.3.1.4   | Insulin Glargine                               | Injection 100 IU/mL                                   | ✓ | ✓ | ✓ | × |
| 18.3.1.5   | Insulin Premix Injection 30:70 (Regular : NPH) | Injection 40 IU/mL                                    | ✓ | ✓ | ✓ | × |
| 18.3.1.6   | Metformin                                      | Tablet 500 mg   | ✓ | ✓ | ✓ | × |
|  |  | Tablet 1000 mg  | ✓ | ✓ | ✓ | × |
|  |  | Modified release Tablet 1000 mg                       | ✓ | ✓ | ✓ | × |
| 18.3.1.7   | Teneligliptin                                  | Tablet 20 mg  | ✓ | ✓ | ✓ | ✓ |
| 18.3.1.8   | Injection Lispro 100 units ml                  | Injection Lispro 100 units ml                         | ✓ | ✓ | × | × |

|   |  |   |   |   |   |   |
|---|--|---|---|---|---|---|
| 18.3.1.9  | Dapaglifozin<br>5mg/10mg<br>Sitagliptin 50mg | Dapaglifozin 5mg/10mg<br>Sitagliptin 50mg   | ✓ | ✓ | ✓ | × |
| 18.3.1.10   | Telmisartan                                  | Tab 40mg  | ✓ | ✓ | ✓ | ✓ |
| <b>18.3.2 - Medicines used to treat Hypoglycemia</b>  |  |   |   |   |   |   |
| 18.3.2.1  | Glucose*                                     | Injection 25 %  | ✓ | ✓ | ✓ | ✓ |
| 18.3.2.2  | Oral Glucose                                 | Sachet 75 gm  | ✓ | ✓ | ✓ | ✓ |
| <b>18.4-Ovulation Inducers</b>  |  |   |   |   |   |   |
| 18.4.1  | Clomiphene<br>citrate                        | Tablet 50 mg  | ✓ | × | × | × |
|   |  | Tablet 100 mg   | ✓ | × | × | × |
| 18.4.2  | Human chorionic<br>gonadotropin              | Injection 2000 IU   | ✓ | × | × | × |
|   |  | Injection 5000 IU   | ✓ | × | × | × |
|   |  | Injection 10000 IU  | ✓ | × | × | × |
| <i>*Glucose formulations are also listed in <b>Section 25.1</b> - Solutions correcting water, electrolyte disturbances and acid-base disturbances</i> |  |   |   |   |   |   |
| <b>18.5-Progestogens</b>  |  |   |   |   |   |   |
| 18.5.1  | Medroxyprogester<br>one acetate              | Tablet 5 mg   | ✓ | ✓ | × | × |
|   |  | Tablet 10 mg  | ✓ | ✓ | × | × |
|   |  | Injection 150 mg/ mL  | ✓ | ✓ | × | × |
| 18.5.2  | Norethisterone                               | Tablet 5 mg   | ✓ | ✓ | × | × |
| 18.5.3  | Norethisterone<br>sustained release          | Tab 10 mg   | ✓ | ✓ | × | × |
| 18.5.4  | Dydrogesterone                               | Tab 10 mg   | ✓ | ✓ | ✓ | ✓ |
| 18.5.5  | Micronised<br>progesterone                   | Sofgel 200 mg   | ✓ | ✓ | ✓ | ✓ |
| <b>18.6-Thyroid and Antithyroid Medicines</b>   |  |   |   |   |   |   |
| 18.6.1  | Carbimazole                                  | Tablet 5 mg   | ✓ | ✓ | ✓ | × |
|   |  | Tablet 10 mg  | ✓ | ✓ | ✓ | × |
|   |  | Tablet 20 mg  | ✓ | ✓ | ✓ | × |
| 18.6.2  | Levothyroxine                                | Tablet 12.5 mcg to 150 mcg*<br>(*Several strengths are available<br>in market such as<br>12.5,25,50,62.5, 75, 88,100,<br>112mcg. Therefore, it was<br>considered to give a range of<br>available strengths) | ✓ | ✓ | ✓ | ✓ |
| 18.6.3  | Medroxyprogester<br>one acetate              | Tablet 160 mg   | ✓ | × | × | × |

|  |   |  |   |   |   |   |
|--|---|--|---|---|---|---|
| 18.6.4   | Propylthiouracil                        | Propylthiouracil 50mg tab                  | ✓ | ✓ | ✓ | ✓ |
|  |   | Propylthiouracil 100 mg tab                | ✓ | ✓ | ✓ | ✓ |
| <b>Section 19 Immunologicals</b>   |   |  |   |   |   |   |
| In case of these biologicals, irrespective of variation in source, composition and strengths, all the products of the same vaccine/ sera/ immunoglobulin, as approved by licensing authority are considered as included in NLEM. However, considering the source, process, technology and other relevant aspects, different products of the same biological should be considered differently for purposes such as procurement policy, pricing etc. |   |  |   |   |   |   |
| <b>19.1-Diagnostic agents</b>  |   |  |   |   |   |   |
| 19.1.1   | Tuberculin, Purified Protein derivative | As Licensed                                | ✓ | ✓ | ✓ | × |
| <b>19.2-Sera and Immunoglobulins (Liquid/ Lyophilized)</b>   |   |  | . | . |   |   |
| 19.2.1   | Anti-rabies immunoglobulin              | As Licensed                                | ✓ | ✓ | ✓ | × |
| 19.2.2   | Anti-tetanus immunoglobulin             | As Licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.2.3   | Anti-D immunoglobulin                   | As Licensed                                | ✓ | ✓ | × | × |
| 19.2.4   | Diphtheria antitoxin                    | As Licensed                                | ✓ | ✓ | × | × |
| 19.2.5   | Inj. Hepatitis B immunoglobulin         | 100 IU/1ml vial                            | ✓ | ✓ | × | × |
| 19.2.6   | Human normal immunoglobulin             | As Licensed                                | ✓ | ✓ | × | × |
| 19.2.7   | Snake Venom Antiserum*                  | a) Soluble/ liquid polyvalent -As Licensed | ✓ | ✓ | ✓ | × |
|  |   | b) Lyophilized polyvalent - As Licensed    | ✓ | ✓ | ✓ | × |
| <i>*Snake Venom antiserum also listed in <b>Section 4.2.12 - Antidotes and Other Substances used in Management of Poisonings/Envenomation Specific</b></i>   |   |  |   |   |   |   |
| <b>For Universal Immunization</b>  |   |  |   |   |   |   |
| 19.3.1   | BCG vaccine                             | As licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.3.2   | DPT+ Hib+ Hep B vaccine                 | As licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.3.3   | DPT vaccine                             | As licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.3.4   | Hepatitis B vaccine                     | As licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.3.5   | Japanese encephalitis vaccine           | As licensed                                | ✓ | ✓ | ✓ | ✓ |
| 19.3.6   | Measles vaccine                         | As licensed                                | ✓ | ✓ | ✓ | ✓ |

|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 19.3.7  | Oral poliomyelitis vaccine                  | As licensed                                   | ✓ | ✓ | ✓ | ✓ |
| 19.3.8  | Rotavirus vaccine                           | As licensed                                   | ✓ | ✓ | ✓ | ✓ |
| 19.3.9  | Tetanus toxoid                              | As licensed                                   | ✓ | ✓ | ✓ | ✗ |
| <b>19.4 - For Specific Group of Individuals</b> |   |   |   |   |   |   |
| 19.4.1  | Tissue Culture Anti Rabies Vaccine per vial | As licensed                                   | ✓ | ✓ | ✓ | ✗ |
| 19.4.2  | Anti Rabies Serum Per ml                    | As licensed                                   | ✓ | ✓ | ✓ | ✗ |
| <b>Section 20 Medicines for Neonatal Care</b>   |   |   |   |   |   |   |
| 20.1  | Alprostadil                                 | Injection 0.5 mg/mL                           | ✓ | ✗ | ✗ | ✗ |
|   |   | Oral liquid 20 mg/mL                          | ✓ | ✗ | ✗ | ✗ |
| 20.2  | Caffeine citrate                            | Injection 20 mg/mL                            | ✓ | ✓ | ✗ | ✗ |
| 20.3  | Surfactant                                  | Suspension for intratracheal instillation 5ml | ✓ | ✓ | ✗ | ✗ |
| 20.4  | Sildenafil tab 100mg                        | Sildenafil tab 100mg                          | ✓ | ✓ | ✗ | ✗ |
| 20.5  | Caffeine Drop citrate                       | Caffeine Drop/ Oral 20mg per ml               | ✓ | ✓ | ✓ | ✗ |
| <b>Section 21 Ophthalmological Medicines</b>    |   |   |   |   |   |   |
| <b>21.1-Anti-infective Medicines</b>            |   |   |   |   |   |   |
| 21.1.1  | Acyclovir*                                  | Ointment 3%                                   | ✓ | ✓ | ✓ | ✓ |
| 21.1.2  | Ciprofloxacin**                             | Drops 0.3%                                    | ✓ | ✓ | ✓ | ✓ |
|   |   | Ointment 0.3%                                 | ✓ | ✓ | ✓ | ✓ |
| 21.1.3  | Natamycin                                   | Drops 5 %                                     | ✓ | ✗ | ✗ | ✗ |
| 21.1.4  | Povidone iodine***                          | Drops 5 %                                     | ✓ | ✗ | ✗ | ✗ |
| <b>21.2-Anti-inflammatory Medicine</b>          |   |   |   |   |   |   |
| 21.2.1  | Prednisolone****                            | Drops 1 %                                     | ✓ | ✗ | ✗ | ✗ |

\*Acyclovir formulations are also listed in -

**A. Anti-infective Medicines -Antiviral medicines -Anti-herpes medicines Section 6.6.1.1**

**B. Anti-infective Medicines -Medicines used in the management of HIV -Medicines for treating Opportunistic Infections in People living with HIV Section 6.7.5.1**

\*\*Ciprofloxacin formulations are also listed in -

**A. Section 6.2.2.3 - Anti-infective Medicines- Antibacterials - Other Antibacterials**

**B. Section 16.2 Ear, Nose and Throat Medicines**

\*\*\*Povidone Iodine Also listed in **Section 14.1.5 - Antiseptics and Disinfectants- Antiseptics**

\*\*\*\*Prednisolone formulations are also listed in -

**A. Section 3.7 - Antiallergics and Medicines used in Anaphylaxis**

**B. Section 7.2.4 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative Care Hormones and anti-hormones used in cancer therapy**

**C. Section 18.1.5 - Hormones, other Endocrine Medicines and Contraceptives- Adrenal**



*Hormones and synthetic substitutes*

| <b>21.3- Local Anaesthetic</b>  |                               |               |   |   |   |   |
|---|-------------------------------|---------------|---|---|---|---|
| 21.3.1  | Proparacaine*                 | Drops 0.5 %   | ✓ | x | x | x |
| <b>21.4-Miotics and Antiglaucoma Medicines</b>  |                               |               |   |   |   |   |
| 21.4.1  | Acetazolamide                 | Tablet 250 mg | ✓ | x | x | x |
| 21.4.2  | Latanoprost                   | Drops 0.005 % | ✓ | x | x | x |
| 21.4.3  | Pilocarpine                   | Drops 2 %     | ✓ | x | x | x |
|   |                               | Drops 4 %     | ✓ | x | x | x |
| 21.4.4  | Timolol                       | Drops 0.25 %  | ✓ | x | x | x |
|   |                               | Drops 0.5 %   | ✓ | x | x | x |
| <b>21.5-Mydriatics</b>  |                               |               |   |   |   |   |
| 21.5.0  | Atropine**                    | Drops 1%      | ✓ | x | x | x |
| 21.5.1  |                               | Ointment 1%   | ✓ | x | x | x |
| <p><i>*Proparacaine formulations are also listed in listed in <b>Section 12.1.2</b> -</i></p> <p><i>Diagnostic agents- Ophthalmic Medicines</i></p> <p><i>**Atropine formulations are also listed in -</i></p> <p><b>A. Section 1.3.1 - Medicines used in Anaesthesia -Preoperative medication and sedation for short term procedures</b></p> <p><b>B. Section 4.2.1 - Antidotes and Other substances used in Management of poisoning/Envenomation - specific</b></p> |                               |               |   |   |   |   |
| 21.5.2  | Homatropine                   | Drops 2%      | ✓ | x | x | x |
| 21.5.3  | Phenylephrine                 | Drops 5 %     | ✓ | x | x | x |
|   |                               | Drops 10 %    | ✓ | x | x | x |
| 21.5.4  | Tropicamide*                  | Drops 1 %     | ✓ | x | x | x |
| <b>21.6-Miscellaneous</b>   |                               |               |   |   |   |   |
| 21.6.1  | Carboxymethyl cellulose       | Drops 0.5%    | ✓ | x | x | x |
|   |                               | Drops 1%      | ✓ | x | x | x |
| 21.6.2  | Hydroxypropyl methylcellulose | Injection 2%  | ✓ | x | x | x |

| Section 22 Oxytocics and Antioxytocics  |                       |                       |   |   |   |   |
|---|-----------------------|-----------------------|---|---|---|---|
| 22.1 - Oxytocics and Abortifacient  |                       |                       |   |   |   |   |
| 22.1.1  | Dinoprostone          | Tablet 0.5 mg         | x | x | x | x |
|   |                       | Gel 0.5 mg            | ✓ | ✓ | x | x |
| 22.1.2  | Methylergometrin<br>e | Tablet 0.125 mg       | ✓ | ✓ | ✓ | ✓ |
|   |                       | Injection 0.2 mg/mL   | ✓ | ✓ | ✓ | ✓ |
| <i>*Tropicamide formulations are also listed in Section 12.1.3 - Diagnostic agents - Ophthalmic Medicines</i> |                       |                       |   |   |   |   |
| 22.1.3  | Mifepristone          | Tablet 200 mg         | ✓ | ✓ | ✓ | x |
| 22.1.4  | Misoprostol           | Tablet 100 mcg        | ✓ | ✓ | ✓ | ✓ |
|   |                       | Tablet 200 mcg        | ✓ | ✓ | ✓ | ✓ |
| 22.1.5  | Oxytocin              | Injection 5 IU/mL     | ✓ | ✓ | ✓ | ✓ |
|   |                       | Injection 10 IU/mL    | ✓ | ✓ | ✓ | ✓ |
| <b>OXYTOCICS</b>  |                       |                       | . |   |   |   |
| 22.1.6  | Carbetocin            | Injection 100 mcg/ml  | ✓ | ✓ | ✓ | x |
| 22.1.7  | Carboprost            | Injection 250 mcg/ml  | ✓ | ✓ | ✓ | x |
| 22.1.8  | Oxytoxin              | Tab 25mg              | x | x | x | x |
| 22.2 - Medicines used in Preterm Labour   |                       |                       |   |   |   |   |
| 22.2.1  | Betamethasone         | Injection 4 mg/mL     | ✓ | ✓ | ✓ | ✓ |
| 22.2.2  | Nifedipine            | Tablet 10 mg          | ✓ | ✓ | ✓ | x |
| Section 23  |                       |                       |   |   |   |   |
| Medicines used in treatment of Psychiatric Disorders  |                       |                       |   |   |   |   |
| 23.1 - Medicines used in Psychotic Disorders  |                       |                       |   |   |   |   |
| 23.1.1  | Clozapine             | Tablet 25 mg          | x | x | x | x |
|   |                       | Tablet 50 mg          | x | x | x | x |
|   |                       | Tablet 100 mg         | x | x | x | x |
| 23.1.2  | Fluphenazine          | Injection 25 mg/mL    | ✓ | x | x | x |
| 23.1.3  | Haloperidol*          | Tablet 2 mg           | ✓ | ✓ | x | x |
|   |                       | Tablet 5 mg           | ✓ | ✓ | x | x |
|   |                       | Tablet 10 mg          | ✓ | ✓ | x | x |
|   |                       | Tablet 20 mg          | ✓ | ✓ | x | x |
|   |                       | Oral liquid 2 mg/5 mL | ✓ | ✓ | x | x |
|   |                       | Injection 5 mg/mL     | ✓ | ✓ | x | x |
| 23.1.4  | Risperidone           | Tablet 1 mg           | ✓ | ✓ | ✓ | x |
|   |                       | Tablet 2 mg           | ✓ | ✓ | ✓ | x |

|   |                      |                                 |   |   |   |   |
|---|----------------------|---------------------------------|---|---|---|---|
|   |                      | Tablet 4 mg                     | ✓ | ✓ | ✓ | × |
|   |                      | Oral liquid 1 mg/mL             | ✓ | ✓ | ✓ | × |
|   |                      | Injection (Long acting) 25 mg   | ✓ | ✓ | ✓ | × |
|   |                      | Injection (Long acting) 37.5 mg | ✓ | ✓ | ✓ | × |
| <b>23.2 - Medicines used in Mood Disorders</b>  |                      |                                 |   |   |   |   |
| <b>23.2.1 - Medicines used in Depressive Disorders</b>  |                      |                                 |   |   |   |   |
| 23.2.1.1  | Amitriptyline**      | Tablet 10 mg                    | ✓ | ✓ | ✓ | × |
|   |                      | Tablet 25 mg                    | ✓ | ✓ | ✓ | × |
|   |                      | Tablet 50 mg                    | ✓ | ✓ | ✓ | × |
|   |                      | Tablet 75 mg                    | ✓ | ✓ | ✓ | × |
| <p><i>*Haloperidol formulations are also listed in <b>Section 7.4.7 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative are- Medicines used in Palliative Care</b></i></p> <p><i>**Amitriptyline formulations are also listed in -</i></p> <p><b>A. Section 5.2.5 - Medicines used in Neurological Disorders - Anti-migraine medicines- For prophylaxis</b></p> <p><b>B. Section 7.4.2 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative are- Medicines used in Palliative Care</b></p> |                      |                                 |   |   |   |   |
| 23.2.1.2  | Escitalopram         | Tablet 5 mg                     | ✓ | ✓ | ✓ | × |
|   |                      | Tablet 10 mg                    | ✓ | ✓ | ✓ | × |
|   |                      | Tablet 20 mg                    | ✓ | ✓ | ✓ | × |
| 23.2.1.3  | Fluoxetine*          | Capsule 10 mg                   | × | ✓ | × | × |
|   |                      | Capsule 20 mg                   | × | ✓ | × | × |
|   |                      | Capsule 40 mg                   | × | ✓ | × | × |
|   |                      | Capsule 60 mg                   | × | ✓ | × | × |
| <b>23.2.2 - Medicines used in Bipolar Disorders</b>   |                      |                                 |   |   |   |   |
| 23.2.2.1  | Lithium              | Tablet 300 mg                   | × | × | × | × |
| 23.2.2.2  | Sodium valproate**   | Tablet 200 mg                   | × | ✓ | × | × |
|   |                      | Tablet 300 mg                   | × | ✓ | × | × |
|   |                      | Tablet 500 mg                   | × | ✓ | × | × |
|   |                      | Modified Release -              | × | ✓ | × | × |
|   |                      | Tablet 300 mg                   | × | ✓ | × | × |
|   |                      | Tablet 500 mg                   | × | ✓ | × | × |
| 23.2.2.3  | Carbamazepine**<br>* | Tablet 100 mg                   | × | ✓ | × | × |
|   |                      | Tablet 200 mg                   | × | ✓ | × | × |
|   |                      | Tablet 400 mg                   | × | ✓ | × | × |
|   |                      | Modified Release -              | × | ✓ | × | × |

|   |                              |   |   |   |   |   |
|---|------------------------------|---|---|---|---|---|
|   |                              | Tablet 200 mg                               | x | ✓ | x | x |
|   |                              | Tablet 400 mg                               | x | ✓ | x | x |
|   |                              | Oral liquid 100 mg/5 mL (p)                 | x | ✓ | x | x |
| *Fluoxetine formulations are also listed in -   |                              |   |   |   |   |   |
| <b>A. Section 7.4.6 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative are- Medicines used in Palliative Care</b>          |                              |   |   |   |   |   |
| <b>B. Section 7.4.6 - Medicines used in treatment of psychiatric Disorders - Medicines used in obsessive compulsive disorders and panic attacks</b>         |                              |   |   |   |   |   |
| ** Sodium Valproate formulations are also listed in <b>Section 5.1.10 - Medicines used in Neurological Disorders -Anticonvulsants /antiepileptics</b>       |                              |   |   |   |   |   |
| ***Carbamazepine formulations are also listed in <b>Section 5.1.1 - Medicines used in Neurological Disorders- Anticonvulsants/antiepileptics</b>            |                              |   |   |   |   |   |
| <b>23.3 - Medicines used in Generalized Anxiety and Sleep Disorders</b>   |                              |   |   |   |   |   |
| 23.3.1  | Clonazepam                   | Tablet 0.25 mg                              | ✓ | ✓ | ✓ | ✓ |
|   |                              | Tablet 0.5 mg                               | ✓ | ✓ | ✓ | ✓ |
|   |                              | Tablet 1 mg                                 | ✓ | ✓ | ✓ | x |
| 23.3.2  | Zolpidem                     | Tablet 5 mg                                 | ✓ | ✓ | ✓ | ✓ |
|   |                              | Tablet 10 mg                                | ✓ | ✓ | ✓ | ✓ |
| <b>23.4 - Medicines used in Obsessive Compulsive Disorders and Panic attacks</b>  |                              |   |   |   |   |   |
| 23.4.1  | Clomipramine                 | Capsule 10 mg                               | x | x | x | x |
|   |                              | Capsule 25 mg                               | x | x | x | x |
|   |                              | Capsule 75 mg                               | x | x | x | x |
| 23.4.2  | Fluoxetine*                  | Capsule 10 mg                               | x | ✓ | x | x |
|   |                              | Capsule 20 mg                               | x | ✓ | x | x |
|   |                              | Capsule 40 mg                               | x | ✓ | x | x |
|   |                              | Capsule 60 mg                               | x | ✓ | x | x |
| *Fluoxetine formulations are also listed in -   |                              |   |   |   |   |   |
| <b>A. Section 7.4.6 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative are- Medicines used in Palliative Care</b>          |                              |   |   |   |   |   |
| <b>B. Section 23.2.1.3 Medicines used in treatment of Psychiatric Disorders - Medicines used in mood disorders - Medicines used in depressive disorders</b> |                              |   |   |   |   |   |
| <b>23.5 Medicines used in Disorders due to Psychoactive substance abuse</b>   |                              |   |   |   |   |   |
| 23.5.1  | Buprenorphine                | Tablet (Sub-lingual) 0.4 mg                 | ✓ | ✓ | ✓ | ✓ |
| 23.5.2  | Buprenorphine (A) + Naloxone | Tablet (Sub-lingual) 0.4 mg (A)+ 0.1 mg (B) | ✓ | ✓ | ✓ | x |

|   |  |  |   |   |   |   |
|---|--|--|---|---|---|---|
|   | (B)  | Tablet (Sub-lingual) 2 mg (A)<br>+0.5 mg (B)           | ✓ | ✓ | ✓ | x |
| 23.5.3  | Nicotine (for<br>nicotine<br>replacement<br>therapy) | Oral Dosage forms 2 mg                                 | ✓ | ✓ | ✓ | ✓ |
|   |  | Oral Dosage forms 4 mg                                 | ✓ | ✓ | ✓ | ✓ |
| 23.5.4  | Buprinorphine<br>Injection<br>300mg/ml               | Buprinorphine Injection<br>300mg/ml                    | ✓ | ✓ | x | x |
| <b>Section 24</b>   |  |  |   |   |   |   |
| <b>Medicines acting on the Respiratory tract</b>  |  |  |   |   |   |   |
| <b>24.1 - Antiasthmatic Medicines</b>   |  |  |   |   |   |   |
| 24.1.1  | Budesonide*  | Inhalation (MDI/DPI) 100<br>mcg/dose                   | ✓ | ✓ | ✓ | x |
|   |  | Inhalation (MDI/DPI) 200<br>mcg/dose                   | ✓ | ✓ | ✓ | x |
|   |  | Respirator solution for use in<br>nebulizer 0.5 mg/mL  | ✓ | ✓ | ✓ | x |
|   |  | Respirator solution for use in<br>nebulizer 1 mg/mL    | ✓ | ✓ | ✓ | x |
| <i>*Budesonide formulations are also listed in <b>Section 16.1 - Ear, Nose and Throat Medicines</b></i> |  |  |   |   |   |   |
| 24.1.2  | Budesonide (A) +<br>Formoterol (B)                   | Inhalation (MDI/DPI) 100 mcg<br>(A)+ 6 mcg (B)         | ✓ | ✓ | ✓ | x |
|   |  | Inhalation (MDI/DPI) 200 mcg<br>(A)+ 6 mcg (B)         | ✓ | ✓ | x | x |
|   |  | Inhalation (MDI/DPI) 400 mcg<br>(A)+ 6 mcg (B)         | ✓ | ✓ | x | x |
| 24.1.3  | Hydrocortisone*                                      | Powder for Injection 100 mg                            | ✓ | ✓ | ✓ | x |
|   |  | Powder for Injection 200 mg                            | ✓ | ✓ | ✓ | x |
| 24.1.4  | Ipratropium  | Inhalation (MDI/DPI) 20<br>mcg/dose                    | ✓ | ✓ | ✓ | x |
|   |  | Respirator solution for use in<br>nebulizer 250 mcg/mL | ✓ | ✓ | ✓ | x |
| 24.1.5  | Montelukast  | Tablet 4 mg  | ✓ | ✓ | ✓ | x |
|   |  | Tablet 5 mg  | ✓ | ✓ | ✓ | x |
|   |  | (including chewable tablets)                           | ✓ | ✓ | ✓ | x |
|   |  | Tablet 10 mg   | ✓ | ✓ | ✓ | x |
| 24.1.6  | Salbutamol   | Tablet 2 mg  | ✓ | ✓ | ✓ | x |
|   |  | Tablet 4 mg  | ✓ | ✓ | ✓ | x |

|   |                      |  |   |   |   |   |
|---|----------------------|--|---|---|---|---|
|   |                      | Oral liquid 2 mg/5 mL                                      | ✓ | ✓ | ✓ | × |
|   |                      | Inhalation (MDI/DPI*) 100 mcg/dose                         | ✓ | ✓ | ✓ | ✓ |
|   |                      | Respirator Solution(Solution for Nebulizer 5 mg/mL)        | ✓ | ✓ | ✓ | ✓ |
| <i>*Hydrocortisone formulations are also listed in</i>  |                      |  |   |   |   |   |
| <i>A. Section 3.5 - Antiallergics and Medicines used in Anaphylaxis</i>   |                      |  |   |   |   |   |
| <i>B. Section 18.1.3 - Hormones, other Endocrine Medicines and Contraceptives- Adrenal hormones and synthetic substitutes</i> |                      |  |   |   |   |   |
| 24.1.7  | Tiotropium           | Inhalation (MDI) 9 mcg/dose                                | ✓ | × | × | × |
|   |                      | Inhalation (DPI) 18 mcg/dose                               | ✓ | × | × | × |
| MDI- Metered Dose Inhaler   |                      |  |   |   |   |   |
| DPI- Dry Powder Inhaler   |                      |  |   |   |   |   |
| 24.1.8  | Glycopyrronium       | 25 mcg, MDI, Respules                                      | ✓ | × | × | × |
| 24.1.9  | Vilanterol           | MDI 100mcg, DPI 200mcg                                     | ✓ | × | × | × |
| 24.1.10   | Sildenafil Tab       | 20, 50 mg  | ✓ | × | × | × |
| 24.1.11   | Injection Amino Acid | Amino Acid (5% w/v) & Sorbitol (5% w/v) Injection 500ml    | ✓ | ✓ | × | × |
|   |                      | Amino Acid (7% w/v) Injection 500ml                        | ✓ | ✓ | × | × |
|   |                      | Amino Acid (8% w/v) Injection 500ml                        | ✓ | ✓ | × | × |
|   |                      | Amino Acid (10% w/v) Injection 100ml                       | ✓ | ✓ | × | × |
|   |                      | Amino Acid (10% w/v) Injection with Electrolytes 500ml     | ✓ | ✓ | × | × |
| 24.1.12   | Injection Albumin    | Human Albumin 25% with Closed System Collapsible Bag 100ml | ✓ | ✓ | × | × |
| 24.1.13   | Injection Botropase  | 250 mg   | ✓ | ✓ | × | × |
| 24.1.14   | Salbutamol           | Syp. Salbutamol 2 mg/ 5ml                                  | ✓ | ✓ | ✓ | ✓ |
|   |                      | Tab. Salbutamol 2 mg                                       | ✓ | ✓ | ✓ | ✓ |
|   |                      | Tab. Salbutamol 4 mg                                       | ✓ | ✓ | ✓ | ✓ |
| 24.1.15   | Budesonide           | Budesonide IP 100mcg 200 MDI                               | ✓ | ✓ | ✓ | ✓ |
|   |                      | Budesonide IP 200mcg 200 MDI                               | ✓ | ✓ | ✓ | ✓ |
|   |                      | Budesonide IP 400mcg 200 MDI                               | ✓ | ✓ | ✓ | ✓ |
|   |                      | Budesonide Respiratory Respules 0.5mg 2ml / 2.5ml          | ✓ | ✓ | ✓ | ✓ |

|         |                                  |  |   |   |   |   |
|---------|----------------------------------|--|---|---|---|---|
|         |                                  | Budesonide Respiratory Respules 1.0mg 2ml / 2.5ml  | ✓ | ✓ | ✓ | ✓ |
| 24.1.16 | Pifpirfenedone                   | 200 mg   | ✓ | ✓ | ✗ | ✗ |
|         |                                  | 400 mg   | ✓ | ✓ | ✗ | ✗ |
|         |                                  | 800 mg   | ✓ | ✓ | ✗ | ✗ |
| 24.1.17 | Cap Acebrophylline               | 100 mg   | ✓ | ✓ | ✓ | ✓ |
| 24.1.18 | Injection Aminophylline          | Aminophylline 250mg/2ml  | ✓ | ✓ | ✗ | ✗ |
| 24.1.19 | Inj/Tab Doxophylline             | Tablet Doxofylline 400mg   | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Tablet Doxofylline 800mg   | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Injection Doxofylline 100mg/5ml  | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Injection Doxofylline 100mg/10 ml  | ✓ | ✓ | ✓ | ✓ |
| 24.1.20 | Cough Syrup                      | Ambroxol HCL 15mg +<br>Guaiphenesin 50mg +<br>Terbutaline Sulphate 1.25mg +<br>Menthol 1mg/5ml 100ml | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Dextromethorphan Hydrobromide 5mg +<br>Phenylephrine HCL 5mg +<br>Cetirizine HCL 2.5mg/5ml 100ml     | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Ambroxol HCL 15mg +<br>Guaiphenesin 50mg +<br>Terbutaline Sulphate 1.25mg/5ml 100ml                  | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Levocetirizine Dihydrochloride 2.5mg/5ml 30ml  | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Phenylephrine HCL 5mg +<br>Chlorpheniramine Maleate 2mg/5ml 60ml                                     | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Levosambutamol 0.5mg +<br>Ambroxol 15mg + Guiaphenesin 50mg 100ml                                    | ✓ | ✓ | ✓ | ✓ |
|         |                                  | Noscapine 7mg/5ml Syrup 100ml  | ✓ | ✓ | ✓ | ✓ |
| 24.1.21 | Cough Syrup, Anti Tussive        | LevocloperastineFendizoate 35.40mg/5ml 100ml   | ✓ | ✓ | ✓ | ✓ |
| 24.1.22 | Tab Montelukast-F/L              | 4mg  | ✓ | ✓ | ✓ | ✓ |
|         |                                  | 10mg   | ✓ | ✓ | ✓ | ✓ |
| 24.1.23 | Formeterol MDI, DPI + Budesonide | 0.5mcg   | ✓ | ✓ | ✗ | ✗ |
|         |                                  | 200mcg   | ✓ | ✓ | ✗ | ✗ |
|         |                                  | 400mcg   | ✓ | ✓ | ✗ | ✗ |

|  |                                  |   |   |   |   |   |
|--|----------------------------------|---|---|---|---|---|
| 24.1.24  | Salmeterol , MDI, DPI            | Salmeterol Respules 50mcg   | ✓ | ✓ | × | × |
|  |                                  | Salmeterol 25mcg MDI  | ✓ | ✓ | × | × |
| 24.1.25  | Inj/TabTheophylline              | Tab. Theophylline 150 mg  | ✓ | ✓ | × | × |
|  |                                  | Tab. Theophylline 200 mg  | ✓ | ✓ | × | × |
|  |                                  | Tab. Theophylline 300 mg  | ✓ | ✓ | × | × |
|  |                                  | Tab. Theophylline 400 mg  | ✓ | ✓ | × | × |
|  |                                  | Injection Theophylline 2mg  | ✓ | ✓ | × | × |
| 24.1.26  | BepostatineBesilate              | Tab 10 mg   | ✓ | ✓ | × | × |
| 24.1.27  | Tobramycin mist or respules      | Respules 300mg/5ml  | ✓ | ✓ | × | × |
| 24.1.28  | Sodium chloride respules         | Respules 3%,7%  | ✓ | ✓ | × | × |
|  |                                  | Respules 7%   | ✓ | ✓ | × | × |
| 24.1.29  | Glycopyrroniumr espules          | Respules 25mcg  | ✓ | ✓ | × | × |
| 24.1.30  | Ambroxolrespules                 | Respules 15mg/2ml   | ✓ | ✓ | × | × |
| 24.1.31  | Colistimethate sodium vial       | Vial 1MIU   | ✓ | ✓ | × | × |
|  |                                  | Vial 2 MIU  | ✓ | ✓ | × | × |
| 24.1.32  | Ipratropium bromide              | Respules 500mcg/2ml   | ✓ | ✓ | × | × |
|  |                                  | Respules 250mcg/1ml   | ✓ | ✓ | × | × |
| 24.1.33  | Acetylcysteine                   | 20% 200mg/ml, in 2ml respules   | ✓ | ✓ | × | × |
|  |                                  | 20% 200mg/ml, in 5 ml respules  | ✓ | ✓ | × | × |
| <b>Section 25</b>  |                                  |   |   |   |   |   |
| <b>Solutions correcting Water, Electrolyte disturbances and Acid-base disturbances</b> |                                  |   |   |   |   |   |
| 25.1.1   | Glucose*                         | Injection 5 %   | ✓ | ✓ | ✓ | ✓ |
|  |                                  | Injection 10 %  | ✓ | ✓ | ✓ | ✓ |
|  |                                  | Injection 25 %  | ✓ | ✓ | ✓ | ✓ |
|  |                                  | Injection 50 %  | ✓ | ✓ | ✓ | ✓ |
| 25.1.2   | Glucose(A) + Sodium chloride (B) | Injection 5% (A) + 0.9 % (B)  | ✓ | ✓ | ✓ | ✓ |
| 25.1.3   | Oral rehydration salts**         | Each Sachet of 20.5gm<br>Contains: Sodium Chloride IP 2.60gm, Potassium Chloride IP 1.50gm, Sodium Citrate IP 2.90gm, Dextrose (Anhydrous) IP 13.50gm, Excipients Q.S | ✓ | ✓ | ✓ | ✓ |
| 25.1.4   | Potassium chloride               | Oral liquid 500 mg/5 mL   | ✓ | ✓ | ✓ | ✓ |
|  |                                  | Injection 150 mg/mL   | ✓ | ✓ | ✓ | ✓ |



|  |                           |   |   |   |   |   |
|--|---------------------------|---|---|---|---|---|
| *Glucose formulations are also listed in <b>Section 18.4.2.1 - Hormones, other Endocrine Medicines and Contraceptives - Medicines used in diabetes mellitus - Medicines used to treat hypoglycemia</b> |                           |   |   |   |   |   |
| **Oral rehydration salts are also listed in <b>Section 17.6.1 - Gastrointestinal Medicines - Medicines used in diarrhea</b>  |                           |   |   |   |   |   |
| 25.1.5   | Ringer lactate            | Injection (as per IP)                                   | ✓ | ✓ | ✓ | ✓ |
| 25.1.6   | Sodium bicarbonate        | Injection (as per IP)                                   | ✓ | ✓ | ✓ | ✓ |
| 25.1.7   | Sodium chloride           | Injection 0.9%  | ✓ | ✓ | ✓ | ✓ |
|  |                           | Injection 3%  | ✓ | ✓ | ✓ | ✓ |
| 25.1.8   | Haemaccel Inj.500ml       | Haemaccel Inj.500ml                                     | ✓ | ✓ | ✓ | × |
| 25.1.9   | Gelofucine Inj. 500ml     | Gelofucine Inj. 500ml                                   | ✓ | ✓ | × | × |
| 25.1.10  | Sterofundin INJ. 500 ml   | Sterofundin INJ. 500 ml                                 | ✓ | ✓ | × | × |
| <b>25.2-Miscellaneous</b>  |                           |   |   |   |   |   |
| 25.2.1   | Water for Injection       | Injection   | ✓ | ✓ | ✓ | ✓ |
| <b>Section 26 Vitamins and Minerals</b>  |                           |   |   |   |   |   |
| 26.1   | Ascorbic acid (Vitamin C) | Tablet 100 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                           | Tablet 500 mg   | ✓ | ✓ | ✓ | ✓ |
| 26.2   | Calcium carbonate         | Tablet 625 mg (equivalent to elemental calcium 250 mg)  | ✓ | ✓ | ✓ | ✓ |
|  |                           | Tablet 1250 mg (equivalent to elemental calcium 500 mg) | ✓ | ✓ | ✓ | ✓ |
| 26.3   | Calcium gluconate*        | Injection 100 mg/mL                                     | ✓ | ✓ | ✓ | × |
| 26.4   | Cholecalciferol           | Solid oral dosage form 1000 IU                          | ✓ | ✓ | ✓ | ✓ |
|  |                           | Solid oral dosage form 60000 IU                         | ✓ | ✓ | ✓ | ✓ |
|  |                           | Oral liquid 400 IU/mL                                   | ✓ | ✓ | ✓ | ✓ |
| *Calcium Gluconate formulations are also listed in <b>Section 4.2.2 - Antidotes and Other substances used in poisoning/Envenomation Specific</b>   |                           |   |   |   |   |   |
| 26.5   | Pyridoxine                | Tablet 10 mg  | ✓ | ✓ | ✓ | ✓ |
|  |                           | Tablet 50 mg  | ✓ | ✓ | ✓ | ✓ |
|  |                           | Tablet 100 mg   | ✓ | ✓ | ✓ | ✓ |
| 26.6   | Riboflavin                | Tablet 10 mg  | ✓ | ✓ | ✓ | ✓ |
| 26.7   | Thiamine                  | Tablet 100 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                           | Injection 100 mg/mL                                     | ✓ | ✓ | ✓ | × |

|  |                      |   |   |   |   |   |
|--|----------------------|---|---|---|---|---|
| 26.8   | Vitamin A            | Capsule/Tablet 50000 IU (including Chewable Tablet)             | ✓ | ✓ | ✓ | ✓ |
|  |                      | Oral liquid 100000 IU/mL  | ✓ | ✓ | ✓ | ✓ |
| 26.9   | Deleted same as 26.8 | -   | - | - | - | - |
| 26.10  | Vitamin D3 drops     | 400IU/ 1ml in 30ml  | ✓ | ✓ | ✓ | ✓ |
| 26.11  | Calcium Tablet       | Calcium Tablet<br>500mg:Elemental Calcium &<br>250 IU in Vit D3 | ✓ | ✓ | ✓ | ✓ |
| <b>Section 27</b>  |                      |   |   |   |   |   |
| <b>Medicines for COVID 19 management</b>   |                      |   |   |   |   |   |
| 27.1   | Dexamethasone*       | Tablet 0.5 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                      | Tablet 2 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                      | Tablet 4 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                      | Oral liquid 0.5 mg/5 mL (p)                                     | ✓ | ✓ | ✓ | ✓ |
|  |                      | Injection 4 mg/mL   | ✓ | ✓ | ✓ | ✓ |
| 27.2   | Enoxaparin**         | Injection 40 mg/ 0.4 mL   | ✓ | ✓ | ✓ | ✗ |
|  |                      | Injection 60 mg/ 0.6 mL   | ✓ | ✓ | ✓ | ✗ |
| <p><i>*Dexamethasone is also listed in -</i></p> <p><b>A. Section 3.4 - Antiallergics and Medicines used in Anaphylaxis</b></p> <p><b>B. Section 7.4.3 - Anti-cancer agents including Immunosuppressives, and Medicines used in Palliative are- Medicines used in Palliative Care</b></p> <p><b>C. Section 18.1.1 - Hormones, other Endocrine Medicines and Contraceptives - Adrenal hormones and synthetic substitutes</b></p> <p><i>**Enoxaparin is also listed in -</i></p> <p><b>A. Section 8.2.1 - Medicines affecting Blood - Medicines affecting coagulation</b></p> <p><b>B. Section 10.5.4 - Cardiovascular medicines - Antiplatelet and Antithrombotic Medicines</b></p> |                      |   |   |   |   |   |
| 27.3   | Methylprednisolone*  | Injection 40 mg/mL  | ✓ | ✓ | ✓ | ✓ |
| 27.4   | Paracetamol**        | Tablet 500 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                      | Tablet 650 mg   | ✓ | ✓ | ✓ | ✓ |
|  |                      | Oral liquid 120 mg/5 mL (p)                                     | ✓ | ✓ | ✓ | ✓ |
|  |                      | Oral Liquid 125 mg/5 mL (p)                                     | ✓ | ✓ | ✓ | ✓ |
|  |                      | Oral Liquid 250 mg/5 mL (p)                                     | ✓ | ✓ | ✓ | ✓ |
| 27.5   | Oxygen***            | As licensed for medical purpose                                 | ✓ | ✓ | ✓ | ✓ |

*\*Methylprednisolone is also listed in **Section 18.1.4 - Hormones, other Endocrine medicines and Contraceptives- Adrenal Hormones and synthetic substitutes***

*\*\*Paracetamol is also listed in*

**A. Section 2.1.5 - Analgesics, antipyretics, non steroidal anti-inflammatory medicines, medicines used to treat Gout and disease Modifying agents used in Rheumatoid Disorders- Non-opioid analgesics, antipyretics and nonsteroidal anti-inflammatory medicines**

**B. Section 5.2.3 - Medicines used in Neurological Disorders-Antimigraine medicines**

*\*\*\* Oxygen is also listed in Medicines used in **Section 1.1.5 - Anaesthesia- General Anaesthetics and Oxygen***

| Section 28                                   |  |                       |   |   |   |   |
|--|--|-----------------------|---|---|---|---|
| Additional List Not Under The Above Category |  |                       |   |   |   |   |
| <b>SUPPLEMENTS FOR IUGR</b>                  |  |                       |   |   |   |   |
| 28.1   | Crystalline Amino Acids                            | Infusion 500 ml       | ✓ | ✓ | × | × |
| 28.2   | Sildenafil   | Tab 25 mg             | ✓ | ✓ | ✓ | × |
| <b>MEDICINES USED IN COLLESTASIS</b>         |  |                       |   |   |   |   |
| 28.3   | Ursodeoxycholic acid                               | Tab 150 mg            | ✓ | ✓ | × | × |
| 28.4   | Ursodeoxycholic acid                               | Tab 300 mg            | ✓ | ✓ | ✓ | × |
| <b>GYNÆ DRUGS</b>                            |  |                       | . | . | . |   |
| 28.5   | Ullipristal Acetate                                | Tab 5 mg              | ✓ | × | × | × |
| 28.6   | Mifepristone                                       | Tab 25 mg             | ✓ | ✓ | × | × |
| 28.7   | Myoinositol  | Tablet 500mg          | ✓ | ✓ | × | × |
|  |  | Sachet 500mg          | ✓ | ✓ | × | × |
| 28.9   | Cap Vit E  | 400 mg                | ✓ | ✓ | ✓ | × |
| 28.10  | Depot Medroxy progesterone acetate                 | Injection 150 mg/ml   | ✓ | ✓ | ✓ | ✓ |
| 28.11  | Tab Desogestrel                                    | 75 mg                 | ✓ | ✓ | ✓ | ✓ |
| <b>HAEMOSTATICS</b>                          |  |                       | . | . | . |   |
| 28.12  | Haemocoagulase injection                           |                       | ✓ | ✓ | ✓ | ✓ |
| 28.13  | Sterile, haemostatic, absorbable gelatin base foam |                       | ✓ | × | × | × |
| <b>INFERTILITY DRUGS</b>                     |  |                       | . | . | . |   |
| 28.14  | Human menopausal Gonadotrophin                     | Injection 75 & 150 IU | ✓ | × | × | × |

|                             |                                  |  |   |   |   |   |
|-----------------------------|----------------------------------|--|---|---|---|---|
|                             | (HMG)                            |  |   |   |   |   |
| 28.15                       | FSH injection                    | 75/150 IU  | ✓ | × | × | × |
| 28.16                       | Cetrorelix Injection             | 0.25 mg  | ✓ | × | × | × |
| 28.17                       | Triptorelin Injection            | 0.1 mg   | ✓ | × | × | × |
| 28.18                       | Dehydroepiandrosterone injection | 75 mg  | ✓ | × | × | × |
| <b>H1NI Drugs</b>           |                                  |  | . | . | . |   |
| 28.19                       | Tamiflu (Oseltamivir)            | Tablet 75 mg   | ✓ | ✓ | ✓ | × |
| 28.20                       | Tamiflu (Oseltamivir)            | Tablet 30 mg   | ✓ | ✓ | ✓ | × |
| 28.21                       | Tamiflu (Oseltamivir)            | Tablet 45 mg   | ✓ | ✓ | ✓ | × |
| 28.22                       | Tamiflu (Oseltamivir)            | Tablet 60 mg   | ✓ | ✓ | ✓ | × |
| 28.23                       | Tamiflu (Oseltamivir)            | Syrup 12mg per ml  | ✓ | ✓ | ✓ | × |
| <b>GENERAL DRUGS</b>        |                                  |  | . | . | . | . |
| 28.24                       | Asthalin respirator              | Solution 1 ml is 5mg   | ✓ | ✓ | ✓ | × |
| 28.25                       | Kenacort mouth gel               | Triamcinalone oral paste 0.1%  | ✓ | × | × | × |
| 28.26                       | Liver Syrup                      | Each 5ml Contains Silymarine 35mg + Vitamin B1 1mg + Vitamin B2 1.2mg + Vitamin B6 1.5mg + Niacinamide 12.50mg + D-Panthenol 4.5mg + Vitamin B 12 0.5mcg | ✓ | ✓ | ✓ | × |
| 28.27                       | Enzyme                           | Diastase (1:2000) 20mg (Fungal;derived from Aspergillus Oryzae) Lactic Acid Bacillus 150x10 <sup>6</sup> spores  | ✓ | ✓ | ✓ | × |
|                             |                                  | Each 5ml Contains Pepsin ( 1; 3000 ) 12.5mg + Alpha Amylase ( 1; 2000) 18.75mg   | ✓ | ✓ | ✓ | × |
| <b>Section 29</b>           |                                  |  |   |   |   |   |
| <b>SUTURE</b>               |                                  |  | . | . | . |   |
| <b>3Vicryl (Round body)</b> |                                  |  | ✓ | × | × | × |
| 29.1                        | 5 – 0 (VP 2303)                  | ANTIBACTERIAL TRICLOSAN COATED POLYGLACTIN 910, VIOLET COLOUR 70CM 5-0 X 16MM NEEDLE 1/2 CIR TAPER   | ✓ | × | × | × |

|                          |                  |   |   |   |   |   |
|--------------------------|------------------|---|---|---|---|---|
|                          |                  | POINT   |   |   |   |   |
| 29.2                     | 4 – 0 (VP 2304)  | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910, VIOLET<br>COLOUR 70CM 4-0 X 20MM<br>NEEDLE 1/2 CIR TAPER<br>POINT | ✓ | x | x | x |
| 29.3                     | 3 – 0 (VP 2437P) | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910, VIOLET<br>COLOUR 70CM 4-0 X 20MM<br>NEEDLE 1/2 CIR TAPER<br>POINT | ✓ | x | x | x |
| 29.4                     | 2 – 0 (VP 2317)  | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910, VIOLET<br>COLOUR 70CM 2-0 X 30MM<br>NEEDLE 1/2 CIR TAPER<br>POINT | ✓ | x | x | x |
| 29.5                     | 1 – 0 (VP 2346)  | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910, VIOLET<br>COLOUR 70CM 0 X 40MM<br>NEEDLE 1/2 CIR TAPER<br>POINT   | ✓ | x | x | x |
| <b>VicrylRapide</b>      |                  |   | . | . | . |   |
| 29.6                     | 4 – 0 (W 9918)   | FAST ABSORBING<br>POLYGLACTIN 910 RAPID<br>UNDYED 75CM 4-0 X 16MM<br>NEEDLE 3/8 CIR CUTTING<br>PRIME                    | ✓ | x | x | x |
| 29.7                     | 3 – 0 (W 9932)   | FAST ABSORBING<br>POLYGLACTIN 910 RAPID<br>UNDYED 75CM 3-0 X 26MM<br>NEEDLE 3/8 CIR CUTTING<br>PRIME                    | ✓ | x | x | x |
| <b>Mersilk (Cutting)</b> |                  |   | . | . | . |   |
| 29.8                     | 4 – 0 (NW 5000)  | BRAIDED SILK BLACK<br>90CM 4-0 X 16MM NEEDLE<br>3/8 CIR CT PRIME  | ✓ | x | x | x |
| 29.9                     | 3 – 0 (NW 5028)  | BRAIDED SILK BLACK<br>76CM 3-0 X 26MM NEEDLE<br>3/8 CIR RC  | ✓ | ✓ | x | x |

|                             |                        |  |   |   |   |   |
|-----------------------------|------------------------|--|---|---|---|---|
| 29.10                       | 2 – 0 (NW 5052)        | BRAIDED SILK BLACK<br>76CM 2-0 X 50MM NEEDLE<br>3/8 CIR REVERSE CUTTING              | ✓ | ✓ | x | x |
| 29.11                       | 1 – 0 (5037)           | BRAIDED SILK BLACK<br>76CM 0 X 45MM NEEDLE 3/8<br>CIR RC                             | ✓ | ✓ | x | x |
|                             | 1-0 (5332)             | BRAIDED SILK BLACK<br>90CM 0 X 30MM NEEDLE 1/2<br>CIR TP                             | ✓ | ✓ | x | x |
| <b>Mersilk (Round body)</b> |                        |  |   |   |   |   |
| 29.12                       | 4 – 0 (NW 5050)        | BRAIDED SILK BLACK<br>90CM 4-0 X 16MM NEEDLE<br>1/2 CIR TP                           | ✓ | x | x | x |
| 29.13                       | 3 – 0 (NW 5085)        | BRAIDED SILK BLACK<br>90CM 3-0 X 25MM NEEDLE<br>1/2 CIR TP                           | ✓ | x | x | x |
| 29.14                       | 2 – 0 (NW 5331)        | BRAIDED SILK BLACK<br>90CM 2-0 X 30MM NEEDLE<br>1/2 CIR TP                           | ✓ | x | x | x |
| <b>Ethilon (Cutting)</b>    |                        |  | . |   |   |   |
| 29.15                       | 3 – 0 (NW 3328)        | MONOFILAMENT<br>POLYAMIDE BLK 70CM 3-0<br>X 26MM NEEDLE 3/8 CIR RC                   | ✓ | x | x | x |
| 29.16                       | 4 – 0 (NW 3326)        | MONIFILAMENT<br>POLYAMIDE BLK 38CM 4-0<br>X 10MM NEEDLE 3/8 CIR RC                   | ✓ | x | x | x |
| <b>Prolene (Cutting)</b>    |                        |  |   |   |   |   |
| 29.17                       | 4 – 0 (NW 816)         | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>60CM 4-0 X 16MM NEEDLE<br>3/8 CIR CT PRIME     | ✓ | x | x | x |
| 29.18                       | 3 – 0 (NW 018)         | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>70CM 3-0 X 22MM NEEDLE<br>3/8 CIR CT           | ✓ | x | x | x |
| <b>SUTURE UNDER ENT</b>     |                        |  |   |   |   |   |
| 29.19                       | Mersilk suture 3-<br>O | BRAIDED SILK BLACK<br>76CM 3-0 X 16MM NEEDLE<br>3/8 CIR CT                           | ✓ | ✓ | ✓ | x |
|                             | Mersilk suture 4-<br>O | SILK BLK 76CM 4-0 X 16MM<br>NEEDLE 1/2 CIR TP  | ✓ | ✓ | ✓ | x |
| 29.20                       | Chromic catgut 3-<br>O | CHROMIC CATGUT<br>SUTURES 76CM 3-0 X 20MM<br>NEEDLE 1/2 CIR TP                       | ✓ | ✓ | ✓ | x |
|                             | Chromic catgut<br>4-O  | CHROMIC CATGUT<br>SUTURES 76CM 4-0 X 16MM<br>NEEDLE 3/8 CIR REVERSE<br>CUTTING PRIME | ✓ | ✓ | ✓ | x |

|   |                       |  |   |   |   |   |
|---|-----------------------|--|---|---|---|---|
| 29.21                                       | Nylon suture 3-O      | MONOFILAMENT<br>POLYAMIDE BLK 110CM<br>NEEDLE 3-0 X 26MM 3/8 CIR<br>RC   | ✓ | ✓ | ✓ | x |
|   | Nylon sutur 4-O       | MONOFILAMENT<br>POLYAMIDE BLACKK 70CM<br>4-0 X 16MM NEEDLE 3/8 CIR<br>CUTTING  | ✓ | ✓ | ✓ | x |
| <b>SUTURE UNDER OPHTHALMIC</b>              |                       |  |   |   |   |   |
| 29.22                                       | 6.0 vicryl            | POLYGLACTIN 910 VIOLET<br>45CM. 6-0 X 8MM NEEDLE<br>1/4 CIR SPATULATED<br>DOUBLE NEEDLE                              | ✓ | x | x | x |
| 29.23                                       | 4.0 silk              | BRAIDED SILK BLACK<br>90CM 4-0 X 16MM NEEDLE<br>3/8 CIR CUTTING PRIME  | ✓ | x | x | x |
| 29.24                                       | 10- 0 ethilon         | MONOFILAMENT<br>POLYAMIDE BLK 38CM 10-0<br>X 6MM NEEDLE 3/8 CIR<br>SPATULATED DOUBLE<br>NEEDLE                       | ✓ | x | x | x |
| <b>SUTURE UNDER ORTHOPEDIC &amp; OTHERS</b> |                       |  |   |   |   |   |
| 29.25                                       | PDS 2.0               | MONOFILAMENT<br>ABSORBABLE<br>POLYDIOXANONE VIOLET<br>70CM 2-0 X 26MM NEEDLE<br>1/2 CIR TAPER POINT                  | ✓ | x | x | x |
| 29.26                                       | PDS 3.0               | MONOFILAMENT<br>ABSORBABLE<br>POLYDIOXANONE VIOLET<br>75CM 3-0 X 20MM NEEDLE<br>1/2 CIR TAPER POINT<br>DOUBLE NEEDLE | ✓ | x | x | x |
| 29.27                                       | PDS 1.0 (loop)        | MONOFILAMENT<br>ABSORBABLE<br>POLYDIOXANONE VIOLET<br>150 CM 1 X 48MM NEEDLE<br>1/2 CIR TAPER POINT LP               | ✓ | x | x | x |
| 29.28                                       | Prolene(round)<br>2.0 | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>70CM 2-0 X 30MM NEEDLE<br>1/2 CIR TAPER POINT                                  | ✓ | x | x | x |
| 29.29                                       | Prolene(round)<br>3.0 | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>90CM 3-0 X 25MM NEEDLE<br>1/2 CIR TAPER POINT                                  | ✓ | x | x | x |
| 29.30                                       | Prolene(round)<br>1.0 | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>70CM 0 X 30MM NEEDLE 1/2<br>CIR TAPER POINT                                    | ✓ | x | x | x |

|       |                                       |  |   |   |   |   |
|-------|---------------------------------------|--|---|---|---|---|
| 29.31 | Ethilon (cutting) 2.0                 | MONOFILAMENT<br>POLYAMIDE BLACK 70CM<br>2-0 X 45MM NEEDLE 3/8 CIR<br>REVERSE CUTTING                       | ✓ | x | x | x |
| 29.32 | Ethilon (cutting) 1.0                 | MONOFILAMENT<br>POLYAMIDE BLACK 70CM 0<br>X 45MM NEEDLE 3/8 CIR<br>REVERSE CUTTING                         | ✓ | x | x | x |
| 29.33 | Monocryl 3.0                          | MONOFILAMENT<br>POLYGLECAPRONE 25<br>UNDYED 70CM 3-0 X 25MM<br>NEEDLE 3/8 CIR CT PRIME                     | ✓ | x | x | x |
| 29.34 | Monocryl 4.0                          | MONOFILAMENT<br>POLIGLECAPRONE 25<br>UNDYED, 70 CM,4-0 X 16MM<br>3/8 CIRCLE, REVERSE<br>CUTTING            | ✓ | x | x | x |
| 29.35 | Endosutures(vicryl, self locking 3.0) | NA   | ✓ | x | x | x |
| 29.36 | Fibrewire(arthrex) no.2               | NA   | ✓ | x | x | x |
| 29.37 | Fibrewire(arthrex) no.5               | NA   | ✓ | x | x | x |
| 29.38 | Ethibond number 0                     | NA   | ✓ | x | x | x |
| 29.39 | Ethibond number 2                     | NON ABSORBABLE<br>BRAIDED POLYESTER<br>GREEN 75CM 2 X 45MM<br>NEEDLE 1/2 CIR TAPER<br>CUTTING HEAVY NEEDLE | ✓ | x | x | x |
| 29.40 | Ethibond number 5                     | NON ABSORBABLE<br>BRAIDED GREEN 100CM 5 X<br>55MM NEEDLE 1/2 CIR<br>TAPER CUTTING HEAVY<br>NEEDLE          | ✓ | x | x | x |
| 29.41 | Vicryl 0                              | POLYGLACTIN 910 VIOLET<br>90CM 0 X 40MM NEEDLE 1/2<br>CIR TAPER POINT                                      | ✓ | x | x | x |
| 29.42 | Vicryl 1                              | POLYGLACTIN 910 VIOLET<br>90CM 1 X 40MM NEEDLE 1/2<br>CIR TAPER POINT HV                                   | ✓ | x | x | x |
| 29.43 | Vicryl 2                              | POLYGLACTIN 910 VIO<br>90CM 2 X 40MM NEEDLE 1/2<br>CIR TAPER POINT HV                                      | ✓ | x | x | x |
| 29.44 | Vicryl 3                              | NA   | ✓ | x | x | x |
| 29.45 | Vicryl OS various sizes               | POLYGLACTIN 910 VIOLET<br>90CM 1 X 40MM NEEDLE 1/2<br>CIR REVERSE CUTTING HV                               | ✓ | x | x | x |



|       |                           |  |   |   |   |   |
|-------|---------------------------|--|---|---|---|---|
|       |                           | POLYGLACTIN 910 VIOLET<br>90CM 2-0 X 40MM NEEDLE<br>1/2 CIR REVERSE CUTTING                    | ✓ | x | x | x |
|       |                           | POLYGLACTIN 910 VIOLET<br>90CM 2 X 40MM NEEDLE 1/2<br>CIR REVERSE CUTTING HV                   | ✓ | x | x | x |
|       |                           | POLYGLACTIN 910 VIOLET<br>90CM 0 X 36MM NEEDLE 1/2<br>CIR REVERSE CUTTING                      | ✓ | x | x | x |
| 29.46 | Ethilon various<br>sizes  | MONOFILAMENT<br>POLYAMIDE BLACK 70CM 0<br>X 45MM NEEDLE 3/8 CIR<br>REVERSE CUTTING             | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLACK 100CM<br>1 X 45MM NEEDLE 1/2 CIR<br>REVERSE CUTTING HV         | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLK 70CM 2-0<br>X 45MM NEEDLE 3/8 CIR<br>REVERSE CUTTING             | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLK 70CM 3-0<br>X 30MM NEEDLE 3/8 CIR<br>REVERSE CUTTING             | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLK 150CM 1 X<br>48MM NEEDLE 1/2 CIR<br>TAPER POINT LP HV            | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLACK 90CM<br>4-0 X 16MM NEEDLE 3/8 CIR<br>CUTTING PRIME             | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLYAMIDE BLACK 35CM<br>5-0 X 16MM 3/8 CIR<br>CUTTING PRIME                    | ✓ | x | x | x |
| 29.47 | Monocryl various<br>sizes | MONOFILAMENT<br>POLIGLECAPRONE 25<br>UNDYED 70CM 3-0 X 25MM<br>NEEDLE 3/8 CIR CUTTING<br>PRIME | ✓ | x | x | x |
|       |                           | MONOFILAMENT<br>POLIGLECAPRONE 25<br>UNDYED 70CM 2-0 X 30MM<br>1/2 CIR TAPER POINT             | ✓ | x | x | x |

|                                     |  |  |   |   |   |   |
|-------------------------------------|--|--|---|---|---|---|
|                                     |  | MONFILAMENT<br>POLIGLECAPRONE 25<br>UNDYED 70CM 0 X 30MM<br>1/2 CIR TAPER POINT                        | ✓ | x | x | x |
|                                     |  | MONOFILAMENT<br>POLIGLECAPRONE 25<br>UNDYED 45CM 5-0 X 13MM<br>NEEDLE 3/8 CIR REVERSE<br>CUTTING PRIME | ✓ | x | x | x |
| 29.48                               | Sutures anchor<br>various sizes  | NA   | ✓ | x | x | x |
| <b>SUTURE UNDER OBS &amp; GYNAE</b> |  |  | . | ▪ | ▪ | ▪ |
| 29.49                               | Chromic Catgut,<br>½ Circle R.B , 20<br>mm, 76 cm. Size<br>3-0   | CHROMIC CATGUT 76CM 3-<br>0 X 20MM 1/2 CIR TAPER<br>POINT  | ✓ | x | x | x |
| 29.50                               | Chromic Catgut ,<br>½ Circle R.B. , 30<br>mm, 76 cm , Size<br>2-0  | CHROMIC CATGUT 76CM 2-<br>0 X 30MM 1/2 CIR TAPER<br>POINT  | ✓ | x | x | x |
| 29.51                               | Chromic Catgut,<br>½ Circle R.B. , 30<br>mm, 76 cm, Size<br>1 - 0  | CHROMIC CATGUT 76CM 0<br>X 30MM 1/2 CIR TAPER<br>POINT   | ✓ | x | x | x |
| 29.52                               | Chromic Catgut,<br>½ Circle R.B. 40<br>mm , 76 cm, Size<br>1 - 0   | CHROMIC CATGUT 76CM 0<br>X 40MM NEEDLE 1/2 CIR<br>TAPER POINT  | ✓ | x | x | x |
| 29.53                               | Chromic Catgut,<br>½ Circle R.B.<br>Heavy , 40 mm,<br>76 cm, Size 1  | CHROMIC CATGUT 76CM 1<br>X 40MM NEEDLE 1/2 CIR<br>TAEPR POINT HV                                       | ✓ | x | x | x |
| 29.54                               | Monofilament<br>Polypropylene , ½<br>Circle R.B Heavy,<br>30 mm, 70cm,<br>Size 1   | MONOFILAMENT<br>POLYPROPYLENE BLUE<br>70CM 1 X 30MM 1/2 CIR<br>TAPER POINT HV                          | ✓ | x | x | x |
| 29.55                               | Fast Absorbing<br>Polyglactin 910<br>Undyed,1/2 Circle<br>Taper Point, 40<br>mm, 110 cm ,<br>Size 1 - 0-<br>VicrylRapide | FAST ABSORBING<br>POLYGLACTIN 910 UNDYED<br>110CM 0 X 40MM 1/2 CIR<br>TAPER POINT                      | ✓ | x | x | x |
| 29.56                               | Antibacterial<br>triclosan Coated<br>Polyglactin910 ,<br>O S Needle<br>Dimension ,<br>34mm, 90cm ,                       | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910 VIOLET<br>90CM 0 X 36MM NEEDLE 1/2<br>OS NEEDLE   | ✓ | x | x | x |

|       |  |  |   |   |   |   |
|-------|--|--|---|---|---|---|
|       | Size 1-0   |  |   |   |   |   |
| 29.57 | Antibacterial<br>Triclosan Coated<br>Polyglactin 910 ,<br>½ Circle Round<br>Body & 1/2<br>Cutting , 40 mm ,<br>140 cm , Size 1   | ANTIBACTERIAL<br>TRICLOSAN COATED<br>POLYGLACTIN 910 VIOLET<br>140CM 1 X 40MM NEEDLE<br>1/2 CIR TP, TC DA HV | ✓ | x | x | x |
| 29.58 | Black Braided<br>Silk, 3/8 Circle<br>R.B., 45 mm, 76<br>cm, Size 1 - 0-<br>Reverse Cutting   | BRAIDED SILK BLACK<br>76CM 0 X 45MM NEEDLE 3/8<br>CIR REVERSE CUTTING  | ✓ | x | x | x |
| 29.59 | Oxidized<br>Regenerated<br>Cellulose based<br>Topical<br>Absorbable<br>Hemostat, Multi<br>layered form, with<br>Bactericidal<br>property. Size<br>1X2 inch.<br>Approved by US<br>FDA | Oxidized Regenerated Cellulose<br>1in x 2in (2.5 cm x 5.1 cm)  | ✓ | x | x | x |
| 29.60 | Oxidized<br>Regenerated<br>Cellulose based<br>Topical<br>Absorbable<br>Hemostat, Multi<br>layered form, with<br>Bactericidal<br>property. Size<br>2X4inch .<br>Approved by US<br>FDA | Oxidized Regenerated Cellulose<br>2in x 4in (5.1 cm x 10.2 cm)   | ✓ | x | x | x |

|       |   |  |   |   |   |   |
|-------|---|--|---|---|---|---|
| 29.61 | Oxidized Regenerated Cellulose based Topical Absorbable Hemostat, Structured Non-Woven material, with Bactericidal property. Ease-of-use in both open and minimally invasive procedures. Size 2X4inch. Approved by US FDA | Oxidized Regenerated Cellulose 4in x 4in (10.2 cm x 10.2 cm) | ✓ | x | x | x |
| 29.62 | Braided Silk black 60mm 3/8 circle cutting/ SUC015062   | BRAIDED SILK BLACK 76CM 1 X 60MM 3/8 CIR CUTTING             | ✓ | x | x | x |
| 29.63 | Absorbable GelatinSpongstandard 80 mm x 50 mm x 10 mm   | Absorbable GelatinSpongstandard 80 mm x 50 mm x 10 mm        | ✓ | x | x | x |

The background is a light teal color with a repeating pattern of various medical icons in a darker teal shade. These icons include syringes, medicine bottles with crosses, hearts, ECG lines, bandages, pills, stethoscopes, flasks, and first aid kits. There are also decorative white circular patterns in the top and bottom corners.

• • •  
• • •  
• • • Meghalayan Medical Drugs & Services Limited  
• • • Health & Family Welfare Department  
• • • Government of Meghalaya  
• • •